{ "version": "2.2", "instance": { "adxn-20260630xex99d1.htm": { "nsprefix": "adxn", "nsuri": "http://addextherapeutics.com/20260630", "dts": { "schema": { "local": [ "adxn-20260630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/2023/calculation-1.1.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd", "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions-ea/rol_ifrs_ea-dim_2025-03-27.xsd", "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions/rol_full_ifrs-dim_2025-03-27.xsd", "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd", "https://xbrl.sec.gov/country/2025/country-2025.xsd", "https://xbrl.sec.gov/currency/2025/currency-2025.xsd", "https://xbrl.sec.gov/dei/2025/dei-2025.xsd" ] }, "calculationLink": { "local": [ "adxn-20260630_cal.xml" ] }, "definitionLink": { "local": [ "adxn-20260630_def.xml" ], "remote": [ "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions-ea/dim_ifrs_ea_2025-03-27_role-995000.xml", "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions/dim_full_ifrs_2025-03-27_role-995000.xml" ] }, "labelLink": { "local": [ "adxn-20260630_lab.xml" ] }, "presentationLink": { "local": [ "adxn-20260630_pre.xml" ] }, "inline": { "local": [ "adxn-20260630xex99d1.htm" ] } }, "keyStandard": 176, "keyCustom": 74, "axisStandard": 25, "axisCustom": 2, "memberStandard": 33, "memberCustom": 25, "hidden": { "total": 9, "http://xbrl.sec.gov/dei/2025": 8, "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full": 1 }, "contextCount": 274, "entityCount": 1, "segmentCount": 62, "elementCount": 449, "unitCount": 11, "baseTaxonomies": { "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full": 752, "http://xbrl.sec.gov/dei/2025": 8 }, "report": { "R1": { "role": "http://addextherapeutics.com/role/DocumentDocumentAndEntityInformation", "longName": "00090 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": null, "uniqueAnchor": null }, "R2": { "role": "http://addextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets", "longName": "00100 - Statement - Condensed Consolidated Balance Sheets", "shortName": "Condensed Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "As_Of_6_30_2026_nEpApE3lTkmeh-lEOADX7g", "name": "ifrs-full:CashAndCashEquivalents", "unitRef": "Unit_Standard_CHF_veB9_Q4q_kaAYWswP-S8rw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2026_nEpApE3lTkmeh-lEOADX7g", "name": "ifrs-full:CurrentAssets", "unitRef": "Unit_Standard_CHF_veB9_Q4q_kaAYWswP-S8rw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "unique": true } }, "R3": { "role": "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss", "longName": "00200 - Statement - Condensed Consolidated Statements of Comprehensive Loss", "shortName": "Condensed Consolidated Statements of Comprehensive Loss", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "Duration_4_1_2026_To_6_30_2026_ZsBj5eF9f0uttRvc3J0eBQ", "name": "ifrs-full:OtherIncome", "unitRef": "Unit_Standard_CHF_veB9_Q4q_kaAYWswP-S8rw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_4_1_2026_To_6_30_2026_ZsBj5eF9f0uttRvc3J0eBQ", "name": "ifrs-full:ResearchAndDevelopmentExpense", "unitRef": "Unit_Standard_CHF_veB9_Q4q_kaAYWswP-S8rw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "unique": true } }, "R4": { "role": "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfChangesInEquity", "longName": "00300 - Statement - Condensed Consolidated Statements of Changes in Equity", "shortName": "Condensed Consolidated Statements of Changes in Equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "As_Of_12_31_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_xW4nu30nRUmkrey5PNiNQw", "name": "ifrs-full:Equity", "unitRef": "Unit_Standard_CHF_veB9_Q4q_kaAYWswP-S8rw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_3_31_2025_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_xBHAKWsOlUSWeVnNvyfZ6Q", "name": "ifrs-full:ProfitLoss", "unitRef": "Unit_Standard_CHF_veB9_Q4q_kaAYWswP-S8rw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "unique": true } }, "R5": { "role": "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "longName": "00400 - Statement - Condensed Consolidated Statements of Cash Flows", "shortName": "Condensed Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_dCDbcN4ixkm5Px7HaCcpBQ", "name": "ifrs-full:ProfitLoss", "unitRef": "Unit_Standard_CHF_veB9_Q4q_kaAYWswP-S8rw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_6_30_2025_UiDyo22NCEOmhBDA1VZ3mQ", "name": "adxn:AdjustmentsForGainLossOnDiscontinuanceNetOfTax", "unitRef": "Unit_Standard_CHF_veB9_Q4q_kaAYWswP-S8rw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "unique": true } }, "R6": { "role": "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsParenthetical", "longName": "00405 - Statement - Condensed Consolidated Statements of Cash Flows (Parenthetical)", "shortName": "Condensed Consolidated Statements of Cash Flows (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_dCDbcN4ixkm5Px7HaCcpBQ", "name": "ifrs-full:AdjustmentsForUndistributedProfitsOfAssociates", "unitRef": "Unit_Standard_CHF_veB9_Q4q_kaAYWswP-S8rw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true }, "uniqueAnchor": null }, "R7": { "role": "http://addextherapeutics.com/role/DisclosureGeneralInformation", "longName": "10101 - Disclosure - General information", "shortName": "General information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_dCDbcN4ixkm5Px7HaCcpBQ", "name": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_dCDbcN4ixkm5Px7HaCcpBQ", "name": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true } }, "R8": { "role": "http://addextherapeutics.com/role/DisclosureBasisOfPreparation", "longName": "10201 - Disclosure - Basis of preparation", "shortName": "Basis of preparation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_dCDbcN4ixkm5Px7HaCcpBQ", "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_dCDbcN4ixkm5Px7HaCcpBQ", "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true } }, "R9": { "role": "http://addextherapeutics.com/role/DisclosureMaterialAccountingEstimatesAndJudgments", "longName": "10301 - Disclosure - Material accounting estimates and judgments", "shortName": "Material accounting estimates and judgments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_dCDbcN4ixkm5Px7HaCcpBQ", "name": "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_dCDbcN4ixkm5Px7HaCcpBQ", "name": "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true } }, "R10": { "role": "http://addextherapeutics.com/role/DisclosureInterimMeasurementNote", "longName": "10401 - Disclosure - Interim measurement note", "shortName": "Interim measurement note", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_dCDbcN4ixkm5Px7HaCcpBQ", "name": "adxn:DisclosureOfInterimMeasurementNoteTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_dCDbcN4ixkm5Px7HaCcpBQ", "name": "adxn:DisclosureOfInterimMeasurementNoteTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true } }, "R11": { "role": "http://addextherapeutics.com/role/DisclosureSegmentReporting", "longName": "10501 - Disclosure - Segment reporting", "shortName": "Segment reporting", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_dCDbcN4ixkm5Px7HaCcpBQ", "name": "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_dCDbcN4ixkm5Px7HaCcpBQ", "name": "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true } }, "R12": { "role": "http://addextherapeutics.com/role/DisclosureCashAndCashEquivalents", "longName": "10601 - Disclosure - Cash and cash equivalents", "shortName": "Cash and cash equivalents", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_dCDbcN4ixkm5Px7HaCcpBQ", "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_dCDbcN4ixkm5Px7HaCcpBQ", "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true } }, "R13": { "role": "http://addextherapeutics.com/role/DisclosureOtherCurrentAssets", "longName": "10701 - Disclosure - Other current assets", "shortName": "Other current assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_dCDbcN4ixkm5Px7HaCcpBQ", "name": "ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_dCDbcN4ixkm5Px7HaCcpBQ", "name": "ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true } }, "R14": { "role": "http://addextherapeutics.com/role/DisclosureRightOfUseAssets", "longName": "10801 - Disclosure - Right-of-use assets", "shortName": "Right-of-use assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_dCDbcN4ixkm5Px7HaCcpBQ", "name": "adxn:DisclosureOfRightOfUseAssetsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_dCDbcN4ixkm5Px7HaCcpBQ", "name": "adxn:DisclosureOfRightOfUseAssetsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true } }, "R15": { "role": "http://addextherapeutics.com/role/DisclosureEquipment", "longName": "10901 - Disclosure - Equipment", "shortName": "Equipment", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_dCDbcN4ixkm5Px7HaCcpBQ", "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_dCDbcN4ixkm5Px7HaCcpBQ", "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true } }, "R16": { "role": "http://addextherapeutics.com/role/DisclosureIntangibleAssets", "longName": "11001 - Disclosure - Intangible assets", "shortName": "Intangible assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_dCDbcN4ixkm5Px7HaCcpBQ", "name": "ifrs-full:DisclosureOfIntangibleAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_dCDbcN4ixkm5Px7HaCcpBQ", "name": "ifrs-full:DisclosureOfIntangibleAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true } }, "R17": { "role": "http://addextherapeutics.com/role/DisclosureNonCurrentFinancialAssets", "longName": "11101 - Disclosure - Non-current financial assets", "shortName": "Non-current financial assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_dCDbcN4ixkm5Px7HaCcpBQ", "name": "adxn:DisclosureOfNonCurrentFinancialAssetsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_dCDbcN4ixkm5Px7HaCcpBQ", "name": "adxn:DisclosureOfNonCurrentFinancialAssetsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true } }, "R18": { "role": "http://addextherapeutics.com/role/DisclosurePayablesAccrualsAndOtherCurrentLiabilities", "longName": "11201 - Disclosure - Payables, accruals and other current liabilities", "shortName": "Payables, accruals and other current liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_dCDbcN4ixkm5Px7HaCcpBQ", "name": "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_dCDbcN4ixkm5Px7HaCcpBQ", "name": "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true } }, "R19": { "role": "http://addextherapeutics.com/role/DisclosureShareCapital", "longName": "11301 - Disclosure - Share capital", "shortName": "Share capital", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_dCDbcN4ixkm5Px7HaCcpBQ", "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_dCDbcN4ixkm5Px7HaCcpBQ", "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true } }, "R20": { "role": "http://addextherapeutics.com/role/DisclosureShareBasedCompensation", "longName": "11401 - Disclosure - Share-based compensation", "shortName": "Share-based compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_dCDbcN4ixkm5Px7HaCcpBQ", "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_dCDbcN4ixkm5Px7HaCcpBQ", "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true } }, "R21": { "role": "http://addextherapeutics.com/role/DisclosureRetirementBenefitsObligations", "longName": "11501 - Disclosure - Retirement benefits obligations", "shortName": "Retirement benefits obligations", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_dCDbcN4ixkm5Px7HaCcpBQ", "name": "ifrs-full:DisclosureOfDefinedBenefitPlansExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_dCDbcN4ixkm5Px7HaCcpBQ", "name": "ifrs-full:DisclosureOfDefinedBenefitPlansExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true } }, "R22": { "role": "http://addextherapeutics.com/role/DisclosureRevenueFromContractWithCustomer", "longName": "11601 - Disclosure - Revenue from contract with customer", "shortName": "Revenue from contract with customer", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_dCDbcN4ixkm5Px7HaCcpBQ", "name": "ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_dCDbcN4ixkm5Px7HaCcpBQ", "name": "ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true } }, "R23": { "role": "http://addextherapeutics.com/role/DisclosureOtherIncome", "longName": "11701 - Disclosure - Other income", "shortName": "Other income", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_dCDbcN4ixkm5Px7HaCcpBQ", "name": "ifrs-full:DisclosureOfOtherOperatingIncomeExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_dCDbcN4ixkm5Px7HaCcpBQ", "name": "ifrs-full:DisclosureOfOtherOperatingIncomeExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true } }, "R24": { "role": "http://addextherapeutics.com/role/DisclosureOperatingCosts", "longName": "11801 - Disclosure - Operating costs", "shortName": "Operating costs", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_dCDbcN4ixkm5Px7HaCcpBQ", "name": "ifrs-full:DisclosureOfExpensesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_dCDbcN4ixkm5Px7HaCcpBQ", "name": "ifrs-full:DisclosureOfExpensesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true } }, "R25": { "role": "http://addextherapeutics.com/role/DisclosureStaffCosts", "longName": "11901 - Disclosure - Staff costs", "shortName": "Staff costs", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_dCDbcN4ixkm5Px7HaCcpBQ", "name": "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_dCDbcN4ixkm5Px7HaCcpBQ", "name": "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true } }, "R26": { "role": "http://addextherapeutics.com/role/DisclosureFinanceResultNet", "longName": "12001 - Disclosure - Finance result, net", "shortName": "Finance result, net", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "26", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_dCDbcN4ixkm5Px7HaCcpBQ", "name": "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_dCDbcN4ixkm5Px7HaCcpBQ", "name": "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true } }, "R27": { "role": "http://addextherapeutics.com/role/DisclosureDiscontinuedOperations", "longName": "12101 - Disclosure - Discontinued operations", "shortName": "Discontinued operations", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "27", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_dCDbcN4ixkm5Px7HaCcpBQ", "name": "ifrs-full:DisclosureOfDiscontinuedOperationsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_dCDbcN4ixkm5Px7HaCcpBQ", "name": "ifrs-full:DisclosureOfDiscontinuedOperationsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true } }, "R28": { "role": "http://addextherapeutics.com/role/DisclosureInterestsInAssociates", "longName": "12201 - Disclosure - Interests in associates", "shortName": "Interests in associates", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "28", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_dCDbcN4ixkm5Px7HaCcpBQ", "name": "ifrs-full:DisclosureOfInterestsInAssociatesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_dCDbcN4ixkm5Px7HaCcpBQ", "name": "ifrs-full:DisclosureOfInterestsInAssociatesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true } }, "R29": { "role": "http://addextherapeutics.com/role/DisclosureFinancialAssetsAtFairValueThroughOtherComprehensiveIncome", "longName": "12301 - Disclosure - Financial assets at fair value through other comprehensive income", "shortName": "Financial assets at fair value through other comprehensive income", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "29", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_dCDbcN4ixkm5Px7HaCcpBQ", "name": "ifrs-full:DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_dCDbcN4ixkm5Px7HaCcpBQ", "name": "ifrs-full:DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true } }, "R30": { "role": "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstruments", "longName": "12401 - Disclosure - Derivative financial instruments", "shortName": "Derivative financial instruments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "30", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_dCDbcN4ixkm5Px7HaCcpBQ", "name": "ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_dCDbcN4ixkm5Px7HaCcpBQ", "name": "ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true } }, "R31": { "role": "http://addextherapeutics.com/role/DisclosureLossPerShare", "longName": "12501 - Disclosure - Loss per share", "shortName": "Loss per share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "31", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_dCDbcN4ixkm5Px7HaCcpBQ", "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_dCDbcN4ixkm5Px7HaCcpBQ", "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true } }, "R32": { "role": "http://addextherapeutics.com/role/DisclosureRelatedPartyTransactions", "longName": "12601 - Disclosure - Related party transactions", "shortName": "Related party transactions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "32", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_dCDbcN4ixkm5Px7HaCcpBQ", "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_dCDbcN4ixkm5Px7HaCcpBQ", "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true } }, "R33": { "role": "http://addextherapeutics.com/role/DisclosureEventsAfterBalanceSheetDate", "longName": "12701 - Disclosure - Events after the balance sheet date", "shortName": "Events after the balance sheet date", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "33", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_dCDbcN4ixkm5Px7HaCcpBQ", "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_dCDbcN4ixkm5Px7HaCcpBQ", "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true } }, "R34": { "role": "http://addextherapeutics.com/role/DisclosureBasisOfPreparationPolicies", "longName": "20202 - Disclosure - Basis of preparation (Policies)", "shortName": "Basis of preparation (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "34", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_dCDbcN4ixkm5Px7HaCcpBQ", "name": "ifrs-full:ExplanationOfAccountingPoliciesAndMethodsOfComputationFollowedInInterimFinancialStatements", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_dCDbcN4ixkm5Px7HaCcpBQ", "name": "ifrs-full:ExplanationOfAccountingPoliciesAndMethodsOfComputationFollowedInInterimFinancialStatements", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true } }, "R35": { "role": "http://addextherapeutics.com/role/DisclosureSegmentReportingTables", "longName": "30503 - Disclosure - Segment reporting (Tables)", "shortName": "Segment reporting (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_dCDbcN4ixkm5Px7HaCcpBQ", "name": "ifrs-full:DisclosureOfProductsAndServicesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_dCDbcN4ixkm5Px7HaCcpBQ", "name": "ifrs-full:DisclosureOfProductsAndServicesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true } }, "R36": { "role": "http://addextherapeutics.com/role/DisclosureCashAndCashEquivalentsTables", "longName": "30603 - Disclosure - Cash and cash equivalents (Tables)", "shortName": "Cash and cash equivalents (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_dCDbcN4ixkm5Px7HaCcpBQ", "name": "adxn:DisclosureOfDetailedInformationAboutCashAndCashEquivalentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_dCDbcN4ixkm5Px7HaCcpBQ", "name": "adxn:DisclosureOfDetailedInformationAboutCashAndCashEquivalentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true } }, "R37": { "role": "http://addextherapeutics.com/role/DisclosureOtherCurrentAssetsTables", "longName": "30703 - Disclosure - Other current assets (Tables)", "shortName": "Other current assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "37", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_dCDbcN4ixkm5Px7HaCcpBQ", "name": "adxn:DisclosureOfDetailedInformationAboutOtherCurrentAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_dCDbcN4ixkm5Px7HaCcpBQ", "name": "adxn:DisclosureOfDetailedInformationAboutOtherCurrentAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true } }, "R38": { "role": "http://addextherapeutics.com/role/DisclosureRightOfUseAssetsTables", "longName": "30803 - Disclosure - Right-of-use assets (Tables)", "shortName": "Right-of-use assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "38", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_dCDbcN4ixkm5Px7HaCcpBQ", "name": "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "adxn:DisclosureOfRightOfUseAssetsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_dCDbcN4ixkm5Px7HaCcpBQ", "name": "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "adxn:DisclosureOfRightOfUseAssetsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true } }, "R39": { "role": "http://addextherapeutics.com/role/DisclosureEquipmentTables", "longName": "30903 - Disclosure - Equipment (Tables)", "shortName": "Equipment (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "39", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_dCDbcN4ixkm5Px7HaCcpBQ", "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_dCDbcN4ixkm5Px7HaCcpBQ", "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true } }, "R40": { "role": "http://addextherapeutics.com/role/DisclosureIntangibleAssetsTables", "longName": "31003 - Disclosure - Intangible assets (Tables)", "shortName": "Intangible assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "40", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_dCDbcN4ixkm5Px7HaCcpBQ", "name": "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfIntangibleAssetsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_dCDbcN4ixkm5Px7HaCcpBQ", "name": "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfIntangibleAssetsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true } }, "R41": { "role": "http://addextherapeutics.com/role/DisclosureNonCurrentFinancialAssetsTables", "longName": "31103 - Disclosure - Non-current financial assets (Tables)", "shortName": "Non-current financial assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "41", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_dCDbcN4ixkm5Px7HaCcpBQ", "name": "adxn:DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "adxn:DisclosureOfNonCurrentFinancialAssetsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_dCDbcN4ixkm5Px7HaCcpBQ", "name": "adxn:DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "adxn:DisclosureOfNonCurrentFinancialAssetsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true } }, "R42": { "role": "http://addextherapeutics.com/role/DisclosurePayablesAccrualsAndOtherCurrentLiabilitiesTables", "longName": "31203 - Disclosure - Payables, accruals and other current liabilities (Tables)", "shortName": "Payables, accruals and other current liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "42", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_dCDbcN4ixkm5Px7HaCcpBQ", "name": "adxn:DisclosureOfDetailedInformationAboutPayablesAndAccrualsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_dCDbcN4ixkm5Px7HaCcpBQ", "name": "adxn:DisclosureOfDetailedInformationAboutPayablesAndAccrualsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true } }, "R43": { "role": "http://addextherapeutics.com/role/DisclosureShareCapitalTables", "longName": "31303 - Disclosure - Share capital (Tables)", "shortName": "Share capital (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "43", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_dCDbcN4ixkm5Px7HaCcpBQ", "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_dCDbcN4ixkm5Px7HaCcpBQ", "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true } }, "R44": { "role": "http://addextherapeutics.com/role/DisclosureRetirementBenefitsObligationsTables", "longName": "31503 - Disclosure - Retirement benefits obligations (Tables)", "shortName": "Retirement benefits obligations (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "44", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_dCDbcN4ixkm5Px7HaCcpBQ", "name": "adxn:DisclosureOfAmountsRecognizedInProfitOrLossForEmploymentBenefitObligationsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfDefinedBenefitPlansExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_dCDbcN4ixkm5Px7HaCcpBQ", "name": "adxn:DisclosureOfAmountsRecognizedInProfitOrLossForEmploymentBenefitObligationsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfDefinedBenefitPlansExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true } }, "R45": { "role": "http://addextherapeutics.com/role/DisclosureOperatingCostsTables", "longName": "31803 - Disclosure - Operating costs (Tables)", "shortName": "Operating costs (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "45", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_dCDbcN4ixkm5Px7HaCcpBQ", "name": "ifrs-full:DisclosureOfExpensesByNatureExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfExpensesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_dCDbcN4ixkm5Px7HaCcpBQ", "name": "ifrs-full:DisclosureOfExpensesByNatureExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfExpensesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true } }, "R46": { "role": "http://addextherapeutics.com/role/DisclosureStaffCostsTables", "longName": "31903 - Disclosure - Staff costs (Tables)", "shortName": "Staff costs (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "46", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_dCDbcN4ixkm5Px7HaCcpBQ", "name": "adxn:DisclosureOfStaffCostsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_dCDbcN4ixkm5Px7HaCcpBQ", "name": "adxn:DisclosureOfStaffCostsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true } }, "R47": { "role": "http://addextherapeutics.com/role/DisclosureFinanceResultNetTables", "longName": "32003 - Disclosure - Finance result, net (Tables)", "shortName": "Finance result, net (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "47", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_dCDbcN4ixkm5Px7HaCcpBQ", "name": "adxn:DisclosureOfFinanceIncomeExpenseTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_dCDbcN4ixkm5Px7HaCcpBQ", "name": "adxn:DisclosureOfFinanceIncomeExpenseTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true } }, "R48": { "role": "http://addextherapeutics.com/role/DisclosureInterestsInAssociatesTables", "longName": "32203 - Disclosure - Interests in associates (Tables)", "shortName": "Interests in associates (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "48", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_6_30_2025_UiDyo22NCEOmhBDA1VZ3mQ", "name": "ifrs-full:DisclosureOfSignificantInvestmentsInAssociatesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfInterestsInAssociatesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_6_30_2025_UiDyo22NCEOmhBDA1VZ3mQ", "name": "ifrs-full:DisclosureOfSignificantInvestmentsInAssociatesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfInterestsInAssociatesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true } }, "R49": { "role": "http://addextherapeutics.com/role/DisclosureFinancialAssetsAtFairValueThroughOtherComprehensiveIncomeTables", "longName": "32303 - Disclosure - Financial assets at fair value through other comprehensive income (Tables)", "shortName": "Financial assets at fair value through other comprehensive income (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "49", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_6_30_2025_UiDyo22NCEOmhBDA1VZ3mQ", "name": "adxn:TabularDisclosureOfInformationAboutFinancialAssetsAtFairValueThroughOtherComprehensiveIncomeTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_6_30_2025_UiDyo22NCEOmhBDA1VZ3mQ", "name": "adxn:TabularDisclosureOfInformationAboutFinancialAssetsAtFairValueThroughOtherComprehensiveIncomeTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true } }, "R50": { "role": "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsTables", "longName": "32403 - Disclosure - Derivative financial instruments (Tables)", "shortName": "Derivative financial instruments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "50", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_dCDbcN4ixkm5Px7HaCcpBQ", "name": "adxn:DisclosureOfFairValueMeasurementOfDerivativeFinancialInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_dCDbcN4ixkm5Px7HaCcpBQ", "name": "adxn:DisclosureOfFairValueMeasurementOfDerivativeFinancialInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true } }, "R51": { "role": "http://addextherapeutics.com/role/DisclosureLossPerShareTables", "longName": "32503 - Disclosure - Loss per share (Tables)", "shortName": "Loss per share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "51", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_dCDbcN4ixkm5Px7HaCcpBQ", "name": "ifrs-full:EarningsPerShareExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_dCDbcN4ixkm5Px7HaCcpBQ", "name": "ifrs-full:EarningsPerShareExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true } }, "R52": { "role": "http://addextherapeutics.com/role/DisclosureRelatedPartyTransactionsTables", "longName": "32603 - Disclosure - Related party transactions (Tables)", "shortName": "Related party transactions (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "52", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_6_30_2025_UiDyo22NCEOmhBDA1VZ3mQ", "name": "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfRelatedPartyExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_6_30_2025_UiDyo22NCEOmhBDA1VZ3mQ", "name": "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfRelatedPartyExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true } }, "R53": { "role": "http://addextherapeutics.com/role/DisclosureGeneralInformationDetails", "longName": "40101 - Disclosure - General information (Details)", "shortName": "General information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "Duration_6_30_2026_To_6_30_2026_ifrs-full_SignificantInvestmentsInAssociatesAxis_adxn_NeurosterixUsHoldingsLlcMember_l8Pzuor89E6Tu8SLev6mdw", "name": "ifrs-full:ProportionOfOwnershipInterestInAssociate", "unitRef": "Unit_Standard_pure_5WMDik9kYEScz0Evx4PwGw", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true }, "uniqueAnchor": null }, "R54": { "role": "http://addextherapeutics.com/role/DisclosureMaterialAccountingEstimatesAndJudgmentsDetails", "longName": "40301 - Disclosure - Material accounting estimates and judgments - (Details)", "shortName": "Material accounting estimates and judgments - (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "Duration_6_30_2026_To_6_30_2026_ifrs-full_SignificantInvestmentsInAssociatesAxis_adxn_NeurosterixUsHoldingsLlcMember_l8Pzuor89E6Tu8SLev6mdw", "name": "ifrs-full:ProportionOfOwnershipInterestInAssociate", "unitRef": "Unit_Standard_pure_5WMDik9kYEScz0Evx4PwGw", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_4_1_2026_To_6_30_2026_ifrs-full_SignificantInvestmentsInAssociatesAxis_adxn_NeurosterixUsHoldingsLlcMember_GKvRlER6b0SB706FQhB_3g", "name": "ifrs-full:ImpairmentLoss", "unitRef": "Unit_Standard_CHF_veB9_Q4q_kaAYWswP-S8rw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "ifrs-full:ImpairmentLoss", "ifrs-full:ImpairmentLoss", "ifrs-full:ImpairmentLoss", "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "unique": true } }, "R55": { "role": "http://addextherapeutics.com/role/DisclosureSegmentInformationDetails", "longName": "40501 - Disclosure - Segment information (Details)", "shortName": "Segment information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_dCDbcN4ixkm5Px7HaCcpBQ", "name": "adxn:NumberOfSegments", "unitRef": "Unit_Standard_segment_HLl2clqyZUCEByKNjTyapQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_dCDbcN4ixkm5Px7HaCcpBQ", "name": "adxn:NumberOfSegments", "unitRef": "Unit_Standard_segment_HLl2clqyZUCEByKNjTyapQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true } }, "R56": { "role": "http://addextherapeutics.com/role/DisclosureCashAndCashEquivalentsDetails", "longName": "40601 - Disclosure - Cash and cash equivalents (Details)", "shortName": "Cash and cash equivalents (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "As_Of_6_30_2026_nEpApE3lTkmeh-lEOADX7g", "name": "ifrs-full:Cash", "unitRef": "Unit_Standard_CHF_veB9_Q4q_kaAYWswP-S8rw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "adxn:DisclosureOfDetailedInformationAboutCashAndCashEquivalentsTableTextBlock", "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2026_nEpApE3lTkmeh-lEOADX7g", "name": "ifrs-full:Cash", "unitRef": "Unit_Standard_CHF_veB9_Q4q_kaAYWswP-S8rw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "adxn:DisclosureOfDetailedInformationAboutCashAndCashEquivalentsTableTextBlock", "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true } }, "R57": { "role": "http://addextherapeutics.com/role/DisclosureOtherCurrentAssetsDetails", "longName": "40701 - Disclosure - Other current assets (Details)", "shortName": "Other current assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "As_Of_6_30_2026_nEpApE3lTkmeh-lEOADX7g", "name": "ifrs-full:OtherCurrentFinancialAssets", "unitRef": "Unit_Standard_CHF_veB9_Q4q_kaAYWswP-S8rw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2026_nEpApE3lTkmeh-lEOADX7g", "name": "ifrs-full:OtherCurrentAssets", "unitRef": "Unit_Standard_CHF_veB9_Q4q_kaAYWswP-S8rw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "b", "p", "td", "tr", "table", "adxn:DisclosureOfDetailedInformationAboutOtherCurrentAssetsTableTextBlock", "ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "unique": true } }, "R58": { "role": "http://addextherapeutics.com/role/DisclosureRightOfUseAssetsDetails", "longName": "40801 - Disclosure - Right-of-use assets (Details)", "shortName": "Right-of-use assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "As_Of_12_31_2025_qdGpNZKgIka9Py92H_fPTA", "name": "ifrs-full:RightofuseAssets", "unitRef": "Unit_Standard_CHF_veB9_Q4q_kaAYWswP-S8rw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2024_ifrs-full_ClassesOfAssetsAxis_ifrs-full_LandAndBuildingsMember_BdF2eUEuZEqbv_GMD5Jwrg", "name": "ifrs-full:RightofuseAssets", "unitRef": "Unit_Standard_CHF_veB9_Q4q_kaAYWswP-S8rw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory", "adxn:DisclosureOfRightOfUseAssetsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "unique": true } }, "R59": { "role": "http://addextherapeutics.com/role/DisclosureEquipmentDetails", "longName": "40901 - Disclosure - Equipment (Details)", "shortName": "Equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "As_Of_12_31_2025_qdGpNZKgIka9Py92H_fPTA", "name": "ifrs-full:PropertyPlantAndEquipment", "unitRef": "Unit_Standard_CHF_veB9_Q4q_kaAYWswP-S8rw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2024_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_adxn_IfrsEquipmentMember_7HoLUqtmx0ms-L1J2s0ZiQ", "name": "ifrs-full:PropertyPlantAndEquipment", "unitRef": "Unit_Standard_CHF_veB9_Q4q_kaAYWswP-S8rw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "unique": true } }, "R60": { "role": "http://addextherapeutics.com/role/DisclosureIntangibleAssetsDetails", "longName": "41001 - Disclosure - Intangible assets (Details)", "shortName": "Intangible assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "Duration_4_1_2026_To_6_30_2026_ZsBj5eF9f0uttRvc3J0eBQ", "name": "adxn:IncomeRecognisedForServicesReceivedAtZeroCosts", "unitRef": "Unit_Standard_CHF_veB9_Q4q_kaAYWswP-S8rw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfProductsAndServicesExplanatory", "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_adxn_ServiceAgreementMember_IbGBuHUQt0q2gsIXkAfYWg", "name": "ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill", "unitRef": "Unit_Standard_CHF_veB9_Q4q_kaAYWswP-S8rw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "ifrs-full:DisclosureOfIntangibleAssetsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "unique": true } }, "R61": { "role": "http://addextherapeutics.com/role/DisclosureNonCurrentFinancialAssetsDetails", "longName": "41101 - Disclosure - Non-current financial assets (Details)", "shortName": "Non-current financial assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "As_Of_6_30_2026_nEpApE3lTkmeh-lEOADX7g", "name": "ifrs-full:LongtermDeposits", "unitRef": "Unit_Standard_CHF_veB9_Q4q_kaAYWswP-S8rw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "adxn:DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsTableTextBlock", "adxn:DisclosureOfNonCurrentFinancialAssetsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2026_nEpApE3lTkmeh-lEOADX7g", "name": "ifrs-full:LongtermDeposits", "unitRef": "Unit_Standard_CHF_veB9_Q4q_kaAYWswP-S8rw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "adxn:DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsTableTextBlock", "adxn:DisclosureOfNonCurrentFinancialAssetsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true } }, "R62": { "role": "http://addextherapeutics.com/role/DisclosurePayablesAccrualsAndOtherCurrentLiabilitiesDetails", "longName": "41201 - Disclosure - Payables, accruals and other current liabilities (Details)", "shortName": "Payables, accruals and other current liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "As_Of_6_30_2026_nEpApE3lTkmeh-lEOADX7g", "name": "ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers", "unitRef": "Unit_Standard_CHF_veB9_Q4q_kaAYWswP-S8rw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "adxn:DisclosureOfDetailedInformationAboutPayablesAndAccrualsTableTextBlock", "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2026_nEpApE3lTkmeh-lEOADX7g", "name": "ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers", "unitRef": "Unit_Standard_CHF_veB9_Q4q_kaAYWswP-S8rw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "adxn:DisclosureOfDetailedInformationAboutPayablesAndAccrualsTableTextBlock", "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true } }, "R63": { "role": "http://addextherapeutics.com/role/DisclosureShareCapitalDetails", "longName": "41301 - Disclosure - Share capital (Details)", "shortName": "Share capital (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "As_Of_12_31_2025_qdGpNZKgIka9Py92H_fPTA", "name": "ifrs-full:NumberOfSharesOutstanding", "unitRef": "Unit_Standard_shares_b4NqgRzstk-fxCOn6_iHqA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_6_30_2025_UiDyo22NCEOmhBDA1VZ3mQ", "name": "adxn:NumberOfTreasurySharesSoldPurchased", "unitRef": "Unit_Standard_shares_b4NqgRzstk-fxCOn6_iHqA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "unique": true } }, "R64": { "role": "http://addextherapeutics.com/role/DisclosureShareBasedCompensationDetails", "longName": "41401 - Disclosure - Share-based compensation (Details)", "shortName": "Share-based compensation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_dCDbcN4ixkm5Px7HaCcpBQ", "name": "ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets", "unitRef": "Unit_Standard_CHF_veB9_Q4q_kaAYWswP-S8rw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_dCDbcN4ixkm5Px7HaCcpBQ", "name": "ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets", "unitRef": "Unit_Standard_CHF_veB9_Q4q_kaAYWswP-S8rw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true } }, "R65": { "role": "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionsOrSharesOutstandingDetails", "longName": "41402 - Disclosure - Share-based compensation - Share options or shares outstanding (Details)", "shortName": "Share-based compensation - Share options or shares outstanding (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "As_Of_6_30_2026_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_adxn_EmployeeShareOptionPlansMember_RVKhwzvM-E-CH_Oq9lG-mQ", "name": "ifrs-full:NumberOfOutstandingShareOptions", "unitRef": "Unit_Standard_Options_SBEQyHydkEW_cinNdotaBA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2026_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_adxn_EmployeeShareOptionPlansMember_RVKhwzvM-E-CH_Oq9lG-mQ", "name": "ifrs-full:NumberOfOutstandingShareOptions", "unitRef": "Unit_Standard_Options_SBEQyHydkEW_cinNdotaBA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true } }, "R66": { "role": "http://addextherapeutics.com/role/DisclosureRetirementBenefitsObligationsComprehensiveLossDetails", "longName": "41501 - Disclosure - Retirement benefits obligations - Comprehensive loss (Details)", "shortName": "Retirement benefits obligations - Comprehensive loss (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "Duration_4_1_2026_To_6_30_2026_ZsBj5eF9f0uttRvc3J0eBQ", "name": "ifrs-full:CurrentServiceCostDefinedBenefitPlans", "unitRef": "Unit_Standard_CHF_veB9_Q4q_kaAYWswP-S8rw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "adxn:DisclosureOfAmountsRecognizedInProfitOrLossForEmploymentBenefitObligationsTableTextBlock", "ifrs-full:DisclosureOfDefinedBenefitPlansExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_4_1_2026_To_6_30_2026_ZsBj5eF9f0uttRvc3J0eBQ", "name": "ifrs-full:CurrentServiceCostDefinedBenefitPlans", "unitRef": "Unit_Standard_CHF_veB9_Q4q_kaAYWswP-S8rw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "adxn:DisclosureOfAmountsRecognizedInProfitOrLossForEmploymentBenefitObligationsTableTextBlock", "ifrs-full:DisclosureOfDefinedBenefitPlansExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true } }, "R67": { "role": "http://addextherapeutics.com/role/DisclosureRetirementBenefitsObligationsBalanceSheetDetails", "longName": "41502 - Disclosure - Retirement benefits obligations - Balance sheet (Details)", "shortName": "Retirement benefits obligations - Balance sheet (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "As_Of_6_30_2026_nEpApE3lTkmeh-lEOADX7g", "name": "ifrs-full:LiabilityAssetOfDefinedBenefitPlans", "unitRef": "Unit_Standard_CHF_veB9_Q4q_kaAYWswP-S8rw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "b", "p", "td", "tr", "table", "adxn:DisclosureOfAmountsRecognizedInBalanceSheetForEmploymentBenefitObligationsTableTextBlock", "ifrs-full:DisclosureOfDefinedBenefitPlansExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2026_nEpApE3lTkmeh-lEOADX7g", "name": "ifrs-full:LiabilityAssetOfDefinedBenefitPlans", "unitRef": "Unit_Standard_CHF_veB9_Q4q_kaAYWswP-S8rw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "b", "p", "td", "tr", "table", "adxn:DisclosureOfAmountsRecognizedInBalanceSheetForEmploymentBenefitObligationsTableTextBlock", "ifrs-full:DisclosureOfDefinedBenefitPlansExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true } }, "R68": { "role": "http://addextherapeutics.com/role/DisclosureRevenueFromContractWithCustomerDetails", "longName": "41601 - Disclosure - Revenue from contract with customer (Details)", "shortName": "Revenue from contract with customer (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "Duration_4_1_2026_To_6_30_2026_ifrs-full_CounterpartiesAxis_adxn_IndiviorPlcMember_-bTEnFHzmE6tMAAsBn1oZA", "name": "ifrs-full:RevenueFromContractsWithCustomers", "unitRef": "Unit_Standard_CHF_veB9_Q4q_kaAYWswP-S8rw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "ifrs-full:RevenueFromContractsWithCustomers", "ifrs-full:RevenueFromContractsWithCustomers", "ifrs-full:RevenueFromContractsWithCustomers", "p", "ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_4_1_2026_To_6_30_2026_ifrs-full_CounterpartiesAxis_adxn_IndiviorPlcMember_-bTEnFHzmE6tMAAsBn1oZA", "name": "ifrs-full:RevenueFromContractsWithCustomers", "unitRef": "Unit_Standard_CHF_veB9_Q4q_kaAYWswP-S8rw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "ifrs-full:RevenueFromContractsWithCustomers", "ifrs-full:RevenueFromContractsWithCustomers", "ifrs-full:RevenueFromContractsWithCustomers", "p", "ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true } }, "R69": { "role": "http://addextherapeutics.com/role/DisclosureOtherIncomeDetails", "longName": "41701 - Disclosure - Other income (Details)", "shortName": "Other income (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "Duration_4_1_2026_To_6_30_2026_ZsBj5eF9f0uttRvc3J0eBQ", "name": "ifrs-full:OtherIncome", "unitRef": "Unit_Standard_CHF_veB9_Q4q_kaAYWswP-S8rw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_4_1_2026_To_6_30_2026_ifrs-full_CounterpartiesAxis_adxn_NeurosterixGroupMember_udB09Y8FXEy4xvjMfVx7Jg", "name": "ifrs-full:OtherIncome", "unitRef": "Unit_Standard_CHF_veB9_Q4q_kaAYWswP-S8rw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "ifrs-full:DisclosureOfOtherOperatingIncomeExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "unique": true } }, "R70": { "role": "http://addextherapeutics.com/role/DisclosureOperatingCostsDetails", "longName": "41801 - Disclosure - Operating costs (Details)", "shortName": "Operating costs (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "Duration_4_1_2026_To_6_30_2026_ZsBj5eF9f0uttRvc3J0eBQ", "name": "ifrs-full:EmployeeBenefitsExpense", "unitRef": "Unit_Standard_CHF_veB9_Q4q_kaAYWswP-S8rw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "b", "p", "td", "tr", "table", "adxn:DisclosureOfStaffCostsTableTextBlock", "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_4_1_2026_To_6_30_2026_ZsBj5eF9f0uttRvc3J0eBQ", "name": "ifrs-full:DepreciationExpense", "unitRef": "Unit_Standard_CHF_veB9_Q4q_kaAYWswP-S8rw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfExpensesByNatureExplanatory", "ifrs-full:DisclosureOfExpensesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "unique": true } }, "R71": { "role": "http://addextherapeutics.com/role/DisclosureOperatingCostsAdditionalInformationDetails", "longName": "41802 - Disclosure - Operating costs - Additional Information (Details)", "shortName": "Operating costs - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "Duration_4_1_2026_To_6_30_2026_ZsBj5eF9f0uttRvc3J0eBQ", "name": "adxn:IncreaseDecreaseInOperatingExpenses", "unitRef": "Unit_Standard_CHF_veB9_Q4q_kaAYWswP-S8rw", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ifrs-full:DisclosureOfExpensesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_4_1_2026_To_6_30_2026_ZsBj5eF9f0uttRvc3J0eBQ", "name": "adxn:IncreaseDecreaseInOperatingExpenses", "unitRef": "Unit_Standard_CHF_veB9_Q4q_kaAYWswP-S8rw", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ifrs-full:DisclosureOfExpensesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true } }, "R72": { "role": "http://addextherapeutics.com/role/DisclosureStaffCostsDetails", "longName": "41901 - Disclosure - Staff costs (Details)", "shortName": "Staff costs (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "Duration_4_1_2026_To_6_30_2026_ZsBj5eF9f0uttRvc3J0eBQ", "name": "ifrs-full:WagesAndSalaries", "unitRef": "Unit_Standard_CHF_veB9_Q4q_kaAYWswP-S8rw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "adxn:DisclosureOfStaffCostsTableTextBlock", "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_4_1_2026_To_6_30_2026_ZsBj5eF9f0uttRvc3J0eBQ", "name": "ifrs-full:WagesAndSalaries", "unitRef": "Unit_Standard_CHF_veB9_Q4q_kaAYWswP-S8rw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "adxn:DisclosureOfStaffCostsTableTextBlock", "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true } }, "R73": { "role": "http://addextherapeutics.com/role/DisclosureStaffCostsAdditionalInformationDetails", "longName": "41902 - Disclosure - Staff costs - Additional Information (Details)", "shortName": "Staff costs - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "Duration_4_1_2026_To_6_30_2026_ZsBj5eF9f0uttRvc3J0eBQ", "name": "adxn:IncreaseDecreaseInEmployeeBenefitsExpenses", "unitRef": "Unit_Standard_CHF_veB9_Q4q_kaAYWswP-S8rw", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true }, "uniqueAnchor": null }, "R74": { "role": "http://addextherapeutics.com/role/DisclosureFinanceResultNetDetails", "longName": "42001 - Disclosure - Finance result, net (Details)", "shortName": "Finance result, net (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": { "contextRef": "Duration_4_1_2025_To_6_30_2025_90_tOMzWQUuTTt970ETGZQ", "name": "ifrs-full:InterestExpense", "unitRef": "Unit_Standard_CHF_veB9_Q4q_kaAYWswP-S8rw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "adxn:DisclosureOfFinanceIncomeExpenseTableTextBlock", "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_4_1_2025_To_6_30_2025_90_tOMzWQUuTTt970ETGZQ", "name": "ifrs-full:InterestExpense", "unitRef": "Unit_Standard_CHF_veB9_Q4q_kaAYWswP-S8rw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "adxn:DisclosureOfFinanceIncomeExpenseTableTextBlock", "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true } }, "R75": { "role": "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsGeneralDetails", "longName": "42101 - Disclosure - Discontinued operations - General (Details)", "shortName": "Discontinued operations - General (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "75", "firstAnchor": { "contextRef": "Duration_4_2_2024_To_4_2_2024_dei_LegalEntityAxis_adxn_NeurosterixPharmaSarlMember_osq1ndCOiEWuxoOfuUnsLA", "name": "adxn:AmountOfCommitmentFundingReceived", "unitRef": "Unit_Standard_USD_agp3-R2pbk6eCe95QAQKyQ", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "p", "ifrs-full:DisclosureOfDiscontinuedOperationsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_4_2_2024_To_4_2_2024_dei_LegalEntityAxis_adxn_NeurosterixPharmaSarlMember_osq1ndCOiEWuxoOfuUnsLA", "name": "adxn:AmountOfCommitmentFundingReceived", "unitRef": "Unit_Standard_USD_agp3-R2pbk6eCe95QAQKyQ", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "p", "ifrs-full:DisclosureOfDiscontinuedOperationsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true } }, "R76": { "role": "http://addextherapeutics.com/role/DisclosureInterestsInAssociatesDetails", "longName": "42201 - Disclosure - Interests in associates (Details)", "shortName": "Interests in associates (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "76", "firstAnchor": { "contextRef": "As_Of_12_31_2025_qdGpNZKgIka9Py92H_fPTA", "name": "ifrs-full:InvestmentsInAssociatesAccountedForUsingEquityMethod", "unitRef": "Unit_Standard_CHF_veB9_Q4q_kaAYWswP-S8rw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_3_31_2026_ifrs-full_SignificantInvestmentsInAssociatesAxis_adxn_NeurosterixGroupMember_Q5GLW5iWfkCyo5FUbSfdrw", "name": "ifrs-full:InvestmentsInAssociatesAccountedForUsingEquityMethod", "unitRef": "Unit_Standard_CHF_veB9_Q4q_kaAYWswP-S8rw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfSignificantInvestmentsInAssociatesExplanatory", "ifrs-full:DisclosureOfInterestsInAssociatesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "unique": true } }, "R77": { "role": "http://addextherapeutics.com/role/DisclosureFinancialAssetsAtFairValueThroughOtherComprehensiveIncomeDetails", "longName": "42301 - Disclosure - Financial assets at fair value through other comprehensive income (Details)", "shortName": "Financial assets at fair value through other comprehensive income (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "77", "firstAnchor": { "contextRef": "As_Of_6_30_2026_nEpApE3lTkmeh-lEOADX7g", "name": "ifrs-full:NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome", "unitRef": "Unit_Standard_CHF_veB9_Q4q_kaAYWswP-S8rw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_6_1_2025_To_6_30_2025_ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_adxn_StaliclaSaMember_aTva7aGtQUOa2h8VPVwVtQ", "name": "adxn:PreferredSharesReceivedOnInvestment", "unitRef": "Unit_Standard_shares_b4NqgRzstk-fxCOn6_iHqA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ifrs-full:DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "unique": true } }, "R78": { "role": "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails", "longName": "42401 - Disclosure - Derivative financial instruments (Details)", "shortName": "Derivative financial instruments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "78", "firstAnchor": { "contextRef": "As_Of_6_30_2026_nEpApE3lTkmeh-lEOADX7g", "name": "ifrs-full:NoncurrentDerivativeFinancialAssets", "unitRef": "Unit_Standard_CHF_veB9_Q4q_kaAYWswP-S8rw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2026_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level3OfFairValueHierarchyMember_ifrs-full_MeasurementAxis_ifrs-full_AtFairValueMember_x6CIZr75PUWc4_K3eBZrFg", "name": "ifrs-full:FinancialAssets", "unitRef": "Unit_Standard_CHF_veB9_Q4q_kaAYWswP-S8rw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfFairValueMeasurementOfAssetsExplanatory", "ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "unique": true } }, "R79": { "role": "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsInputsDetails", "longName": "42402 - Disclosure - Derivative financial instruments - inputs (Details)", "shortName": "Derivative financial instruments - inputs (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "79", "firstAnchor": { "contextRef": "As_Of_6_30_2026_ifrs-full_ClassesOfFinancialInstrumentsAxis_ifrs-full_PreferenceSharesMember_MFye9iCMKUqycuPRrwJKXg", "name": "ifrs-full:FinancialAssets", "unitRef": "Unit_Standard_CHF_veB9_Q4q_kaAYWswP-S8rw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfAssetsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2026_ifrs-full_ClassesOfFinancialInstrumentsAxis_ifrs-full_PreferenceSharesMember_ifrs-full_UnobservableInputsAxis_adxn_UnderlyingSharePriceMember_CBxYmgEyZ0aYCzSNDkXWGg", "name": "ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputAssets", "unitRef": "Unit_Standard_pure_5WMDik9kYEScz0Evx4PwGw", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "ifrs-full:PercentageOfReasonablyPossibleDecreaseInUnobservableInputAssets", "ifrs-full:PercentageOfReasonablyPossibleDecreaseInUnobservableInputAssets", "div", "ifrs-full:DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfAssetsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "unique": true } }, "R80": { "role": "http://addextherapeutics.com/role/DisclosureLossPerShareDetails", "longName": "42501 - Disclosure - Loss per share (Details)", "shortName": "Loss per share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "80", "firstAnchor": { "contextRef": "Duration_4_1_2026_To_6_30_2026_ZsBj5eF9f0uttRvc3J0eBQ", "name": "ifrs-full:ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity", "unitRef": "Unit_Standard_CHF_veB9_Q4q_kaAYWswP-S8rw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:EarningsPerShareExplanatory", "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_4_1_2026_To_6_30_2026_ZsBj5eF9f0uttRvc3J0eBQ", "name": "ifrs-full:ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity", "unitRef": "Unit_Standard_CHF_veB9_Q4q_kaAYWswP-S8rw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:EarningsPerShareExplanatory", "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true } }, "R81": { "role": "http://addextherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails", "longName": "42601 - Disclosure - Related party transactions (Details)", "shortName": "Related party transactions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "81", "firstAnchor": { "contextRef": "Duration_4_1_2026_To_6_30_2026_ZsBj5eF9f0uttRvc3J0eBQ", "name": "adxn:KeyManagementPersonnelCompensationSalariesOtherShortTermEmployeeBenefitsAndPostEmploymentBenefits", "unitRef": "Unit_Standard_CHF_veB9_Q4q_kaAYWswP-S8rw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory", "ifrs-full:DisclosureOfRelatedPartyExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_4_1_2026_To_6_30_2026_ZsBj5eF9f0uttRvc3J0eBQ", "name": "adxn:KeyManagementPersonnelCompensationSalariesOtherShortTermEmployeeBenefitsAndPostEmploymentBenefits", "unitRef": "Unit_Standard_CHF_veB9_Q4q_kaAYWswP-S8rw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory", "ifrs-full:DisclosureOfRelatedPartyExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true, "unique": true } }, "R82": { "role": "http://addextherapeutics.com/role/DisclosureEventsAfterBalanceSheetDateDetails", "longName": "42701 - Disclosure - Events after the balance sheet date (Details)", "shortName": "Events after the balance sheet date (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "82", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_dCDbcN4ixkm5Px7HaCcpBQ", "name": "adxn:SaleOfTreasuryShares", "unitRef": "Unit_Standard_shares_b4NqgRzstk-fxCOn6_iHqA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2026_To_8_25_2026_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_ifrs-full_MajorOrdinaryShareTransactionsMember_DhxzarG2yEOfWjfnvgDeHg", "name": "adxn:ShareSalePrice", "unitRef": "Unit_Divide_CHF_shares_Qqax5XN9gk-jVZ_6uNeu0A", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "p", "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adxn-20260630xex99d1.htm", "unique": true } } }, "tag": { "ifrs-full_AccrualsClassifiedAsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AccrualsClassifiedAsCurrent", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/DisclosurePayablesAccrualsAndOtherCurrentLiabilitiesDetails": { "parentTag": "adxn_TradeAndOtherCurrentPayablesAndOtherCurrentLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosurePayablesAccrualsAndOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Accruals classified as current", "terseLabel": "Accrued expenses" } }, "en": { "role": { "documentation": "The amount of accruals classified as current. [Refer: Accruals]" } } }, "auth_ref": [ "r282" ] }, "ifrs-full_AccumulatedDepreciationAndAmortisationMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AccumulatedDepreciationAndAmortisationMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureEquipmentDetails", "http://addextherapeutics.com/role/DisclosureIntangibleAssetsDetails", "http://addextherapeutics.com/role/DisclosureRightOfUseAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Accumulated depreciation", "terseLabel": "Accumulated depreciation" } } }, "auth_ref": [ "r7", "r259", "r265", "r266", "r267" ] }, "ifrs-full_AccumulatedImpairmentMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AccumulatedImpairmentMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Accumulated impairment" } } }, "auth_ref": [ "r103", "r109", "r181", "r241", "r259", "r265", "r266", "r267" ] }, "adxn_AcquisitionOfSharesForfeitedFromDeferredStrikePricePaymentPlan": { "xbrltype": "sharesItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "AcquisitionOfSharesForfeitedFromDeferredStrikePricePaymentPlan", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "Acquisition of shares forfeited from Deferred Strike Price Payment Plan (DSPPP).", "label": "Acquisition Of Shares Forfeited From Deferred Strike Price Payment Plan", "negatedLabel": "Acquisition of shares forfeited from DSPPP" } } }, "auth_ref": [] }, "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill", "crdr": "debit", "presentation": [ "http://addextherapeutics.com/role/DisclosureIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Additions other than through business combinations, intangible assets other than goodwill", "terseLabel": "Additions" } }, "en": { "role": { "documentation": "The amount of additions to intangible assets other than goodwill, other than those acquired through business combinations. [Refer: Total for all business combinations [member]; Intangible assets other than goodwill]" } } }, "auth_ref": [ "r43", "r162" ] }, "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsRightofuseAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdditionsOtherThanThroughBusinessCombinationsRightofuseAssets", "crdr": "debit", "presentation": [ "http://addextherapeutics.com/role/DisclosureRightOfUseAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Additions other than through business combinations, right-of-use assets", "terseLabel": "Additions" } }, "en": { "role": { "documentation": "The amount of additions to right-of-use assets other than those acquired through business combinations. [Refer: Total for all business combinations [member]; Right-of-use assets]" } } }, "auth_ref": [ "r260" ] }, "ifrs-full_AdjustedWeightedAverageShares": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustedWeightedAverageShares", "presentation": [ "http://addextherapeutics.com/role/DisclosureLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average number of ordinary shares used in calculating diluted earnings per share", "terseLabel": "Weighed average number of shares in issue - diluted" } }, "en": { "role": { "documentation": "The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]" } } }, "auth_ref": [ "r34" ] }, "adxn_AdjustmentsForCostOfFairValueOfServicesReceivedAtZeroCost": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "AdjustmentsForCostOfFairValueOfServicesReceivedAtZeroCost", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Adjustments for cost of fair value of services received at zero cost", "label": "Adjustments for cost of fair value of services received at zero cost", "terseLabel": "Fair value of services received at zero cost recorded as other operating costs" } } }, "auth_ref": [] }, "adxn_AdjustmentsForDecreaseIncreaseInMiscellaneousOtherCurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "AdjustmentsForDecreaseIncreaseInMiscellaneousOtherCurrentAssets", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 14.0 } }, "presentation": [ "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Adjustments for decrease (increase) in miscellaneous other current assets", "label": "Adjustments for decrease (increase) in miscellaneous other current assets", "terseLabel": "Decrease in other current assets" } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForDecreaseIncreaseInOtherFinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForDecreaseIncreaseInOtherFinancialAssets", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments for decrease (increase) in other financial assets", "verboseLabel": "Decrease / (increase) in other financial assets" } }, "en": { "role": { "documentation": "Adjustments for decrease (increase) in financial assets that the entity does not separately disclose in the same statement or note to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Other financial assets; Profit (loss)]" } } }, "auth_ref": [ "r271" ] }, "ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForDecreaseIncreaseInPrepaidExpenses", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments for decrease (increase) in prepayments", "verboseLabel": "Increase in prepayments" } }, "en": { "role": { "documentation": "Adjustments for the decrease (increase) in prepaid expenses to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Current prepaid expenses; Profit (loss)]" } } }, "auth_ref": [ "r271" ] }, "ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments for decrease (increase) in trade and other receivables", "verboseLabel": "Decrease / (increase) in trade and other receivables" } }, "en": { "role": { "documentation": "Adjustments for decrease (increase) in trade and other receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other receivables; Profit (loss)]" } } }, "auth_ref": [ "r271" ] }, "ifrs-full_AdjustmentsForDepreciationExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForDepreciationExpense", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments for depreciation expense", "terseLabel": "Depreciation" } }, "en": { "role": { "documentation": "Adjustments for depreciation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r271" ] }, "ifrs-full_AdjustmentsForFinanceIncomeCost": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForFinanceIncomeCost", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments for finance income (cost)", "negatedLabel": "Finance cost net" } } }, "auth_ref": [ "r271" ] }, "adxn_AdjustmentsForGainLossOnDiscontinuanceNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "AdjustmentsForGainLossOnDiscontinuanceNetOfTax", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Adjustments for gain (loss), net of tax on discontinuance when operations are discontinued to reconcile profit (loss) to net cash flow from (used in) operating activities.", "label": "Adjustments for Gain (Loss) On Discontinuance, Net Of Tax", "negatedLabel": "Net gain on Neurosterix Transaction" } } }, "auth_ref": [] }, "adxn_AdjustmentsForIncomeOfFairValueOfServicesReceivedAtZeroCost": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "AdjustmentsForIncomeOfFairValueOfServicesReceivedAtZeroCost", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": -1.0, "order": 11.0 } }, "presentation": [ "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Adjustments for income of fair value of services received at zero cost", "label": "Adjustments for income of fair value of services received at zero cost", "negatedLabel": "Fair value of services received at zero cost recorded as income" } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForIncreaseDecreaseInOtherLiabilities", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments for increase (decrease) in other liabilities", "terseLabel": "Increase in other liabilities" } }, "en": { "role": { "documentation": "Adjustments for increase (decrease) in other liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Other liabilities; Profit (loss)]" } } }, "auth_ref": [ "r271" ] }, "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments for increase (decrease) in trade and other payables", "terseLabel": "Increase in payables and accruals" } }, "en": { "role": { "documentation": "Adjustments for increase (decrease) in trade and other payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other payables; Profit (loss)]" } } }, "auth_ref": [ "r271" ] }, "ifrs-full_AdjustmentsForProvisions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForProvisions", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments for provisions", "verboseLabel": "Post-employment benefits" } } }, "auth_ref": [ "r270" ] }, "ifrs-full_AdjustmentsForReconcileProfitLossAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForReconcileProfitLossAbstract", "presentation": [ "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile profit (loss) [abstract]", "terseLabel": "Adjustments for:" } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForSharebasedPayments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForSharebasedPayments", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments for share-based payments", "terseLabel": "Value of share-based services" } } }, "auth_ref": [ "r270" ] }, "ifrs-full_AdjustmentsForUndistributedProfitsOfAssociates": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForUndistributedProfitsOfAssociates", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": -1.0, "order": 13.0 } }, "presentation": [ "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsParenthetical" ], "lang": { "en-us": { "role": { "label": "Adjustments for undistributed profits of associates", "negatedLabel": "Share of the net loss of associates" } } }, "auth_ref": [ "r270" ] }, "dei_AdrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AdrMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureEventsAfterBalanceSheetDateDetails", "http://addextherapeutics.com/role/DisclosureShareCapitalDetails" ], "lang": { "en-us": { "role": { "label": "American Depositary Shares", "terseLabel": "ADS", "documentation": "American Depositary Receipt (or American Depositary Share, ADS)." } } }, "auth_ref": [ "r258" ] }, "currency_AllCurrenciesDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2025", "localname": "AllCurrenciesDomain", "presentation": [ "http://addextherapeutics.com/role/DisclosureCashAndCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "label": "All Currencies [Domain]" } } }, "auth_ref": [] }, "adxn_AllostericModulatorDrugDiscoveryTechnologyPlatformAndPortfolioOfPreclinicalProgramsDisposalGroupDiscontinuedOperationsMember": { "xbrltype": "domainItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "AllostericModulatorDrugDiscoveryTechnologyPlatformAndPortfolioOfPreclinicalProgramsDisposalGroupDiscontinuedOperationsMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsGeneralDetails", "http://addextherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for allosteric modulator drug discovery technology platform and a portfolio of preclinical programs constituting as discontinued operations.", "label": "Allosteric Modulator Drug Discovery Technology Platform And A Portfolio Of Preclinical Programs, Disposal Group, Discontinued Operations [Member]", "terseLabel": "Discontinued operations as disclosed below" } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AmendmentFlag", "presentation": [ "http://addextherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "adxn_AmountNotRecordedAsPhantomSharesDueToCapOnFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "AmountNotRecordedAsPhantomSharesDueToCapOnFairValue", "crdr": "debit", "presentation": [ "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount not recorded as phantom shares due to cap on fair value", "label": "Amount not recorded as phantom shares due to cap on fair value" } } }, "auth_ref": [] }, "adxn_AmountOfCommitmentFundingReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "AmountOfCommitmentFundingReceived", "crdr": "debit", "presentation": [ "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsGeneralDetails" ], "lang": { "en-us": { "role": { "documentation": "The cash inflow from committed funding.", "label": "Amount of Commitment Funding Received", "terseLabel": "Amount of committed funding received" } } }, "auth_ref": [] }, "adxn_AmountOfEquityInterestReceivedOnDisposalOfDiscontinuedOperation": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "AmountOfEquityInterestReceivedOnDisposalOfDiscontinuedOperation", "crdr": "credit", "presentation": [ "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsGeneralDetails", "http://addextherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of equity interest received on disposal of discontinued operation", "label": "Amount of equity interest received on disposal of discontinued operation", "terseLabel": "Fair value of Neurosterix US Holdings LLC's participation", "verboseLabel": "Value of equity interest received" } } }, "auth_ref": [] }, "ifrs-full_AmountsPayableRelatedPartyTransactions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AmountsPayableRelatedPartyTransactions", "crdr": "credit", "presentation": [ "http://addextherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Amounts payable, related party transactions", "terseLabel": "Net payable" } }, "en": { "role": { "documentation": "The amounts payable resulting from related party transactions. [Refer: Total for all related parties [member]]" } } }, "auth_ref": [ "r20", "r23", "r153" ] }, "adxn_AntiDilutionProtectionMember": { "xbrltype": "domainItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "AntiDilutionProtectionMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails", "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsInputsDetails" ], "lang": { "en-us": { "role": { "documentation": "Anti-dilution protection", "label": "Anti-dilution protection" } } }, "auth_ref": [] }, "ifrs-full_Assets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Assets", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://addextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets", "totalLabel": "Total assets" } }, "en": { "role": { "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits." } } }, "auth_ref": [ "r79", "r80", "r82", "r119", "r121", "r186", "r187", "r210" ] }, "ifrs-full_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AssetsAbstract", "presentation": [ "http://addextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets [abstract]", "terseLabel": "ASSETS" } } }, "auth_ref": [] }, "ifrs-full_AtFairValueMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AtFairValueMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "label": "At fair value [member]", "terseLabel": "Measured at fair value" } }, "en": { "role": { "documentation": "This member stands for measurement based on fair value. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date." } } }, "auth_ref": [ "r48", "r52", "r67", "r79", "r169", "r185", "r186" ] }, "adxn_BalanceSheetLocationMember": { "xbrltype": "domainItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "BalanceSheetLocationMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "Balance sheet location", "label": "Balance sheet location [Member]" } } }, "auth_ref": [] }, "ifrs-full_BasicEarningsLossPerShare": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BasicEarningsLossPerShare", "calculation": { "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureLossPerShareDetails", "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Basic earnings (loss) per share", "totalLabel": "Basic loss per share for loss attributable to the ordinary equity holders of the Company" } }, "en": { "role": { "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator)." } } }, "auth_ref": [ "r31", "r32" ] }, "ifrs-full_BasicEarningsLossPerShareFromContinuingOperations": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BasicEarningsLossPerShareFromContinuingOperations", "calculation": { "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss": { "parentTag": "ifrs-full_BasicEarningsLossPerShare", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureLossPerShareDetails", "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Basic earnings (loss) per share from continuing operations", "terseLabel": "From continuing operations" } }, "en": { "role": { "documentation": "Basic earnings (loss) per share from continuing operations. [Refer: Basic earnings (loss) per share; Continuing operations, unless line item indicates otherwise [member]]" } } }, "auth_ref": [ "r31", "r32" ] }, "ifrs-full_BasicEarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BasicEarningsPerShareAbstract", "presentation": [ "http://addextherapeutics.com/role/DisclosureLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Basic earnings per share [abstract]", "terseLabel": "Basic profit / (loss) per share" } } }, "auth_ref": [] }, "adxn_BasisOfPreparationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "BasisOfPreparationAbstract", "lang": { "en-us": { "role": { "documentation": "Basis of preparation.", "label": "Basis of preparation" } } }, "auth_ref": [] }, "ifrs-full_BottomOfRangeMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BottomOfRangeMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsInputsDetails" ], "lang": { "en-us": { "role": { "label": "Minimum", "terseLabel": "Minimum" } }, "en": { "role": { "documentation": "This member stands for the bottom of a range." } } }, "auth_ref": [ "r58", "r85", "r96", "r100", "r138", "r235", "r236", "r277" ] }, "country_CH": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2025", "localname": "CH", "presentation": [ "http://addextherapeutics.com/role/DisclosureSegmentInformationDetails" ], "lang": { "en-us": { "role": { "label": "SWITZERLAND", "terseLabel": "Switzerland" } } }, "auth_ref": [] }, "currency_CHF": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2025", "localname": "CHF", "presentation": [ "http://addextherapeutics.com/role/DisclosureCashAndCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "label": "CHF" } } }, "auth_ref": [] }, "ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis", "presentation": [ "http://addextherapeutics.com/role/DisclosureEquipmentDetails", "http://addextherapeutics.com/role/DisclosureIntangibleAssetsDetails", "http://addextherapeutics.com/role/DisclosureOtherCurrentAssetsDetails", "http://addextherapeutics.com/role/DisclosureRightOfUseAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r2", "r4", "r42", "r44", "r49", "r50", "r51", "r52", "r53", "r103", "r109", "r110", "r141", "r143", "r161", "r163", "r166", "r167", "r168", "r169", "r170", "r177", "r181", "r182" ] }, "ifrs-full_CarryingAmountMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CarryingAmountMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureEquipmentDetails", "http://addextherapeutics.com/role/DisclosureIntangibleAssetsDetails", "http://addextherapeutics.com/role/DisclosureOtherCurrentAssetsDetails", "http://addextherapeutics.com/role/DisclosureRightOfUseAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Carrying amount [member]" } } }, "auth_ref": [ "r4", "r44", "r49", "r51", "r52", "r103", "r109", "r110", "r143", "r163", "r166", "r168", "r169", "r177", "r181", "r182" ] }, "ifrs-full_Cash": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Cash", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/DisclosureCashAndCashEquivalentsDetails": { "parentTag": "ifrs-full_CashAndCashEquivalents", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureCashAndCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "label": "Cash", "terseLabel": "Cash at bank and on hand" } }, "en": { "role": { "documentation": "The amount of cash on hand and demand deposits. [Refer: Cash on hand]" } } }, "auth_ref": [ "r272" ] }, "adxn_CashAndCashEquivalentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "CashAndCashEquivalentLineItems", "presentation": [ "http://addextherapeutics.com/role/DisclosureCashAndCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "documentation": "Cash and cash equivalents", "label": "Cash and cash equivalent [Line Items]", "terseLabel": "Cash and cash equivalents" } } }, "auth_ref": [] }, "ifrs-full_CashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashAndCashEquivalents", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 1.0 }, "http://addextherapeutics.com/role/DisclosureCashAndCashEquivalentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureCashAndCashEquivalentsDetails", "http://addextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets", "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash and cash equivalents.", "periodEndLabel": "Cash and cash equivalents at the end of the period", "periodStartLabel": "Cash and cash equivalents at the beginning of the period", "terseLabel": "Cash and cash equivalents", "totalLabel": "Total cash and cash equivalents" } }, "en": { "role": { "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]" } } }, "auth_ref": [ "r59", "r76", "r139", "r208" ] }, "ifrs-full_CashAndCashEquivalentsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashAndCashEquivalentsAbstract", "lang": { "en-us": { "role": { "label": "Cash and cash equivalents" } } }, "auth_ref": [] }, "adxn_CashAndCashEquivalentsTable": { "xbrltype": "stringItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "CashAndCashEquivalentsTable", "presentation": [ "http://addextherapeutics.com/role/DisclosureCashAndCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "documentation": "Cash and cash equivalents", "label": "Cash and cash equivalents [Table]" } } }, "auth_ref": [] }, "ifrs-full_CashFlowsFromUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) financing activities", "totalLabel": "Net cash from financing activities" } }, "en": { "role": { "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity, from continuing and discontinued operations." } } }, "auth_ref": [ "r54", "r60" ] }, "ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInFinancingActivitiesAbstract", "presentation": [ "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) financing activities [abstract]", "terseLabel": "Cash flows from financing activities" } } }, "auth_ref": [] }, "ifrs-full_CashFlowsFromUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) investing activities", "totalLabel": "Net cash used in investing activities" } }, "en": { "role": { "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents, from continuing and discontinued operations." } } }, "auth_ref": [ "r54", "r60" ] }, "ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInInvestingActivitiesAbstract", "presentation": [ "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) investing activities [abstract]", "terseLabel": "Cash flows used in investing activities" } } }, "auth_ref": [] }, "ifrs-full_CashFlowsFromUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInOperatingActivities", "calculation": { "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) operating activities", "totalLabel": "Net cash used in operating activities" } } }, "auth_ref": [ "r54", "r60" ] }, "ifrs-full_CategoriesOfFinancialAssetsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CategoriesOfFinancialAssetsAxis", "presentation": [ "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "label": "Categories of financial assets [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r116", "r180" ] }, "ifrs-full_CategoriesOfFinancialAssetsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CategoriesOfFinancialAssetsDomain", "presentation": [ "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "label": "Categories of financial assets [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregated categories of financial assets. It also represents the standard value for the 'Categories of financial assets' axis if no other member is used. [Refer: Financial assets]" } } }, "auth_ref": [ "r116", "r180" ] }, "ifrs-full_CategoriesOfNoncurrentFinancialAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CategoriesOfNoncurrentFinancialAssetsAbstract", "lang": { "en-us": { "role": { "label": "Non-current financial assets" } } }, "auth_ref": [] }, "ifrs-full_CategoriesOfRelatedPartiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CategoriesOfRelatedPartiesAxis", "presentation": [ "http://addextherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Categories of related parties [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r22", "r155" ] }, "ifrs-full_CategoriesOfRelatedPartiesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CategoriesOfRelatedPartiesDomain", "presentation": [ "http://addextherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Categories of related parties [domain]" } }, "en": { "role": { "documentation": "This member stands for the standard value for the 'Categories of related parties' axis if no other member is used." } } }, "auth_ref": [ "r22", "r155" ] }, "ifrs-full_ClassesOfAssetsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfAssetsAxis", "presentation": [ "http://addextherapeutics.com/role/DisclosureRightOfUseAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Classes of assets [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r37", "r39", "r84", "r95", "r131", "r159", "r188" ] }, "ifrs-full_ClassesOfAssetsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfAssetsDomain", "presentation": [ "http://addextherapeutics.com/role/DisclosureRightOfUseAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Classes of assets [domain]" } }, "en": { "role": { "documentation": "This member stands for a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits. It also represents the standard value for the 'Classes of assets' axis if no other member is used." } } }, "auth_ref": [ "r37", "r84", "r95", "r131", "r159", "r188" ] }, "ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfEmployeeBenefitsExpenseAbstract", "lang": { "en-us": { "role": { "label": "Staff costs" } } }, "auth_ref": [] }, "ifrs-full_ClassesOfFinancialInstrumentsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfFinancialInstrumentsAxis", "presentation": [ "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails", "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsInputsDetails", "http://addextherapeutics.com/role/DisclosureOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Classes of financial instruments [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r109", "r111", "r112", "r113", "r181", "r183" ] }, "ifrs-full_ClassesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfFinancialInstrumentsDomain", "presentation": [ "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails", "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsInputsDetails", "http://addextherapeutics.com/role/DisclosureOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Classes of financial instruments [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregated classes of financial instruments. Financial instruments are contracts that give rise to a financial asset of one entity and a financial liability or equity instrument of another entity. It also represents the standard value for the 'Classes of financial instruments' axis if no other member is used. [Refer: Financial assets; Financial liabilities]" } } }, "auth_ref": [ "r109", "r111", "r112", "r113", "r181", "r183" ] }, "ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfIntangibleAssetsOtherThanGoodwillAxis", "presentation": [ "http://addextherapeutics.com/role/DisclosureIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Classes of intangible assets other than goodwill [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r45", "r164" ] }, "ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfIntangibleAssetsOtherThanGoodwillDomain", "presentation": [ "http://addextherapeutics.com/role/DisclosureIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Classes of intangible assets other than goodwill [domain]" } }, "en": { "role": { "documentation": "This member stands for the standard value for the 'Classes of intangible assets other than goodwill' axis if no other member is used." } } }, "auth_ref": [ "r45", "r164" ] }, "ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfPropertyPlantAndEquipmentAxis", "presentation": [ "http://addextherapeutics.com/role/DisclosureEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Classes of property, plant and equipment [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r5", "r144" ] }, "ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfPropertyPlantAndEquipmentDomain", "presentation": [ "http://addextherapeutics.com/role/DisclosureEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Classes of property, plant and equipment [domain]" } }, "en": { "role": { "documentation": "This member stands for the standard value for the 'Classes of property, plant and equipment' axis if no other member is used." } } }, "auth_ref": [ "r5", "r144" ] }, "ifrs-full_ClassesOfShareCapitalAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfShareCapitalAxis", "presentation": [ "http://addextherapeutics.com/role/DisclosureEventsAfterBalanceSheetDateDetails", "http://addextherapeutics.com/role/DisclosureShareCapitalDetails" ], "lang": { "en-us": { "role": { "label": "Classes of share capital [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r136", "r191", "r218" ] }, "ifrs-full_ClassesOfShareCapitalDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfShareCapitalDomain", "presentation": [ "http://addextherapeutics.com/role/DisclosureEventsAfterBalanceSheetDateDetails", "http://addextherapeutics.com/role/DisclosureShareCapitalDetails" ], "lang": { "en-us": { "role": { "label": "Classes of share capital [domain]" } }, "en": { "role": { "documentation": "This member stands for share capital of the entity. It also represents the standard value for the 'Classes of share capital' axis if no other member is used." } } }, "auth_ref": [ "r136", "r191", "r218" ] }, "ifrs-full_ComponentsOfEquityAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ComponentsOfEquityAxis", "presentation": [ "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Components of equity [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r201" ] }, "ifrs-full_ComponentsOfEquityDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ComponentsOfEquityDomain", "presentation": [ "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Components of equity [domain]" } }, "en": { "role": { "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used." } } }, "auth_ref": [ "r201" ] }, "ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract", "presentation": [ "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Components of other comprehensive income that will be reclassified to profit or loss, net of tax [abstract]", "verboseLabel": "Items that may be classified subsequently to profit or loss:" } } }, "auth_ref": [] }, "ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract", "presentation": [ "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Components of other comprehensive income that will not be reclassified to profit or loss, net of tax [abstract]", "verboseLabel": "Items that will never be reclassified to profit or loss :" } } }, "auth_ref": [] }, "ifrs-full_ComprehensiveIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ComprehensiveIncome", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://addextherapeutics.com/role/DisclosureConsolidatedStatementsOfComprehensiveProfitOrLossCalc2": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfChangesInEquity", "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Comprehensive income", "totalLabel": "Total comprehensive loss for the period" } }, "en": { "role": { "documentation": "The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners." } } }, "auth_ref": [ "r62", "r64", "r72", "r157", "r172", "r197", "r222", "r234" ] }, "ifrs-full_ComprehensiveIncomeFromContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ComprehensiveIncomeFromContinuingOperations", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/DisclosureConsolidatedStatementsOfComprehensiveProfitOrLossCalc2": { "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Comprehensive income from continuing operations", "terseLabel": "From continuing operations" } }, "en": { "role": { "documentation": "The comprehensive income from continuing operations. [Refer: Continuing operations, unless line item indicates otherwise [member]; Comprehensive income]" } } }, "auth_ref": [ "r276" ] }, "ifrs-full_ComprehensiveIncomeFromDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ComprehensiveIncomeFromDiscontinuedOperations", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/DisclosureConsolidatedStatementsOfComprehensiveProfitOrLossCalc2": { "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Comprehensive income from discontinued operations", "terseLabel": "From discontinued operations" } }, "en": { "role": { "documentation": "The comprehensive income from discontinued operations. [Refer: Discontinued operations [member]; Comprehensive income]" } } }, "auth_ref": [ "r276" ] }, "ifrs-full_ContinuingAndDiscontinuedOperationsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ContinuingAndDiscontinuedOperationsAxis", "presentation": [ "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsGeneralDetails", "http://addextherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Continuing and discontinued operations [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r107" ] }, "ifrs-full_ContinuingOperationsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ContinuingOperationsMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsGeneralDetails", "http://addextherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Continuing operations [member]" } }, "en": { "role": { "documentation": "This member stands for components of the entity that are not discontinued operations. A component of an entity comprises operations and cash flows that can be clearly distinguished, operationally and for financial reporting purposes, from the rest of the entity. This meaning may be overridden for line items which are either intrinsically related to discontinued operations (or disposal groups held for sale), or which are typically reported for the aggregate of continuing and discontinued. This member also represents the standard value for the 'Continuing and discontinued operations' axis if no other member is used. [Refer: Discontinued operations [member]; Aggregate continuing and discontinued operations [member]]" } } }, "auth_ref": [ "r107" ] }, "adxn_ContractAssetsAndTradeAndOtherReceivablesMember": { "xbrltype": "domainItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "ContractAssetsAndTradeAndOtherReceivablesMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Contract assets and trade and other receivables", "label": "Trade and other receivables" } } }, "auth_ref": [] }, "adxn_CostOfSaleOfTreasurySharesEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "CostOfSaleOfTreasurySharesEquity", "crdr": "debit", "presentation": [ "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "documentation": "Amount of costs on sale of treasury shares.", "label": "Cost of sale of treasury shares, equity", "negatedTerseLabel": "Costs related to the sale of treasury ADSs and shares" } } }, "auth_ref": [] }, "adxn_CostsPaidOnSaleOfTreasuryShares": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "CostsPaidOnSaleOfTreasuryShares", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Costs paid on sale of treasury shares", "label": "Costs paid on sale of treasury shares", "negatedLabel": "Cost paid on sale of treasury ADSs and shares" } } }, "auth_ref": [] }, "ifrs-full_CounterpartiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CounterpartiesAxis", "presentation": [ "http://addextherapeutics.com/role/DisclosureOtherIncomeDetails", "http://addextherapeutics.com/role/DisclosureRevenueFromContractWithCustomerDetails", "http://addextherapeutics.com/role/DisclosureShareCapitalDetails" ], "lang": { "en-us": { "role": { "label": "Counterparties [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r117" ] }, "ifrs-full_CounterpartiesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CounterpartiesDomain", "presentation": [ "http://addextherapeutics.com/role/DisclosureOtherIncomeDetails", "http://addextherapeutics.com/role/DisclosureRevenueFromContractWithCustomerDetails", "http://addextherapeutics.com/role/DisclosureShareCapitalDetails" ], "lang": { "en-us": { "role": { "label": "Counterparties [domain]" } }, "en": { "role": { "documentation": "This member stands for the parties to the transaction other than the entity. It also represents the standard value for the 'Counterparties' axis if no other member is used." } } }, "auth_ref": [ "r117" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Document and Entity Information", "documentation": "Cover page." } } }, "auth_ref": [] }, "adxn_CriticalAccountingEstimatesAndJudgmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "CriticalAccountingEstimatesAndJudgmentsAbstract", "lang": { "en-us": { "role": { "documentation": "Material accounting estimates and judgments", "label": "Material accounting estimates and judgments" } } }, "auth_ref": [] }, "srt_CurrencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "CurrencyAxis", "presentation": [ "http://addextherapeutics.com/role/DisclosureCashAndCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "label": "Currency [Axis]" } } }, "auth_ref": [] }, "ifrs-full_CurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentAssets", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "ifrs-full_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://addextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current assets", "totalLabel": "Total current assets" } }, "en": { "role": { "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]" } } }, "auth_ref": [ "r68", "r211", "r234" ] }, "ifrs-full_CurrentAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentAssetsAbstract", "presentation": [ "http://addextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current assets [abstract]", "terseLabel": "Current assets" } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://addextherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "ifrs-full_CurrentLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentLeaseLiabilities", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://addextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current lease liabilities", "terseLabel": "Current lease liabilities" } }, "en": { "role": { "documentation": "The amount of current lease liabilities. [Refer: Lease liabilities]" } } }, "auth_ref": [ "r91" ] }, "ifrs-full_CurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentLiabilities", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://addextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current liabilities", "totalLabel": "Total current liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period." } } }, "auth_ref": [ "r70", "r212", "r234" ] }, "ifrs-full_CurrentLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentLiabilitiesAbstract", "presentation": [ "http://addextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current liabilities [abstract]", "terseLabel": "Current liabilities" } } }, "auth_ref": [] }, "ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/DisclosurePayablesAccrualsAndOtherCurrentLiabilitiesDetails": { "parentTag": "adxn_TradeAndOtherCurrentPayablesAndOtherCurrentLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosurePayablesAccrualsAndOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Current payables on social security and taxes other than income tax", "terseLabel": "Social security and other taxes" } }, "en": { "role": { "documentation": "The amount of current payables on social security and taxes other than incomes tax. [Refer: Payables on social security and taxes other than income tax]" } } }, "auth_ref": [ "r282" ] }, "ifrs-full_CurrentPrepayments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentPrepayments", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/DisclosureOtherCurrentAssetsDetails": { "parentTag": "ifrs-full_OtherCurrentAssets", "weight": 1.0, "order": 1.0 }, "http://addextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureOtherCurrentAssetsDetails", "http://addextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current prepayments", "terseLabel": "Prepayments" } }, "en": { "role": { "documentation": "The amount of current prepayments. [Refer: Prepayments]" } } }, "auth_ref": [ "r248", "r254" ] }, "ifrs-full_CurrentServiceCostDefinedBenefitPlans": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentServiceCostDefinedBenefitPlans", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/DisclosureRetirementBenefitsObligationsComprehensiveLossDetails": { "parentTag": "ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureRetirementBenefitsObligationsComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "label": "Current service cost on defined benefit plans", "negatedLabel": "Current service cost" } } }, "auth_ref": [ "r261" ] }, "adxn_DeferredStrikePricePaymentPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "DeferredStrikePricePaymentPlanMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureEventsAfterBalanceSheetDateDetails", "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionsOrSharesOutstandingDetails" ], "lang": { "en-us": { "role": { "documentation": "Deferred Strike Price Payment Plan", "label": "Deferred Strike Price Payment Plan (DSPPP)", "terseLabel": "Deferred Strike Price Payment Plan" } } }, "auth_ref": [] }, "ifrs-full_DepreciationExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DepreciationExpense", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/DisclosureOperatingCostsDetails": { "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureOperatingCostsDetails" ], "lang": { "en-us": { "role": { "label": "Depreciation expense", "terseLabel": "Depreciation (notes 8/9)" } } }, "auth_ref": [ "r280" ] }, "ifrs-full_DepreciationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DepreciationPropertyPlantAndEquipment", "presentation": [ "http://addextherapeutics.com/role/DisclosureEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Depreciation, property, plant and equipment", "negatedLabel": "Depreciation charge" } } }, "auth_ref": [ "r3", "r6", "r142" ] }, "ifrs-full_DepreciationRightofuseAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DepreciationRightofuseAssets", "presentation": [ "http://addextherapeutics.com/role/DisclosureRightOfUseAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Depreciation, right-of-use assets", "negatedTerseLabel": "Depreciation charge" } } }, "auth_ref": [ "r92", "r128" ] }, "ifrs-full_DilutedEarningsLossPerShare": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DilutedEarningsLossPerShare", "calculation": { "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureLossPerShareDetails", "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Diluted earnings (loss) per share", "totalLabel": "Diluted loss per share for loss attributable to the ordinary equity holders of the Company" } }, "en": { "role": { "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]" } } }, "auth_ref": [ "r31", "r32" ] }, "ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DilutedEarningsLossPerShareFromContinuingOperations", "calculation": { "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss": { "parentTag": "ifrs-full_DilutedEarningsLossPerShare", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureLossPerShareDetails", "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Diluted earnings (loss) per share from continuing operations", "terseLabel": "From continuing operations" } }, "en": { "role": { "documentation": "Diluted earnings (loss) per share from continuing operations. [Refer: Continuing operations, unless line item indicates otherwise [member]; Diluted earnings (loss) per share]" } } }, "auth_ref": [ "r31", "r32" ] }, "ifrs-full_DilutedEarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DilutedEarningsPerShareAbstract", "presentation": [ "http://addextherapeutics.com/role/DisclosureLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Diluted earnings per share [abstract]", "terseLabel": "Diluted profit / (loss) per share" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfAccountingJudgementsAndEstimatesExplanatory", "presentation": [ "http://addextherapeutics.com/role/DisclosureMaterialAccountingEstimatesAndJudgments" ], "lang": { "en-us": { "role": { "label": "Disclosure of accounting judgements and estimates [text block]", "terseLabel": "Material accounting estimates and judgments" } }, "en": { "role": { "documentation": "The disclosure of judgements that management has made in the process of applying the entity's accounting policies that have the most significant effect on amounts recognised in the financial statements along with information about the assumptions that the entity makes about the future, and other major sources of estimation uncertainty at the end of the reporting period, that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next year. [Refer: Carrying amount [member]]" } } }, "auth_ref": [ "r278" ] }, "adxn_DisclosureOfAmountsRecognizedInBalanceSheetForEmploymentBenefitObligationsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "DisclosureOfAmountsRecognizedInBalanceSheetForEmploymentBenefitObligationsTableTextBlock", "presentation": [ "http://addextherapeutics.com/role/DisclosureRetirementBenefitsObligationsTables" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of amounts recognized in balance sheet for employment benefit obligations", "label": "Disclosure of amounts recognized in balance sheet for employment benefit obligations [Table Text Block]", "terseLabel": "Schedule of amounts recognized in balance sheet for employment benefit obligations" } } }, "auth_ref": [] }, "adxn_DisclosureOfAmountsRecognizedInProfitOrLossForEmploymentBenefitObligationsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "DisclosureOfAmountsRecognizedInProfitOrLossForEmploymentBenefitObligationsTableTextBlock", "presentation": [ "http://addextherapeutics.com/role/DisclosureRetirementBenefitsObligationsTables" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of amounts recognized in profit or loss for employment benefit obligations", "label": "Disclosure of amounts recognized in profit or loss for employment benefit obligations [Table Text Block]", "terseLabel": "Schedule of amounts recognized in statement of profit or loss for employment benefit obligations" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems", "presentation": [ "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsGeneralDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of analysis of single amount of discontinued operations [line items]", "terseLabel": "Disclosure" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsTable", "presentation": [ "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsGeneralDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of analysis of single amount of discontinued operations [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to the analysis of the single amount of discontinued operations." } } }, "auth_ref": [ "r106" ] }, "ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory", "presentation": [ "http://addextherapeutics.com/role/DisclosureBasisOfPreparation" ], "lang": { "en-us": { "role": { "label": "Disclosure of basis of preparation of financial statements [text block]", "terseLabel": "Basis of preparation" } } }, "auth_ref": [ "r278" ] }, "adxn_DisclosureOfCashAndCashEquivalentsByCurrencyTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "DisclosureOfCashAndCashEquivalentsByCurrencyTableTextBlock", "presentation": [ "http://addextherapeutics.com/role/DisclosureCashAndCashEquivalentsTables" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of cash and cash equivalents by currency", "label": "Disclosure of cash and cash equivalents by currency [Table Text Block]", "terseLabel": "Schedule of cash and cash equivalents by currency" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfCashAndCashEquivalentsExplanatory", "presentation": [ "http://addextherapeutics.com/role/DisclosureCashAndCashEquivalents" ], "lang": { "en-us": { "role": { "label": "Disclosure of cash and cash equivalents [text block]", "terseLabel": "Cash and cash equivalents" } }, "en": { "role": { "documentation": "The disclosure of cash and cash equivalents. [Refer: Cash and cash equivalents]" } } }, "auth_ref": [ "r278" ] }, "ifrs-full_DisclosureOfClassesOfShareCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfClassesOfShareCapitalAbstract", "lang": { "en-us": { "role": { "label": "Share capital." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfClassesOfShareCapitalExplanatory", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareCapitalTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of classes of share capital [text block]", "terseLabel": "Schedule of share capital" } }, "en": { "role": { "documentation": "The disclosure of classes of share capital. [Refer: Classes of share capital [domain]]" } } }, "auth_ref": [ "r136", "r191", "r218" ] }, "ifrs-full_DisclosureOfClassesOfShareCapitalLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfClassesOfShareCapitalLineItems", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareCapitalDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of classes of share capital [line items]", "terseLabel": "Share capital" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfClassesOfShareCapitalTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfClassesOfShareCapitalTable", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareCapitalDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of classes of share capital [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to classes of share capital." } } }, "auth_ref": [ "r136", "r191", "r218" ] }, "ifrs-full_DisclosureOfDefinedBenefitPlansAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDefinedBenefitPlansAbstract", "lang": { "en-us": { "role": { "label": "Retirement benefits obligations" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDefinedBenefitPlansExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDefinedBenefitPlansExplanatory", "presentation": [ "http://addextherapeutics.com/role/DisclosureRetirementBenefitsObligations" ], "lang": { "en-us": { "role": { "label": "Disclosure of defined benefit plans [text block]", "terseLabel": "Retirement benefits obligations" } }, "en": { "role": { "documentation": "The disclosure of defined benefit plans. [Refer: Defined benefit plans [domain]]" } } }, "auth_ref": [ "r9", "r145" ] }, "ifrs-full_DisclosureOfDefinedBenefitPlansLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDefinedBenefitPlansLineItems", "presentation": [ "http://addextherapeutics.com/role/DisclosureRetirementBenefitsObligationsBalanceSheetDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of defined benefit plans [line items]", "terseLabel": "Defined benefit plans" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDefinedBenefitPlansTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDefinedBenefitPlansTable", "presentation": [ "http://addextherapeutics.com/role/DisclosureRetirementBenefitsObligationsBalanceSheetDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of defined benefit plans [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to defined benefit plans." } } }, "auth_ref": [ "r9", "r145" ] }, "ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDerivativeFinancialInstrumentsExplanatory", "presentation": [ "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstruments" ], "lang": { "en-us": { "role": { "label": "Disclosure of derivative financial instruments [text block]", "terseLabel": "Derivative financial instruments" } }, "en": { "role": { "documentation": "The disclosure of derivative financial instruments. [Refer: Derivatives [member]]" } } }, "auth_ref": [ "r278" ] }, "adxn_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "DisclosureOfDetailedInformationAboutCashAndCashEquivalentsTableTextBlock", "presentation": [ "http://addextherapeutics.com/role/DisclosureCashAndCashEquivalentsTables" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of detailed information about cash and cash equivalents", "label": "Disclosure of detailed information about cash and cash equivalents [Table Text Block]", "terseLabel": "Schedule of cash and cash equivalents" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory", "presentation": [ "http://addextherapeutics.com/role/DisclosureIntangibleAssetsTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about intangible assets [text block]", "terseLabel": "Schedule of intangible assets" } }, "en": { "role": { "documentation": "The disclosure of detailed information about intangible assets. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r45", "r164" ] }, "adxn_DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsTableTextBlock", "presentation": [ "http://addextherapeutics.com/role/DisclosureNonCurrentFinancialAssetsTables" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of detailed information about non-current financial assets", "label": "Disclosure of detailed information about non-current financial assets [Table Text Block]", "terseLabel": "Schedule of non-current financial assets" } } }, "auth_ref": [] }, "adxn_DisclosureOfDetailedInformationAboutOtherCurrentAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "DisclosureOfDetailedInformationAboutOtherCurrentAssetsTableTextBlock", "presentation": [ "http://addextherapeutics.com/role/DisclosureOtherCurrentAssetsTables" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of detailed information about other current assets", "label": "Disclosure of detailed information about other current assets [Table Text Block]", "terseLabel": "Schedule of other current assets" } } }, "auth_ref": [] }, "adxn_DisclosureOfDetailedInformationAboutPayablesAndAccrualsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "DisclosureOfDetailedInformationAboutPayablesAndAccrualsTableTextBlock", "presentation": [ "http://addextherapeutics.com/role/DisclosurePayablesAccrualsAndOtherCurrentLiabilitiesTables" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of detailed information about payables and accruals", "label": "Disclosure of detailed information about payables and accruals [Table Text Block]", "terseLabel": "Schedule of payables, accruals and other current liabilities" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "presentation": [ "http://addextherapeutics.com/role/DisclosureEquipmentTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about property, plant and equipment [text block]", "terseLabel": "Schedule of changes in equipment" } }, "en": { "role": { "documentation": "The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r5", "r144" ] }, "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems", "presentation": [ "http://addextherapeutics.com/role/DisclosureRevenueFromContractWithCustomerDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of disaggregation of revenue from contracts with customers [line items]", "terseLabel": "Revenue from contract with customer" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable", "presentation": [ "http://addextherapeutics.com/role/DisclosureRevenueFromContractWithCustomerDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of disaggregation of revenue from contracts with customers [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to the disaggregation of revenue from contracts with customers." } } }, "auth_ref": [ "r87", "r127" ] }, "ifrs-full_DisclosureOfDiscontinuedOperationsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDiscontinuedOperationsExplanatory", "presentation": [ "http://addextherapeutics.com/role/DisclosureDiscontinuedOperations" ], "lang": { "en-us": { "role": { "label": "Disclosure of discontinued operations [text block]", "terseLabel": "Discontinued operations" } }, "en": { "role": { "documentation": "The disclosure of discontinued operations. [Refer: Discontinued operations [member]]" } } }, "auth_ref": [ "r278" ] }, "ifrs-full_DisclosureOfEarningsPerShareExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfEarningsPerShareExplanatory", "presentation": [ "http://addextherapeutics.com/role/DisclosureLossPerShare" ], "lang": { "en-us": { "role": { "label": "Disclosure of earnings per share [text block]", "terseLabel": "Loss per share" } }, "en": { "role": { "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r35" ] }, "ifrs-full_DisclosureOfEmployeeBenefitsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfEmployeeBenefitsExplanatory", "presentation": [ "http://addextherapeutics.com/role/DisclosureStaffCosts" ], "lang": { "en-us": { "role": { "label": "Disclosure of employee benefits [text block]", "terseLabel": "Staff costs" } }, "en": { "role": { "documentation": "The entire disclosure for employee benefits." } } }, "auth_ref": [ "r15" ] }, "ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfEntitysReportableSegmentsExplanatory", "presentation": [ "http://addextherapeutics.com/role/DisclosureSegmentReporting" ], "lang": { "en-us": { "role": { "label": "Disclosure of entity's operating segments [text block]", "terseLabel": "Segment reporting" } }, "en": { "role": { "documentation": "The entire disclosure for operating segments." } } }, "auth_ref": [ "r126" ] }, "ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfEventsAfterReportingPeriodExplanatory", "presentation": [ "http://addextherapeutics.com/role/DisclosureEventsAfterBalanceSheetDate" ], "lang": { "en-us": { "role": { "label": "Disclosure of events after reporting period [text block]", "terseLabel": "Events after the balance sheet date" } }, "en": { "role": { "documentation": "The entire disclosure for events after the reporting period." } } }, "auth_ref": [ "r1" ] }, "ifrs-full_DisclosureOfExpensesByNatureExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfExpensesByNatureExplanatory", "presentation": [ "http://addextherapeutics.com/role/DisclosureOperatingCostsTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of expenses by nature [text block]", "terseLabel": "Schedule of operating costs" } } }, "auth_ref": [ "r278" ] }, "ifrs-full_DisclosureOfExpensesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfExpensesExplanatory", "presentation": [ "http://addextherapeutics.com/role/DisclosureOperatingCosts" ], "lang": { "en-us": { "role": { "label": "Disclosure of expenses [text block]", "terseLabel": "Operating costs" } }, "en": { "role": { "documentation": "The disclosure of expenses." } } }, "auth_ref": [ "r278" ] }, "ifrs-full_DisclosureOfFairValueMeasurementOfAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFairValueMeasurementOfAssetsExplanatory", "presentation": [ "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of fair value measurement of assets [text block]", "terseLabel": "Schedule of fair value measurement of assets" } }, "en": { "role": { "documentation": "The disclosure of the fair value measurement of assets." } } }, "auth_ref": [ "r84", "r188" ] }, "ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFairValueMeasurementOfAssetsLineItems", "presentation": [ "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails", "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsInputsDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of fair value measurement of assets" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFairValueMeasurementOfAssetsTable", "presentation": [ "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails", "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsInputsDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of fair value measurement of assets [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to the fair value measurement of assets." } } }, "auth_ref": [ "r84", "r188" ] }, "adxn_DisclosureOfFairValueMeasurementOfDerivativeFinancialInstrumentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "DisclosureOfFairValueMeasurementOfDerivativeFinancialInstrumentsTextBlock", "presentation": [ "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of the fair value measurement of derivative financial instruments.", "label": "Disclosure of fair value measurement of derivative financial instruments [text block]", "terseLabel": "Schedule of fair value (level 3) of derivative financial instruments" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory", "presentation": [ "http://addextherapeutics.com/role/DisclosureFinancialAssetsAtFairValueThroughOtherComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Disclosure of fair value of investments in equity instruments designated at fair value through other comprehensive income [text block]", "terseLabel": "Financial assets at fair value through other comprehensive income" } }, "en": { "role": { "documentation": "The disclosure of the fair value of investments in equity instruments that the entity has designated at fair value through other comprehensive income. [Refer: Investments in equity instruments designated at fair value through other comprehensive income]" } } }, "auth_ref": [ "r195" ] }, "ifrs-full_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeLineItems", "presentation": [ "http://addextherapeutics.com/role/DisclosureFinancialAssetsAtFairValueThroughOtherComprehensiveIncomeDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of fair value of investments in equity instruments designated at fair value through other comprehensive income [line items]", "terseLabel": "Financial assets at fair value through other comprehensive income" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeTable", "presentation": [ "http://addextherapeutics.com/role/DisclosureFinancialAssetsAtFairValueThroughOtherComprehensiveIncomeDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of fair value of investments in equity instruments designated at fair value through other comprehensive income [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to the fair value of investments in equity instruments designated at fair value through other comprehensive income." } } }, "auth_ref": [ "r195" ] }, "ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinanceIncomeExpenseExplanatory", "presentation": [ "http://addextherapeutics.com/role/DisclosureFinanceResultNet" ], "lang": { "en-us": { "role": { "label": "Disclosure of finance income (cost) [text block]", "verboseLabel": "Finance result, net" } } }, "auth_ref": [ "r278" ] }, "adxn_DisclosureOfFinanceIncomeExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "DisclosureOfFinanceIncomeExpenseTableTextBlock", "presentation": [ "http://addextherapeutics.com/role/DisclosureFinanceResultNetTables" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of finance income (expense)", "label": "Disclosure of finance income (expense) [Table Text Block]", "terseLabel": "Schedule of finance result, net" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFinancialInstrumentsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinancialInstrumentsAbstract", "lang": { "en-us": { "role": { "label": "Derivative financial instruments" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory", "presentation": [ "http://addextherapeutics.com/role/DisclosureGeneralInformation" ], "lang": { "en-us": { "role": { "label": "Disclosure of general information about financial statements [text block]", "terseLabel": "General information" } }, "en": { "role": { "documentation": "The entire disclosure for general information about financial statements." } } }, "auth_ref": [ "r132", "r203" ] }, "ifrs-full_DisclosureOfGeographicalAreasExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfGeographicalAreasExplanatory", "presentation": [ "http://addextherapeutics.com/role/DisclosureSegmentReportingTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of geographical areas [text block]", "terseLabel": "Schedule of geographical areas" } }, "en": { "role": { "documentation": "The disclosure of geographical information." } } }, "auth_ref": [ "r124" ] }, "ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfInformationAboutKeyManagementPersonnelExplanatory", "presentation": [ "http://addextherapeutics.com/role/DisclosureRelatedPartyTransactionsTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of information about key management personnel [text block]", "terseLabel": "Schedule of key management compensation" } }, "en": { "role": { "documentation": "The disclosure of information about key management personnel. [Refer: Key management personnel of entity or parent [member]]" } } }, "auth_ref": [ "r278" ] }, "ifrs-full_DisclosureOfIntangibleAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfIntangibleAssetsAbstract", "lang": { "en-us": { "role": { "label": "Intangible assets" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfIntangibleAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfIntangibleAssetsExplanatory", "presentation": [ "http://addextherapeutics.com/role/DisclosureIntangibleAssets" ], "lang": { "en-us": { "role": { "label": "Disclosure of intangible assets [text block]", "terseLabel": "Intangible assets" } }, "en": { "role": { "documentation": "The entire disclosure for intangible assets." } } }, "auth_ref": [ "r47" ] }, "ifrs-full_DisclosureOfIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfIntangibleAssetsLineItems", "presentation": [ "http://addextherapeutics.com/role/DisclosureIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about intangible assets [line items]", "terseLabel": "Intangible assets" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfIntangibleAssetsTable", "presentation": [ "http://addextherapeutics.com/role/DisclosureIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about intangible assets [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to details of intangible assets." } } }, "auth_ref": [ "r45", "r164" ] }, "ifrs-full_DisclosureOfInterestsInAssociatesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfInterestsInAssociatesExplanatory", "presentation": [ "http://addextherapeutics.com/role/DisclosureInterestsInAssociates" ], "lang": { "en-us": { "role": { "label": "Disclosure of interests in associates [text block]", "terseLabel": "Interests in associates" } }, "en": { "role": { "documentation": "The disclosure of interests in associates. [Refer: Total for all associates [member]]" } } }, "auth_ref": [ "r65" ] }, "adxn_DisclosureOfInterimMeasurementNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "DisclosureOfInterimMeasurementNoteTextBlock", "presentation": [ "http://addextherapeutics.com/role/DisclosureInterimMeasurementNote" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of interim measurement note.", "label": "Disclosure Of Interim Measurement Note [Text Block]", "terseLabel": "Interim measurement note" } } }, "auth_ref": [] }, "adxn_DisclosureOfNonCurrentFinancialAssetsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "DisclosureOfNonCurrentFinancialAssetsTextBlock", "presentation": [ "http://addextherapeutics.com/role/DisclosureNonCurrentFinancialAssets" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of non-current financial assets", "label": "Disclosure of non-current financial assets [Text Block]", "terseLabel": "Non-current financial assets" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract", "lang": { "en-us": { "role": { "label": "Events after the balance sheet date" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems", "presentation": [ "http://addextherapeutics.com/role/DisclosureEventsAfterBalanceSheetDateDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of non-adjusting events after reporting period [line items]", "terseLabel": "Events after balance sheet date" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodTable", "presentation": [ "http://addextherapeutics.com/role/DisclosureEventsAfterBalanceSheetDateDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of non-adjusting events after reporting period [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to non-adjusting events after the reporting period." } } }, "auth_ref": [ "r0", "r140" ] }, "ifrs-full_DisclosureOfOperatingSegmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfOperatingSegmentsAbstract", "lang": { "en-us": { "role": { "label": "Segment reporting" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfOperatingSegmentsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfOperatingSegmentsLineItems", "presentation": [ "http://addextherapeutics.com/role/DisclosureSegmentInformationDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of operating segments [line items]", "terseLabel": "Segments" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfOperatingSegmentsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfOperatingSegmentsTable", "presentation": [ "http://addextherapeutics.com/role/DisclosureSegmentInformationDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of operating segments [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to operating segments." } } }, "auth_ref": [ "r119" ] }, "ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfOtherCurrentAssetsExplanatory", "presentation": [ "http://addextherapeutics.com/role/DisclosureOtherCurrentAssets" ], "lang": { "en-us": { "role": { "label": "Disclosure of other current assets [text block]", "terseLabel": "Other current assets" } }, "en": { "role": { "documentation": "The disclosure of other current assets. [Refer: Other current assets]" } } }, "auth_ref": [ "r278" ] }, "adxn_DisclosureOfOtherCurrentAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "DisclosureOfOtherCurrentAssetsLineItems", "presentation": [ "http://addextherapeutics.com/role/DisclosureOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of other current assets", "label": "Disclosure of other current assets [Line Items]", "terseLabel": "Other current assets" } } }, "auth_ref": [] }, "adxn_DisclosureOfOtherCurrentAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "DisclosureOfOtherCurrentAssetsTable", "presentation": [ "http://addextherapeutics.com/role/DisclosureOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of other current assets", "label": "Disclosure of other current assets [Table]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfOtherOperatingIncomeExplanatory", "presentation": [ "http://addextherapeutics.com/role/DisclosureOtherIncome" ], "lang": { "en-us": { "role": { "label": "Disclosure of other operating income [text block]", "terseLabel": "Other income" } } }, "auth_ref": [ "r278" ] }, "ifrs-full_DisclosureOfProductsAndServicesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfProductsAndServicesExplanatory", "presentation": [ "http://addextherapeutics.com/role/DisclosureSegmentReportingTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of products and services [text block]", "terseLabel": "Schedule of revenue from contract with customer and other income by nature" } }, "en": { "role": { "documentation": "The disclosure of the entity's products and services. [Refer: Products and services [domain]]" } } }, "auth_ref": [ "r123" ] }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfPropertyPlantAndEquipmentExplanatory", "presentation": [ "http://addextherapeutics.com/role/DisclosureEquipment" ], "lang": { "en-us": { "role": { "label": "Disclosure of property, plant and equipment [text block]", "terseLabel": "Equipment" } }, "en": { "role": { "documentation": "The entire disclosure for property, plant and equipment." } } }, "auth_ref": [ "r8" ] }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfPropertyPlantAndEquipmentLineItems", "presentation": [ "http://addextherapeutics.com/role/DisclosureEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about property, plant and equipment [line items]", "terseLabel": "Equipment" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfPropertyPlantAndEquipmentTable", "presentation": [ "http://addextherapeutics.com/role/DisclosureEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about property, plant and equipment [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to details of property, plant and equipment." } } }, "auth_ref": [ "r5", "r144" ] }, "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract", "lang": { "en-us": { "role": { "label": "Right-of-use assets" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory", "presentation": [ "http://addextherapeutics.com/role/DisclosureRightOfUseAssetsTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of quantitative information about right-of-use assets [text block]", "terseLabel": "Schedule of right-of-use assets" } }, "en": { "role": { "documentation": "The disclosure of quantitative information about right-of-use assets. [Refer: Right-of-use assets]" } } }, "auth_ref": [ "r95", "r131" ] }, "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems", "presentation": [ "http://addextherapeutics.com/role/DisclosureRightOfUseAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of quantitative information about right-of-use assets [line items]", "terseLabel": "Right-of-use assets" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable", "presentation": [ "http://addextherapeutics.com/role/DisclosureRightOfUseAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of quantitative information about right-of-use assets [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to right-of-use assets." } } }, "auth_ref": [ "r95", "r131" ] }, "ifrs-full_DisclosureOfRelatedPartyExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfRelatedPartyExplanatory", "presentation": [ "http://addextherapeutics.com/role/DisclosureRelatedPartyTransactions" ], "lang": { "en-us": { "role": { "label": "Disclosure of related party [text block]", "terseLabel": "Related party transactions" } }, "en": { "role": { "documentation": "The entire disclosure for related parties." } } }, "auth_ref": [ "r24" ] }, "ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfRevenueFromContractsWithCustomersExplanatory", "presentation": [ "http://addextherapeutics.com/role/DisclosureRevenueFromContractWithCustomer" ], "lang": { "en-us": { "role": { "label": "Disclosure of revenue from contracts with customers [text block]", "terseLabel": "Revenue from contract with customer" } }, "en": { "role": { "documentation": "The entire disclosure for revenue from contracts with customers." } } }, "auth_ref": [ "r88", "r89" ] }, "adxn_DisclosureOfRightOfUseAssetsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "DisclosureOfRightOfUseAssetsTextBlock", "presentation": [ "http://addextherapeutics.com/role/DisclosureRightOfUseAssets" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of right-of-use assets", "label": "Disclosure of right-of-use assets [Text Block]", "terseLabel": "Right-of-use assets" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfSegmentsMajorCustomersExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfSegmentsMajorCustomersExplanatory", "presentation": [ "http://addextherapeutics.com/role/DisclosureSegmentReportingTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of major customers [text block]", "terseLabel": "Schedule of revenue from contract with customer and other income by major counterparties" } }, "en": { "role": { "documentation": "The disclosure of major customers." } } }, "auth_ref": [ "r125" ] }, "ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareCapital" ], "lang": { "en-us": { "role": { "label": "Disclosure of share capital, reserves and other equity interest [text block]", "terseLabel": "Share capital" } }, "en": { "role": { "documentation": "The entire disclosure for share capital, reserves and other equity interest." } } }, "auth_ref": [ "r137", "r192", "r219" ] }, "ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfSharebasedPaymentArrangementsExplanatory", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareBasedCompensation" ], "lang": { "en-us": { "role": { "label": "Disclosure of share-based payment arrangements [text block]", "terseLabel": "Share-based compensation" } }, "en": { "role": { "documentation": "The entire disclosure for share-based payment arrangements." } } }, "auth_ref": [ "r97" ] }, "ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfSignificantInvestmentsInAssociatesAbstract", "lang": { "en-us": { "role": { "label": "Interests in associates" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfSignificantInvestmentsInAssociatesExplanatory", "presentation": [ "http://addextherapeutics.com/role/DisclosureInterestsInAssociatesTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of associates [text block]", "terseLabel": "Schedule of carrying amount and financial information of equity-accounted investments" } }, "en": { "role": { "documentation": "The disclosure of associates. [Refer: Total for all associates [member]]" } } }, "auth_ref": [ "r27", "r29", "r78", "r184" ] }, "ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfSignificantInvestmentsInAssociatesLineItems", "presentation": [ "http://addextherapeutics.com/role/DisclosureGeneralInformationDetails", "http://addextherapeutics.com/role/DisclosureInterestsInAssociatesDetails", "http://addextherapeutics.com/role/DisclosureMaterialAccountingEstimatesAndJudgmentsDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of associates [line items]", "terseLabel": "General information", "verboseLabel": "Material accounting estimates and judgments" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfSignificantInvestmentsInAssociatesTable", "presentation": [ "http://addextherapeutics.com/role/DisclosureGeneralInformationDetails", "http://addextherapeutics.com/role/DisclosureInterestsInAssociatesDetails", "http://addextherapeutics.com/role/DisclosureMaterialAccountingEstimatesAndJudgmentsDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of associates [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to associates." } } }, "auth_ref": [ "r27", "r29", "r78", "r184" ] }, "ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfAssetsExplanatory", "presentation": [ "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of significant unobservable inputs used in fair value measurement of assets [text block]", "terseLabel": "Schedule of significant unobservable inputs used in fair value measurement" } }, "en": { "role": { "documentation": "The disclosure of significant inputs for which market data are not available and that are developed using the best information available about the assumptions that market participants would use when measuring the fair value of assets." } } }, "auth_ref": [ "r81" ] }, "adxn_DisclosureOfStaffCostsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "DisclosureOfStaffCostsTableTextBlock", "presentation": [ "http://addextherapeutics.com/role/DisclosureStaffCostsTables" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of staff costs", "label": "Disclosure of staff costs [Table Text Block]", "terseLabel": "Schedule of staff costs" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract", "lang": { "en-us": { "role": { "label": "Share-based compensation" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionsOrSharesOutstandingDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of terms and conditions of share-based payment arrangement [line items]", "terseLabel": "Share-based compensation" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionsOrSharesOutstandingDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of terms and conditions of share-based payment arrangement [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to terms and conditions of share-based payment arrangements." } } }, "auth_ref": [ "r101", "r175" ] }, "ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTradeAndOtherPayablesExplanatory", "presentation": [ "http://addextherapeutics.com/role/DisclosurePayablesAccrualsAndOtherCurrentLiabilities" ], "lang": { "en-us": { "role": { "label": "Disclosure of trade and other payables [text block]", "terseLabel": "Payables, accruals and other current liabilities" } }, "en": { "role": { "documentation": "The disclosure of trade and other payables. [Refer: Trade and other payables]" } } }, "auth_ref": [ "r278" ] }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTransactionsBetweenRelatedPartiesLineItems", "presentation": [ "http://addextherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of transactions between related parties [line items]", "verboseLabel": "Related party transactions" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTransactionsBetweenRelatedPartiesTable", "presentation": [ "http://addextherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of transactions between related parties [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to transactions between related parties." } } }, "auth_ref": [ "r22", "r155" ] }, "ifrs-full_DiscontinuedOperationsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DiscontinuedOperationsMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsGeneralDetails", "http://addextherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Discontinued operations [member]", "terseLabel": "Discontinued operations" } }, "en": { "role": { "documentation": "This member stands for a component of an entity that either has been disposed of or is classified as held for sale, and that: (a) represents a separate major line of business or geographical area of operations; (b) is part of a single co-ordinated plan to dispose of a separate major line of business or geographical area of operations; or (c) is a subsidiary acquired exclusively with a view to resale. A component of an entity comprises operations and cash flows that can be clearly distinguished, operationally and for financial reporting purposes, from the rest of the entity. [Refer: Total for all subsidiaries [member]]" } } }, "auth_ref": [ "r107" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://addextherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://addextherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentPeriodEndDate", "presentation": [ "http://addextherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentType", "presentation": [ "http://addextherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "currency_EUR": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2025", "localname": "EUR", "presentation": [ "http://addextherapeutics.com/role/DisclosureCashAndCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "label": "EUR" } } }, "auth_ref": [] }, "ifrs-full_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "label": "Loss per share" } } }, "auth_ref": [] }, "ifrs-full_EarningsPerShareExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EarningsPerShareExplanatory", "presentation": [ "http://addextherapeutics.com/role/DisclosureLossPerShareTables" ], "lang": { "en-us": { "role": { "label": "Earnings per share [text block]", "terseLabel": "Schedule of loss per share" } }, "en": { "role": { "documentation": "The disclosure of earnings per share." } } }, "auth_ref": [ "r31" ] }, "ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EffectOfExchangeRateChangesOnCashAndCashEquivalents", "crdr": "debit", "presentation": [ "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Effect of exchange rate changes on cash and cash equivalents", "terseLabel": "Exchange difference on cash and cash equivalents" } }, "en": { "role": { "documentation": "The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]" } } }, "auth_ref": [ "r55", "r56" ] }, "ifrs-full_EmployeeBenefitsExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EmployeeBenefitsExpense", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/DisclosureOperatingCostsDetails": { "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0, "order": 2.0 }, "http://addextherapeutics.com/role/DisclosureStaffCostsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureOperatingCostsDetails", "http://addextherapeutics.com/role/DisclosureStaffCostsDetails" ], "lang": { "en-us": { "role": { "label": "Employee benefits expense", "terseLabel": "Staff costs (note 19)", "totalLabel": "Total staff costs" } } }, "auth_ref": [ "r133", "r196", "r227", "r250" ] }, "adxn_EmployeeShareOptionPlansMember": { "xbrltype": "domainItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "EmployeeShareOptionPlansMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureEventsAfterBalanceSheetDateDetails", "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionsOrSharesOutstandingDetails" ], "lang": { "en-us": { "role": { "documentation": "Employee share option plans", "label": "Employee share option plans (ESOP)", "terseLabel": "Employee share option plans" } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityCentralIndexKey", "presentation": [ "http://addextherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r257" ] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityDomain", "presentation": [ "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsGeneralDetails" ], "lang": { "en-us": { "role": { "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityRegistrantName", "presentation": [ "http://addextherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r257" ] }, "ifrs-full_Equity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Equity", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://addextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets", "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Equity", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total equity" } }, "en": { "role": { "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities." } } }, "auth_ref": [ "r61", "r63", "r79", "r80", "r82", "r156", "r171", "r186", "r187", "r194", "r210", "r215" ] }, "ifrs-full_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EquityAbstract", "presentation": [ "http://addextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Equity [abstract]", "terseLabel": "Equity" } } }, "auth_ref": [] }, "ifrs-full_EquityAndLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EquityAndLiabilities", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://addextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Equity and liabilities", "totalLabel": "Total liabilities and equity" } }, "en": { "role": { "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]" } } }, "auth_ref": [ "r210" ] }, "ifrs-full_EquityAndLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EquityAndLiabilitiesAbstract", "presentation": [ "http://addextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Equity and liabilities [abstract]", "terseLabel": "LIABILITIES AND EQUITY" } } }, "auth_ref": [] }, "adxn_ExercisePeriodOfWarrants": { "xbrltype": "durationItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "ExercisePeriodOfWarrants", "presentation": [ "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "documentation": "The exercise period of warrants.", "label": "Exercise Period Of Warrants", "verboseLabel": "Exercise period of warrants received on investment in Stalicla SA" } } }, "auth_ref": [] }, "ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets", "crdr": "debit", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareBasedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Expense from share-based payment transactions in which goods or services received did not qualify for recognition as assets", "verboseLabel": "Share-based compensation" } } }, "auth_ref": [ "r102", "r176" ] }, "ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ExpenseFromSharebasedPaymentTransactionsWithEmployees", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/DisclosureStaffCostsDetails": { "parentTag": "ifrs-full_EmployeeBenefitsExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureStaffCostsDetails" ], "lang": { "en-us": { "role": { "label": "Expense from share-based payment transactions with employees", "terseLabel": "Value of share-based services" } } }, "auth_ref": [ "r280" ] }, "adxn_ExpensesRecognisedForServicesReceivedAtZeroCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "ExpensesRecognisedForServicesReceivedAtZeroCosts", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/DisclosureOperatingCostsDetails": { "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureIntangibleAssetsDetails", "http://addextherapeutics.com/role/DisclosureOperatingCostsDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of expenses recognised for services received at zero costs.", "label": "Expenses Recognised For Services Received At Zero Costs", "terseLabel": "Fair value of services received at zero cost recorded as other operating cost", "verboseLabel": "Fair value of services received at zero costs" } } }, "auth_ref": [] }, "ifrs-full_ExplanationOfAccountingPoliciesAndMethodsOfComputationFollowedInInterimFinancialStatements": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ExplanationOfAccountingPoliciesAndMethodsOfComputationFollowedInInterimFinancialStatements", "presentation": [ "http://addextherapeutics.com/role/DisclosureBasisOfPreparationPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policies and methods of computation followed in interim financial statements [text block]", "terseLabel": "Accounting policies and methods of computation followed in interim financial statements" } }, "en": { "role": { "documentation": "The disclosure of a statement that the same accounting policies and methods of computation are followed in the interim financial statements as compared with the most recent annual financial statements or, if those policies or methods have been changed, a description of the nature and effect of the changes." } } }, "auth_ref": [ "r36", "r158" ] }, "ifrs-full_ExternalCreditGradesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ExternalCreditGradesAxis", "presentation": [ "http://addextherapeutics.com/role/DisclosureCashAndCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "label": "External credit grades [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r240", "r242", "r247" ] }, "ifrs-full_ExternalCreditGradesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ExternalCreditGradesDomain", "presentation": [ "http://addextherapeutics.com/role/DisclosureCashAndCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "label": "External credit grades [domain]" } }, "en": { "role": { "documentation": "This member stands for the standard value for the 'External credit grades' axis if no other member is used." } } }, "auth_ref": [ "r240", "r242", "r247" ] }, "adxn_ExternalResearchAndDevelopmentCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "ExternalResearchAndDevelopmentCosts", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/DisclosureOperatingCostsDetails": { "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureOperatingCostsDetails" ], "lang": { "en-us": { "role": { "documentation": "External research and development costs", "label": "External research and development costs", "terseLabel": "External research and development costs" } } }, "auth_ref": [] }, "country_FR": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2025", "localname": "FR", "presentation": [ "http://addextherapeutics.com/role/DisclosureSegmentInformationDetails" ], "lang": { "en-us": { "role": { "label": "FRANCE", "terseLabel": "France" } } }, "auth_ref": [] }, "adxn_FairValueOfServiceAgreementProvidedAfterDisposalOfDiscontinuedOperation": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "FairValueOfServiceAgreementProvidedAfterDisposalOfDiscontinuedOperation", "crdr": "credit", "presentation": [ "http://addextherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Fair value of service agreement provided after disposal of discontinued operation", "label": "Fair value of service agreement provided after disposal of discontinued operation", "terseLabel": "Fair value of service agreement" } } }, "auth_ref": [] }, "ifrs-full_FinanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinanceCosts", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss": { "parentTag": "ifrs-full_FinanceIncomeCost", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Finance costs.", "negatedLabel": "Finance expense" } } }, "auth_ref": [ "r223" ] }, "adxn_FinanceCostsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "FinanceCostsAbstract", "lang": { "en-us": { "role": { "documentation": "Finance costs", "label": "Finance result, net" } } }, "auth_ref": [] }, "ifrs-full_FinanceIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinanceIncome", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss": { "parentTag": "ifrs-full_FinanceIncomeCost", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Finance income", "terseLabel": "Finance income" } } }, "auth_ref": [ "r284" ] }, "ifrs-full_FinanceIncomeCost": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinanceIncomeCost", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss": { "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": 1.0, "order": 2.0 }, "http://addextherapeutics.com/role/DisclosureFinanceResultNetDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureFinanceResultNetDetails", "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Finance income (cost)", "totalLabel": "Finance result" } } }, "auth_ref": [ "r284" ] }, "ifrs-full_FinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinancialAssets", "crdr": "debit", "presentation": [ "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails", "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsInputsDetails", "http://addextherapeutics.com/role/DisclosureOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Financial assets", "negatedTerseLabel": "Expected loss allowance" } }, "en": { "role": { "documentation": "The amount of assets that are: (a) cash; (b) an equity instrument of another entity; (c) a contractual right: (i) to receive cash or another financial asset from another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to the entity; or (d) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to receive a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose the entity\u2019s own equity instruments do not include puttable financial instruments classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. [Refer: Classes of financial instruments [domain]; Financial liabilities]" } } }, "auth_ref": [ "r108", "r109", "r110", "r112", "r181", "r182", "r183", "r241" ] }, "ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "label": "Financial assets at fair value through other comprehensive income" } } }, "auth_ref": [] }, "ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "label": "Financial assets at fair value through other comprehensive income, category [member]", "terseLabel": "Financial assets at fair value through other comprehensive income" } }, "en": { "role": { "documentation": "This member stands for the financial assets at fair value through other comprehensive income category. [Refer: Financial assets at fair value through other comprehensive income]" } } }, "auth_ref": [ "r115", "r179" ] }, "ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "label": "Financial assets at fair value through profit or loss, category [member]", "terseLabel": "Financial assets at fair value through profit or loss" } }, "en": { "role": { "documentation": "This member stands for the financial assets at fair value through profit or loss category. [Refer: Financial assets at fair value through profit or loss]" } } }, "auth_ref": [ "r114", "r178" ] }, "currency_GBP": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2025", "localname": "GBP", "presentation": [ "http://addextherapeutics.com/role/DisclosureCashAndCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "label": "GBP" } } }, "auth_ref": [] }, "adxn_GainLossOnDiscontinuanceNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "GainLossOnDiscontinuanceNetOfTax", "crdr": "credit", "presentation": [ "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsGeneralDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of gain (loss), net of tax on discontinuance when operations are discontinued.", "label": "Gain (Loss) On Discontinuance, Net Of Tax", "terseLabel": "Net gain on Neurosterix Transaction" } } }, "auth_ref": [] }, "ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/DisclosureFinanceResultNetDetails": { "parentTag": "ifrs-full_FinanceIncomeCost", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureFinanceResultNetDetails" ], "lang": { "en-us": { "role": { "label": "Foreign exchange gain (loss)", "terseLabel": "Foreign exchange gains /(losses)" } }, "en": { "role": { "documentation": "The amount of exchange differences recognised in profit or loss that arise from foreign currency transactions, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: At fair value [member]; Classes of financial instruments [domain]]" } } }, "auth_ref": [ "r16", "r150", "r202" ] }, "ifrs-full_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss": { "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "General and administrative expense", "negatedLabel": "General and administration" } } }, "auth_ref": [ "r280" ] }, "adxn_GeneralInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "GeneralInformationAbstract", "lang": { "en-us": { "role": { "documentation": "General information", "label": "General information" } } }, "auth_ref": [] }, "ifrs-full_GeographicalAreasAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GeographicalAreasAxis", "presentation": [ "http://addextherapeutics.com/role/DisclosureSegmentInformationDetails" ], "lang": { "en-us": { "role": { "label": "Geographical areas [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r124", "r230", "r237", "r239", "r245" ] }, "ifrs-full_GeographicalAreasDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GeographicalAreasDomain", "presentation": [ "http://addextherapeutics.com/role/DisclosureSegmentInformationDetails" ], "lang": { "en-us": { "role": { "label": "Geographical areas [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregated geographical areas. It also represents the standard value for the 'Geographical areas' axis if no other member is used." } } }, "auth_ref": [ "r124", "r230", "r237", "r239", "r245" ] }, "ifrs-full_GrossCarryingAmountMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GrossCarryingAmountMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureEquipmentDetails", "http://addextherapeutics.com/role/DisclosureIntangibleAssetsDetails", "http://addextherapeutics.com/role/DisclosureRightOfUseAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Cost", "terseLabel": "Cost" } } }, "auth_ref": [ "r2", "r42", "r50", "r53", "r103", "r110", "r112", "r141", "r161", "r167", "r170", "r182", "r183", "r241" ] }, "adxn_GrossProceedsFromDisposalOfDiscontinuedOperation": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "GrossProceedsFromDisposalOfDiscontinuedOperation", "crdr": "credit", "presentation": [ "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsGeneralDetails", "http://addextherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Gross proceeds from disposal of discontinued operation", "label": "Gross proceeds from disposal of discontinued operation", "terseLabel": "Gross proceeds in cash received from Neurosterix Transaction", "verboseLabel": "Cash in from Neurosterix Pharma Sarl sale" } } }, "auth_ref": [] }, "adxn_IfrsBalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "IfrsBalanceSheetLocationAxis", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "Balance sheet location", "label": "IFRS Balance sheet location [Axis]" } } }, "auth_ref": [] }, "adxn_IfrsEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "IfrsEquipmentMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureEquipmentDetails" ], "lang": { "en-us": { "role": { "documentation": "Equipment", "label": "Equipment" } } }, "auth_ref": [] }, "adxn_IfrsOtherIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "IfrsOtherIncomeAbstract", "lang": { "en-us": { "role": { "documentation": "Other income", "label": "Other income" } } }, "auth_ref": [] }, "ifrs-full_ImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ImpairmentLoss", "crdr": "debit", "presentation": [ "http://addextherapeutics.com/role/DisclosureMaterialAccountingEstimatesAndJudgmentsDetails" ], "lang": { "en-us": { "role": { "label": "Impairment loss", "terseLabel": "Impairment loss" } }, "en": { "role": { "documentation": "The amount recognised as a reduction of the carrying amount of an asset or cash-generating unit to its recoverable amount. [Refer: Carrying amount [member]]" } } }, "auth_ref": [ "r38", "r39" ] }, "adxn_IncomeRecognisedForServicesReceivedAtZeroCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "IncomeRecognisedForServicesReceivedAtZeroCosts", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/DisclosureSegmentInformationDetails": { "parentTag": "ifrs-full_RevenueAndOperatingIncome", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureIntangibleAssetsDetails", "http://addextherapeutics.com/role/DisclosureSegmentInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of income recognised for services received at zero costs.", "label": "Income Recognised For Services Received At Zero Costs", "terseLabel": "Fair value of Income recognised for services received at zero cost", "verboseLabel": "Fair value of services received at zero cost from Neurosterix Group" } } }, "auth_ref": [] }, "ifrs-full_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Condensed Consolidated Statements of Comprehensive Loss" } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) in cash and cash equivalents before effect of exchange rate changes", "totalLabel": "Decrease in cash and cash equivalents" } }, "en": { "role": { "documentation": "The increase (decrease) in cash and cash equivalents before the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]" } } }, "auth_ref": [ "r59", "r139" ] }, "adxn_IncreaseDecreaseInEmployeeBenefitsExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "IncreaseDecreaseInEmployeeBenefitsExpenses", "crdr": "debit", "presentation": [ "http://addextherapeutics.com/role/DisclosureOperatingCostsAdditionalInformationDetails", "http://addextherapeutics.com/role/DisclosureStaffCostsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in employee benefit expenses.", "label": "Increase (Decrease) in Employee Benefits Expenses", "terseLabel": "Increase (decrease) in staff costs" } } }, "auth_ref": [] }, "adxn_IncreaseDecreaseInExpensesRecognizedForServicesReceivedAtZeroCost": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "IncreaseDecreaseInExpensesRecognizedForServicesReceivedAtZeroCost", "crdr": "debit", "presentation": [ "http://addextherapeutics.com/role/DisclosureOperatingCostsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in expenses recognized for services received at zero cost.", "label": "Increase (Decrease) in Expenses Recognized For Services Received at Zero Cost", "terseLabel": "Increase (decrease) in expenses recognized for services received at zero cost" } } }, "auth_ref": [] }, "adxn_IncreaseDecreaseInExternalResearchDevelopmentAndPatentCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "IncreaseDecreaseInExternalResearchDevelopmentAndPatentCosts", "crdr": "debit", "presentation": [ "http://addextherapeutics.com/role/DisclosureOperatingCostsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in external research, development and patent costs.", "label": "Increase (Decrease) In External Research, Development and Patent Costs", "terseLabel": "Increase (decrease) external research and development and patent costs" } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputAssets", "crdr": "debit", "presentation": [ "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsInputsDetails" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) in fair value measurement due to reasonably possible decrease in unobservable input" } }, "en": { "role": { "documentation": "The amount of increase (decrease) in the fair value measurement of assets due to a reasonably possible decrease in an unobservable input." } } }, "auth_ref": [ "r83" ] }, "ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets", "crdr": "debit", "presentation": [ "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsInputsDetails" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input" } }, "en": { "role": { "documentation": "The amount of increase (decrease) in the fair value measurement of assets due to a reasonably possible increase in an unobservable input." } } }, "auth_ref": [ "r83" ] }, "adxn_IncreaseDecreaseInInvestmentsInAssociatesAccountedForUsingEquityMethod": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "IncreaseDecreaseInInvestmentsInAssociatesAccountedForUsingEquityMethod", "crdr": "debit", "presentation": [ "http://addextherapeutics.com/role/DisclosureInterestsInAssociatesDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of increase (decrease) in investments in associates accounted for using equity method.", "label": "Increase (decrease) in investments in associates accounted for using equity method", "terseLabel": "Increase (decrease) in investments in associates" } } }, "auth_ref": [] }, "adxn_IncreaseDecreaseInKeyManagementPersonnelCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "IncreaseDecreaseInKeyManagementPersonnelCompensation", "crdr": "debit", "presentation": [ "http://addextherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in key management personnel compensation.", "label": "Increase (Decrease) in Key Management Personnel Compensation", "terseLabel": "Increase (decrease) in total compensation costs for key management" } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAsset": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseInNetDefinedBenefitLiabilityAsset", "crdr": "credit", "presentation": [ "http://addextherapeutics.com/role/DisclosureRetirementBenefitsObligationsBalanceSheetDetails" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) in net defined benefit liability (asset)", "terseLabel": "Increase (decrease) in retirement benefit obligation" } }, "en": { "role": { "documentation": "The increase (decrease) in the net defined benefit liability (asset). [Refer: Net defined benefit liability (asset)]" } } }, "auth_ref": [ "r13", "r149" ] }, "adxn_IncreaseDecreaseInOperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "IncreaseDecreaseInOperatingExpenses", "crdr": "debit", "presentation": [ "http://addextherapeutics.com/role/DisclosureOperatingCostsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating costs.", "label": "Increase (Decrease) in Operating Expenses", "terseLabel": "Increase (decrease) in total operating costs" } } }, "auth_ref": [] }, "adxn_IncreaseDecreaseInOtherCurrentAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "IncreaseDecreaseInOtherCurrentAsset", "crdr": "debit", "presentation": [ "http://addextherapeutics.com/role/DisclosureOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in other current assets", "label": "Increase (decrease) in other current assets", "terseLabel": "Increase (decrease) in other current assets" } } }, "auth_ref": [] }, "adxn_IncreaseDecreaseInPayablesAccrualsAndOtherCurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "IncreaseDecreaseInPayablesAccrualsAndOtherCurrentLiabilities", "crdr": "credit", "presentation": [ "http://addextherapeutics.com/role/DisclosurePayablesAccrualsAndOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in payables, accruals and other current liabilities", "label": "Increase (decrease) in payables, accruals and other current liabilities" } } }, "auth_ref": [] }, "adxn_IncreaseDecreaseInProfessionalFees": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "IncreaseDecreaseInProfessionalFees", "crdr": "debit", "presentation": [ "http://addextherapeutics.com/role/DisclosureOperatingCostsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in professional fees", "label": "Increase (decrease) in professional fees", "terseLabel": "Increase (decrease) in professional fees" } } }, "auth_ref": [] }, "adxn_IncreaseDecreaseThroughIssuanceOfWarrantsAndPreFundedWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "IncreaseDecreaseThroughIssuanceOfWarrantsAndPreFundedWarrants", "crdr": "credit", "presentation": [ "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in equity through grant of warrants and pre-funded warrants", "label": "Increase Decrease Through Grant Of Warrants And Pre Funded Warrants", "terseLabel": "Value of Warrants granted" } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughSharebasedPaymentTransactions", "crdr": "credit", "presentation": [ "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) through share-based payment transactions, equity", "terseLabel": "Value of share-based services" } }, "en": { "role": { "documentation": "The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]" } } }, "auth_ref": [ "r200" ] }, "ifrs-full_IndividuallyInsignificantCounterpartiesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IndividuallyInsignificantCounterpartiesMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureSegmentInformationDetails" ], "lang": { "en-us": { "role": { "label": "Other counterparties" } }, "en": { "role": { "documentation": "This member stands for individually insignificant parties to the transaction other than the entity." } } }, "auth_ref": [ "r117" ] }, "adxn_IndiviorPlcMember": { "xbrltype": "domainItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "IndiviorPlcMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureRevenueFromContractWithCustomerDetails" ], "lang": { "en-us": { "role": { "documentation": "Indivior PLC", "label": "Indivior PLC", "terseLabel": "Indivior PLC" } } }, "auth_ref": [] }, "ifrs-full_InsuranceExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InsuranceExpense", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/DisclosureOperatingCostsDetails": { "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureOperatingCostsDetails" ], "lang": { "en-us": { "role": { "label": "Insurance expense", "terseLabel": "D&O insurance" } } }, "auth_ref": [ "r280" ] }, "ifrs-full_IntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IntangibleAssetsOtherThanGoodwill", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureIntangibleAssetsDetails", "http://addextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Intangible assets other than goodwill", "terseLabel": "Intangible assets" } }, "en": { "role": { "documentation": "The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]" } } }, "auth_ref": [ "r44", "r163", "r205" ] }, "ifrs-full_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/DisclosureFinanceResultNetDetails": { "parentTag": "ifrs-full_FinanceIncomeCost", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureFinanceResultNetDetails" ], "lang": { "en-us": { "role": { "label": "Interest expense", "negatedLabel": "Interests cost" } }, "en": { "role": { "documentation": "The amount of expense arising from interest." } } }, "auth_ref": [ "r77", "r118", "r122" ] }, "ifrs-full_InterestExpenseDefinedBenefitPlans": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InterestExpenseDefinedBenefitPlans", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/DisclosureRetirementBenefitsObligationsComprehensiveLossDetails": { "parentTag": "ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureRetirementBenefitsObligationsComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "label": "Interest cost on defined benefit plans", "negatedLabel": "Interest cost" } } }, "auth_ref": [ "r261" ] }, "ifrs-full_InterestExpenseOnLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InterestExpenseOnLeaseLiabilities", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/DisclosureFinanceResultNetDetails": { "parentTag": "ifrs-full_FinanceIncomeCost", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureFinanceResultNetDetails" ], "lang": { "en-us": { "role": { "label": "Interest expense on lease liabilities", "negatedTerseLabel": "Interests expense on leases" } } }, "auth_ref": [ "r93", "r129" ] }, "ifrs-full_InterestIncomeDefinedBenefitPlans": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InterestIncomeDefinedBenefitPlans", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/DisclosureRetirementBenefitsObligationsComprehensiveLossDetails": { "parentTag": "ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureRetirementBenefitsObligationsComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "label": "Interest income on defined benefit plans", "terseLabel": "Interest income" } } }, "auth_ref": [ "r261" ] }, "ifrs-full_InterestPaidClassifiedAsFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InterestPaidClassifiedAsFinancingActivities", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Interest paid, classified as financing activities", "negatedTerseLabel": "Interest paid" } }, "en": { "role": { "documentation": "The cash outflow for interest paid, classified as financing activities." } } }, "auth_ref": [ "r57" ] }, "adxn_InterimMeasurementNoteAbstract": { "xbrltype": "stringItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "InterimMeasurementNoteAbstract", "lang": { "en-us": { "role": { "documentation": "Interim measurement note.", "label": "Interim measurement note" } } }, "auth_ref": [] }, "ifrs-full_InvestmentsInAssociatesAccountedForUsingEquityMethod": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InvestmentsInAssociatesAccountedForUsingEquityMethod", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureInterestsInAssociatesDetails", "http://addextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Investments in associates accounted for using equity method", "periodEndLabel": "End of period", "periodStartLabel": "Beginning of the period", "terseLabel": "Investment accounted for using the equity method" } }, "en": { "role": { "documentation": "The amount of investments in associates accounted for using the equity method. [Refer: Total for all associates [member]; Investments accounted for using equity method]" } } }, "auth_ref": [ "r281" ] }, "ifrs-full_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeDomain", "presentation": [ "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails", "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsInputsDetails", "http://addextherapeutics.com/role/DisclosureFinancialAssetsAtFairValueThroughOtherComprehensiveIncomeDetails" ], "lang": { "en-us": { "role": { "label": "Investments in equity instruments designated at fair value through other comprehensive income [domain]" } }, "en": { "role": { "documentation": "This member stands for the standard value for the 'Investments in equity instruments designated at fair value through other comprehensive income' axis if no other member is used." } } }, "auth_ref": [ "r195" ] }, "ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis", "presentation": [ "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails", "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsInputsDetails", "http://addextherapeutics.com/role/DisclosureFinancialAssetsAtFairValueThroughOtherComprehensiveIncomeDetails" ], "lang": { "en-us": { "role": { "label": "Investments in equity instruments designated at fair value through other comprehensive income [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r195" ] }, "ifrs-full_IssuedCapital": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IssuedCapital", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://addextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Issued capital", "terseLabel": "Share capital" } }, "en": { "role": { "documentation": "The nominal value of capital issued." } } }, "auth_ref": [ "r249", "r255" ] }, "ifrs-full_IssuedCapitalMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IssuedCapitalMember", "presentation": [ "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Share Capital" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing issued capital." } } }, "auth_ref": [ "r201" ] }, "adxn_JanssenPharmaceuticalsInc.Member": { "xbrltype": "domainItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "JanssenPharmaceuticalsInc.Member", "presentation": [ "http://addextherapeutics.com/role/DisclosureRevenueFromContractWithCustomerDetails" ], "lang": { "en-us": { "role": { "documentation": "Janssen Pharmaceuticals Inc.", "label": "Janssen Pharmaceuticals Inc.", "terseLabel": "Janssen Pharmaceuticals Inc." } } }, "auth_ref": [] }, "adxn_KeplerCapitalMarketsSaMember": { "xbrltype": "domainItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "KeplerCapitalMarketsSaMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "Kepler Capital Markets SA", "label": "Kepler" } } }, "auth_ref": [] }, "ifrs-full_KeyManagementPersonnelCompensation": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "KeyManagementPersonnelCompensation", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Key management personnel compensation", "totalLabel": "Key management compensation" } } }, "auth_ref": [ "r19", "r152" ] }, "adxn_KeyManagementPersonnelCompensationSalariesOtherShortTermEmployeeBenefitsAndPostEmploymentBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "KeyManagementPersonnelCompensationSalariesOtherShortTermEmployeeBenefitsAndPostEmploymentBenefits", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails": { "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Key management personnel compensation, salaries, other short-term employee benefits and post-employment benefits", "label": "Key management personnel compensation, salaries, other short-term employee benefits and post-employment benefits", "terseLabel": "Salaries, other short-term employee benefits and post-employment benefits" } } }, "auth_ref": [] }, "ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "KeyManagementPersonnelCompensationSharebasedPayment", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails": { "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Key management personnel compensation, share-based payment", "terseLabel": "Share-based compensation" } } }, "auth_ref": [ "r18" ] }, "ifrs-full_KeyManagementPersonnelOfEntityOrParentMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "KeyManagementPersonnelOfEntityOrParentMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Board of Directors and Executive Management", "terseLabel": "Board of Directors and Executive Management" } }, "en": { "role": { "documentation": "This member stands for those persons having authority and responsibility for planning, directing and controlling the activities of the entity, directly or indirectly, including any director (whether executive or otherwise) of that entity." } } }, "auth_ref": [ "r21", "r154" ] }, "ifrs-full_LandAndBuildingsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LandAndBuildingsMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureRightOfUseAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Properties" } }, "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing land and depreciable buildings and similar structures for use in operations. [Refer: Buildings; Land; Property, plant and equipment]" } } }, "auth_ref": [ "r229" ] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "LegalEntityAxis", "presentation": [ "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsGeneralDetails" ], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "ifrs-full_Level3OfFairValueHierarchyMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Level3OfFairValueHierarchyMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "label": "Level 3 of fair value hierarchy [member]", "terseLabel": "Level 3" } }, "en": { "role": { "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are unobservable inputs for the asset or liability. Unobservable inputs are inputs for which market data are not available and that are developed using the best information available about the assumptions that the market participants would use when pricing the asset or liability." } } }, "auth_ref": [ "r40", "r41", "r80", "r160", "r187" ] }, "ifrs-full_LevelsOfFairValueHierarchyAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LevelsOfFairValueHierarchyAxis", "presentation": [ "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "label": "Levels of fair value hierarchy [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r14", "r80", "r187" ] }, "ifrs-full_LevelsOfFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LevelsOfFairValueHierarchyDomain", "presentation": [ "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "label": "Levels of fair value hierarchy [domain]" } }, "en": { "role": { "documentation": "This member stands for all levels of the fair value hierarchy. It also represents the standard value for the 'Levels of fair value hierarchy' axis if no other member is used." } } }, "auth_ref": [ "r14", "r80", "r187" ] }, "ifrs-full_LiabilityAssetOfDefinedBenefitPlans": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LiabilityAssetOfDefinedBenefitPlans", "crdr": "credit", "presentation": [ "http://addextherapeutics.com/role/DisclosureRetirementBenefitsObligationsBalanceSheetDetails" ], "lang": { "en-us": { "role": { "label": "Net defined benefit liability (asset)", "negatedTerseLabel": "Net defined benefit (liability) asset" } }, "en": { "role": { "documentation": "The amount of deficit or surplus in a defined benefit plan, adjusted for any effect of limiting a net defined benefit asset to the asset ceiling. [Refer: Defined benefit plans [domain]]" } } }, "auth_ref": [ "r12", "r148" ] }, "ifrs-full_LongtermDeposits": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LongtermDeposits", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/DisclosureNonCurrentFinancialAssetsDetails": { "parentTag": "ifrs-full_NoncurrentFinancialAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureNonCurrentFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Long-term deposits", "terseLabel": "Security rental deposits" } }, "en": { "role": { "documentation": "The amount of long-term deposits held by the entity." } } }, "auth_ref": [ "r281" ] }, "ifrs-full_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "MajorCustomersAxis", "presentation": [ "http://addextherapeutics.com/role/DisclosureSegmentInformationDetails" ], "lang": { "en-us": { "role": { "label": "Major customers [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r125" ] }, "ifrs-full_MajorCustomersDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "MajorCustomersDomain", "presentation": [ "http://addextherapeutics.com/role/DisclosureSegmentInformationDetails" ], "lang": { "en-us": { "role": { "label": "Major customers [domain]" } }, "en": { "role": { "documentation": "This member stands for customers. It also represents the standard value for the 'Major customers' axis if no other member is used." } } }, "auth_ref": [ "r125" ] }, "ifrs-full_MajorOrdinaryShareTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "MajorOrdinaryShareTransactionsMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureEventsAfterBalanceSheetDateDetails" ], "lang": { "en-us": { "role": { "label": "Major ordinary share transaction", "terseLabel": "Sale of treasury shares" } }, "en": { "role": { "documentation": "This member stands for major ordinary share transactions. [Refer: Ordinary shares [member]]" } } }, "auth_ref": [ "r228", "r246" ] }, "adxn_MaturityPeriodOfPayables": { "xbrltype": "durationItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "MaturityPeriodOfPayables", "presentation": [ "http://addextherapeutics.com/role/DisclosurePayablesAccrualsAndOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Maturity period of payables", "label": "Maturity period of payables" } } }, "auth_ref": [] }, "ifrs-full_MeasurementAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "MeasurementAxis", "presentation": [ "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "label": "Measurement [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r48", "r52", "r79", "r169", "r186" ] }, "ifrs-full_MeasurementDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "MeasurementDomain", "presentation": [ "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "label": "Measurement [domain]" } }, "en": { "role": { "documentation": "This member stands for all types of measurement. It also represents the standard value for the 'Measurement' axis if no other member is used." } } }, "auth_ref": [ "r48", "r52", "r79", "r169", "r186" ] }, "ifrs-full_MiscellaneousOtherOperatingIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "MiscellaneousOtherOperatingIncome", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/DisclosureSegmentInformationDetails": { "parentTag": "ifrs-full_RevenueAndOperatingIncome", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureSegmentInformationDetails" ], "lang": { "en-us": { "role": { "label": "Miscellaneous other operating income", "terseLabel": "Other service income" } } }, "auth_ref": [ "r280" ] }, "adxn_MovementInTreasurySharesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "MovementInTreasurySharesAbstract", "presentation": [ "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "documentation": "Movement in treasury Shares", "label": "Movement in treasury Shares [Abstract]", "terseLabel": "Movement in treasury shares:" } } }, "auth_ref": [] }, "ifrs-full_NetDefinedBenefitLiabilityAssetAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NetDefinedBenefitLiabilityAssetAxis", "presentation": [ "http://addextherapeutics.com/role/DisclosureRetirementBenefitsObligationsBalanceSheetDetails" ], "lang": { "en-us": { "role": { "label": "Net defined benefit liability (asset) [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r12", "r148" ] }, "ifrs-full_NetDefinedBenefitLiabilityAssetDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NetDefinedBenefitLiabilityAssetDomain", "presentation": [ "http://addextherapeutics.com/role/DisclosureRetirementBenefitsObligationsBalanceSheetDetails" ], "lang": { "en-us": { "role": { "label": "Net defined benefit liability (asset) [domain]" } }, "en": { "role": { "documentation": "This member stands for the net defined benefit liability (asset). It also represents the standard value for the 'Net defined benefit liability (asset)' axis if no other member is used. [Refer: Net defined benefit liability (asset)]" } } }, "auth_ref": [ "r12", "r148" ] }, "adxn_NetSalesPurchasesOfTreasurySharesUnderLiquidityAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "NetSalesPurchasesOfTreasurySharesUnderLiquidityAgreement", "crdr": "credit", "presentation": [ "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "documentation": "Net sales (purchases) of treasury shares under liquidity agreement", "label": "Net sales (purchases) of treasury shares under liquidity agreement", "verboseLabel": "Net sale (purchase) under liquidity agreement" } } }, "auth_ref": [] }, "adxn_NeurosterixGroupMember": { "xbrltype": "domainItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "NeurosterixGroupMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureInterestsInAssociatesDetails", "http://addextherapeutics.com/role/DisclosureOtherIncomeDetails", "http://addextherapeutics.com/role/DisclosureSegmentInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Neurosterix Group", "label": "Neurosterix Group" } } }, "auth_ref": [] }, "adxn_NeurosterixPharmaSarlMember": { "xbrltype": "domainItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "NeurosterixPharmaSarlMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsGeneralDetails", "http://addextherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Neurosterix Pharma Sarl", "label": "Neurosterix", "terseLabel": "Neurosterix Pharma Sarl" } } }, "auth_ref": [] }, "adxn_NeurosterixUsHoldingsLlcMember": { "xbrltype": "domainItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "NeurosterixUsHoldingsLlcMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsGeneralDetails", "http://addextherapeutics.com/role/DisclosureGeneralInformationDetails", "http://addextherapeutics.com/role/DisclosureInterestsInAssociatesDetails", "http://addextherapeutics.com/role/DisclosureMaterialAccountingEstimatesAndJudgmentsDetails", "http://addextherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Neurosterix US Holdings LLC.", "label": "Neurosterix US Holdings LLC [Member]", "terseLabel": "Neurosterix US Holdings LLC" } } }, "auth_ref": [] }, "ifrs-full_NonadjustingEventsAfterReportingPeriodAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NonadjustingEventsAfterReportingPeriodAxis", "presentation": [ "http://addextherapeutics.com/role/DisclosureEventsAfterBalanceSheetDateDetails" ], "lang": { "en-us": { "role": { "label": "Non-adjusting events after reporting period [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r0", "r140" ] }, "ifrs-full_NonadjustingEventsAfterReportingPeriodDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NonadjustingEventsAfterReportingPeriodDomain", "presentation": [ "http://addextherapeutics.com/role/DisclosureEventsAfterBalanceSheetDateDetails" ], "lang": { "en-us": { "role": { "label": "Non-adjusting events after reporting period [domain]" } }, "en": { "role": { "documentation": "This member stands for events that occur between the end of the reporting period and the date when the financial statements are authorised for issue and are indicative of conditions that arose after the reporting period. It also represents the standard value for the 'Non-adjusting events after reporting period' axis if no other member is used." } } }, "auth_ref": [ "r0", "r140" ] }, "ifrs-full_NoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentAssets", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "ifrs-full_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureSegmentInformationDetails", "http://addextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Non-current assets", "totalLabel": "Total non-current assets", "verboseLabel": "Long-lived assets" } }, "en": { "role": { "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]" } } }, "auth_ref": [ "r69", "r211", "r234" ] }, "ifrs-full_NoncurrentAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentAssetsAbstract", "presentation": [ "http://addextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Non-current assets [abstract]", "terseLabel": "Non-current assets" } } }, "auth_ref": [] }, "ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwnersAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwnersAbstract", "lang": { "en-us": { "role": { "label": "Discontinued operations" } } }, "auth_ref": [] }, "ifrs-full_NoncurrentDerivativeFinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentDerivativeFinancialAssets", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails", "http://addextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Non-current derivative financial assets", "terseLabel": "Derivative financial instruments" } }, "en": { "role": { "documentation": "The amount of non-current derivative financial assets. [Refer: Derivative financial assets]" } } }, "auth_ref": [ "r281" ] }, "ifrs-full_NoncurrentFinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentFinancialAssets", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 2.0 }, "http://addextherapeutics.com/role/DisclosureNonCurrentFinancialAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureNonCurrentFinancialAssetsDetails", "http://addextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Non-current financial assets.", "terseLabel": "Non-current financial assets", "totalLabel": "Total non-current financial assets" } }, "en": { "role": { "documentation": "The amount of non-current financial assets. [Refer: Financial assets]" } } }, "auth_ref": [ "r108" ] }, "ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureFinancialAssetsAtFairValueThroughOtherComprehensiveIncomeDetails", "http://addextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Non-current financial assets at fair value through other comprehensive income", "terseLabel": "Financial assets at fair value through Other Comprehensive Income", "verboseLabel": "Financial assets at fair value through other comprehensive income" } }, "en": { "role": { "documentation": "The amount of non-current financial assets at fair value through other comprehensive income. [Refer: Financial assets at fair value through other comprehensive income]" } } }, "auth_ref": [ "r115", "r179" ] }, "ifrs-full_NoncurrentLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentLeaseLiabilities", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://addextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Non-current lease liabilities", "terseLabel": "Non-current lease liabilities" } }, "en": { "role": { "documentation": "The amount of non-current lease liabilities. [Refer: Lease liabilities]" } } }, "auth_ref": [ "r91" ] }, "ifrs-full_NoncurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentLiabilities", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://addextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Non-current liabilities", "totalLabel": "Total non-current liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]" } } }, "auth_ref": [ "r71", "r212", "r234" ] }, "ifrs-full_NoncurrentLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentLiabilitiesAbstract", "presentation": [ "http://addextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Non-current liabilities [abstract]", "terseLabel": "Non-current liabilities" } } }, "auth_ref": [] }, "ifrs-full_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentRecognisedLiabilitiesDefinedBenefitPlan", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://addextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Non-current net defined benefit liability", "terseLabel": "Retirement benefits obligations" } }, "en": { "role": { "documentation": "The amount of non-current net defined benefit liability. [Refer: Net defined benefit liability]" } } }, "auth_ref": [ "r281" ] }, "adxn_NumberOfCategoriesOfDilutivePotentialShares": { "xbrltype": "integerItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "NumberOfCategoriesOfDilutivePotentialShares", "presentation": [ "http://addextherapeutics.com/role/DisclosureLossPerShareDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of categories of dilutive potential shares", "label": "Number of categories of dilutive potential shares", "terseLabel": "Number of categories of dilutive potential shares" } } }, "auth_ref": [] }, "adxn_NumberOfOptionsSubjectToStrikePriceReduction": { "xbrltype": "decimalItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "NumberOfOptionsSubjectToStrikePriceReduction", "presentation": [ "http://addextherapeutics.com/role/DisclosureEventsAfterBalanceSheetDateDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of options that are subjected to strike price reduction.", "label": "Number of Options, Subject to Strike Price Reduction", "terseLabel": "Number of options subject to strike price reduction" } } }, "auth_ref": [] }, "adxn_NumberOfOrdinarySharesToWhoseProceedsPhantomSharesEntitlephantomSharesReceivedOnInvestment": { "xbrltype": "sharesItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "NumberOfOrdinarySharesToWhoseProceedsPhantomSharesEntitlephantomSharesReceivedOnInvestment", "presentation": [ "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of ordinary shares to whose proceeds phantom shares entitlePhantom shares received on investment", "label": "Number of ordinary shares to whose proceeds phantom shares entitlePhantom shares received on investment", "terseLabel": "Ordinary shares to proceeds from which phantom shares entitle" } } }, "auth_ref": [] }, "adxn_NumberOfOrdinarySharesToWhosePurchaseWarrantsEntitle": { "xbrltype": "sharesItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "NumberOfOrdinarySharesToWhosePurchaseWarrantsEntitle", "presentation": [ "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of ordinary shares to whose purchase warrants entitle", "label": "Ordinary shares to purchase of which warrants entitle" } } }, "auth_ref": [] }, "ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionsOrSharesOutstandingDetails" ], "lang": { "en-us": { "role": { "label": "Number of other equity instruments outstanding in share-based payment arrangement", "verboseLabel": "Outstanding shares" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement." } } }, "auth_ref": [ "r275" ] }, "adxn_NumberOfOtherEquityInstrumentsSubjectToStrikePriceReduction": { "xbrltype": "decimalItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "NumberOfOtherEquityInstrumentsSubjectToStrikePriceReduction", "presentation": [ "http://addextherapeutics.com/role/DisclosureEventsAfterBalanceSheetDateDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of other equity instruments that are subject to strike price reduction.", "label": "Number of Other Equity Instruments Subject to Strike Price Reduction", "terseLabel": "Number of shares subject to strike price reduction" } } }, "auth_ref": [] }, "ifrs-full_NumberOfOutstandingShareOptions": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfOutstandingShareOptions", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionsOrSharesOutstandingDetails" ], "lang": { "en-us": { "role": { "label": "Number of share options outstanding in share-based payment arrangement", "verboseLabel": "Options outstanding" } }, "en": { "role": { "documentation": "The number of share options outstanding in a share-based payment arrangement." } } }, "auth_ref": [ "r98", "r99", "r100", "r173", "r174" ] }, "adxn_NumberOfPreferredSharesToWhosePurchaseWarrantsEntitle": { "xbrltype": "sharesItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "NumberOfPreferredSharesToWhosePurchaseWarrantsEntitle", "presentation": [ "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of preferred shares to whose purchase warrants entitle", "label": "Preferred shares to purchase of which warrants entitle" } } }, "auth_ref": [] }, "adxn_NumberOfSegments": { "xbrltype": "integerItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "NumberOfSegments", "presentation": [ "http://addextherapeutics.com/role/DisclosureSegmentInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments", "label": "Number of segments", "terseLabel": "Number of segments" } } }, "auth_ref": [] }, "ifrs-full_NumberOfSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfSharesIssued", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareCapitalDetails" ], "lang": { "en-us": { "role": { "label": "Number of shares issued", "periodEndLabel": "Number of shares at end of period", "periodStartLabel": "Number of shares at beginning of period" } }, "en": { "role": { "documentation": "The number of shares issued by the entity." } } }, "auth_ref": [ "r279" ] }, "adxn_NumberOfSharesIssuedIncludingIfrs2Shares": { "xbrltype": "sharesItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "NumberOfSharesIssuedIncludingIfrs2Shares", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued including IFRS 2 shares", "label": "Number of common shares including IFRS 2 shares" } } }, "auth_ref": [] }, "ifrs-full_NumberOfSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfSharesOutstanding", "presentation": [ "http://addextherapeutics.com/role/DisclosureEventsAfterBalanceSheetDateDetails", "http://addextherapeutics.com/role/DisclosureShareCapitalDetails" ], "lang": { "en-us": { "role": { "label": "Number of shares outstanding", "periodEndLabel": "Number of shares at end of period", "periodStartLabel": "Number of shares at beginning of period", "terseLabel": "Number of outstanding shares" } }, "en": { "role": { "documentation": "The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]" } } }, "auth_ref": [ "r134", "r189", "r216" ] }, "adxn_NumberOfSharesOutstandingIncludingIfrs2Shares": { "xbrltype": "sharesItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "NumberOfSharesOutstandingIncludingIfrs2Shares", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of shares outstanding including IFRS 2 shares", "label": "Number of shares including IFRS 2 shares" } } }, "auth_ref": [] }, "adxn_NumberOfSharesReclassedAsTreasurySharesUnderIfrs2SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "NumberOfSharesReclassedAsTreasurySharesUnderIfrs2SharesOutstanding", "presentation": [ "http://addextherapeutics.com/role/DisclosureEventsAfterBalanceSheetDateDetails", "http://addextherapeutics.com/role/DisclosureShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of shares reclassed as treasury shares under IFRS 2, shares outstanding", "label": "Number of shares reclassed as treasury shares under IFRS 2, shares outstanding", "negatedLabel": "Number of shares reclassed as treasury shares under IFRS 2", "terseLabel": "Number of shares reclassed as treasury shares under IFRS 2" } } }, "auth_ref": [] }, "adxn_NumberOfSharesReclassedAsTreasurySharesUnderIfrs2TreasuryShares": { "xbrltype": "sharesItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "NumberOfSharesReclassedAsTreasurySharesUnderIfrs2TreasuryShares", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of shares reclassed as treasury shares under IFRS 2, treasury shares", "label": "Number of shares reclassed as treasury shares under IFRS 2, treasury shares", "negatedLabel": "Number of shares reclassed as treasury shares under IFRS 2" } } }, "auth_ref": [] }, "adxn_NumberOfSwissBanksUsed": { "xbrltype": "integerItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "NumberOfSwissBanksUsed", "presentation": [ "http://addextherapeutics.com/role/DisclosureCashAndCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of Swiss banks used", "label": "Number of Swiss banks used" } } }, "auth_ref": [] }, "adxn_NumberOfTreasurySharesIncludingIfrs2Shares": { "xbrltype": "sharesItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "NumberOfTreasurySharesIncludingIfrs2Shares", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of treasury shares including IFRS 2 shares", "label": "Number of treasury shares including IFRS 2 shares", "negatedLabel": "Number of shares including IFRS 2 shares" } } }, "auth_ref": [] }, "adxn_NumberOfTreasurySharesSoldPurchased": { "xbrltype": "sharesItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "NumberOfTreasurySharesSoldPurchased", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of treasury shares sold (purchased) under liquidity agreement", "label": "Number of treasury shares sold (purchased) under liquidity agreement", "terseLabel": "Movement of shares under liquidity agreement" } } }, "auth_ref": [] }, "adxn_OperatingCostsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "OperatingCostsAbstract", "presentation": [ "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "documentation": "Operating costs", "label": "Operating costs" } } }, "auth_ref": [] }, "ifrs-full_OperatingExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OperatingExpense", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0, "order": 1.0 }, "http://addextherapeutics.com/role/DisclosureOperatingCostsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureOperatingCostsDetails", "http://addextherapeutics.com/role/DisclosureSegmentInformationDetails", "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Operating expense", "negatedTotalLabel": "Total operating costs", "totalLabel": "Total operating costs", "verboseLabel": "Operating costs" } } }, "auth_ref": [ "r284" ] }, "ifrs-full_OrdinarySharesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OrdinarySharesMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareCapitalDetails" ], "lang": { "en-us": { "role": { "label": "Common shares" } }, "en": { "role": { "documentation": "This member stands for equity instruments that are subordinate to all other classes of equity instruments." } } }, "auth_ref": [ "r283" ] }, "ifrs-full_OtherComprehensiveIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherComprehensiveIncome", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss": { "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfChangesInEquity", "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Other comprehensive income", "terseLabel": "Other comprehensive (loss) / Income for the period", "totalLabel": "Other comprehensive income / (loss) for the period, net of tax" } } }, "auth_ref": [ "r75", "r199", "r221", "r225" ] }, "ifrs-full_OtherComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherComprehensiveIncomeAbstract", "presentation": [ "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Other comprehensive income [abstract]", "terseLabel": "Other comprehensive income / (loss)" } } }, "auth_ref": [] }, "ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss": { "parentTag": "ifrs-full_OtherComprehensiveIncome", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Other comprehensive income, net of tax, exchange differences on translation of foreign operations", "terseLabel": "Exchange difference on translation of foreign operations" } }, "en": { "role": { "documentation": "The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r213", "r225" ] }, "adxn_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansContinuingOperations", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss": { "parentTag": "ifrs-full_OtherComprehensiveIncome", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "documentation": "The amount of other comprehensive income, net of tax, related to gains (losses) on remeasurements of defined benefit plans, which comprise actuarial gains and losses; the return on plan assets, excluding amounts included in net interest on the net defined benefit liability (asset); and any change in the effect of the asset ceiling, excluding amounts included in net interest on the net defined benefit liability (asset) attributable to continuing operations.", "label": "Other Comprehensive Income, Net Of Tax, Gains (Losses) On Remeasurements Of Defined Benefit Plans, Continuing Operations", "terseLabel": "Remeasurements of retirement benefits obligation related to continuing operations" } } }, "auth_ref": [] }, "ifrs-full_OtherCurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherCurrentAssets", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/DisclosureOtherCurrentAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Other current assets.", "totalLabel": "Total other current assets" } }, "en": { "role": { "documentation": "The amount of current assets that the entity does not separately disclose in the same statement or note. [Refer: Current assets]" } } }, "auth_ref": [ "r281" ] }, "adxn_OtherCurrentAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "OtherCurrentAssetsAbstract", "lang": { "en-us": { "role": { "documentation": "Other current assets", "label": "Other current assets" } } }, "auth_ref": [] }, "ifrs-full_OtherCurrentFinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherCurrentFinancialAssets", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/DisclosureOtherCurrentAssetsDetails": { "parentTag": "ifrs-full_OtherCurrentAssets", "weight": 1.0, "order": 2.0 }, "http://addextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureOtherCurrentAssetsDetails", "http://addextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Other current financial assets", "terseLabel": "Other financial assets" } }, "en": { "role": { "documentation": "The amount of current financial assets that the entity does not separately disclose in the same statement or note. [Refer: Other financial assets; Current financial assets]" } } }, "auth_ref": [ "r206" ] }, "ifrs-full_OtherCurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherCurrentLiabilities", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 2.0 }, "http://addextherapeutics.com/role/DisclosurePayablesAccrualsAndOtherCurrentLiabilitiesDetails": { "parentTag": "adxn_TradeAndOtherCurrentPayablesAndOtherCurrentLiabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosurePayablesAccrualsAndOtherCurrentLiabilitiesDetails", "http://addextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Other current liabilities", "terseLabel": "Other current liabilities" } }, "en": { "role": { "documentation": "The amount of current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Current liabilities]" } } }, "auth_ref": [ "r281" ] }, "ifrs-full_OtherEquityInterest": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherEquityInterest", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://addextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Other equity interest", "terseLabel": "Other equity" } }, "en": { "role": { "documentation": "The amount of equity interest of an entity without share capital that the entity does not separately disclose in the same statement or note." } } }, "auth_ref": [ "r249", "r255" ] }, "ifrs-full_OtherEquityInterestMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherEquityInterestMember", "presentation": [ "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Other equity interest [member]", "terseLabel": "Other Equity" } }, "en": { "role": { "documentation": "This member stands for equity interest of an entity without share capital that the entity does not separately disclose in the same statement or note." } } }, "auth_ref": [ "r201" ] }, "ifrs-full_OtherExpenseByNature": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherExpenseByNature", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/DisclosureOperatingCostsDetails": { "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureOperatingCostsDetails" ], "lang": { "en-us": { "role": { "label": "Other expenses, by nature", "verboseLabel": "Other operating costs" } } }, "auth_ref": [ "r227", "r250" ] }, "adxn_OtherFinancialAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "OtherFinancialAssetsMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for other financial assets.", "label": "Other financial assets" } } }, "auth_ref": [] }, "ifrs-full_OtherIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherIncome", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureOtherIncomeDetails", "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Other income.", "terseLabel": "Other income" } } }, "auth_ref": [ "r25", "r250", "r251" ] }, "adxn_OtherIncomeLineItems": { "xbrltype": "stringItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "OtherIncomeLineItems", "presentation": [ "http://addextherapeutics.com/role/DisclosureOtherIncomeDetails" ], "lang": { "en-us": { "role": { "documentation": "Other income", "label": "Other income [Line Items]", "terseLabel": "Other income" } } }, "auth_ref": [] }, "adxn_OtherIncomeTable": { "xbrltype": "stringItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "OtherIncomeTable", "presentation": [ "http://addextherapeutics.com/role/DisclosureOtherIncomeDetails" ], "lang": { "en-us": { "role": { "documentation": "Other income", "label": "Other income [Table]" } } }, "auth_ref": [] }, "adxn_OtherReserveMember": { "xbrltype": "domainItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "OtherReserveMember", "presentation": [ "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "documentation": "Other reserves, excluding treasury shares and foreign currency translation", "label": "Other Reserves" } } }, "auth_ref": [] }, "ifrs-full_OtherReserves": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherReserves", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://addextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Other reserves.", "terseLabel": "Other reserves" } }, "en": { "role": { "documentation": "A component of equity representing reserves within equity, not including retained earnings. [Refer: Retained earnings]" } } }, "auth_ref": [ "r249", "r255" ] }, "adxn_P1Or1Member": { "xbrltype": "domainItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "P1Or1Member", "presentation": [ "http://addextherapeutics.com/role/DisclosureCashAndCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "documentation": "P-1 rating by Moody's or A-1 rating by Standard & Poor's", "label": "P-1 / A-1", "terseLabel": "P-1 / A-1" } } }, "auth_ref": [] }, "adxn_PatentMaintenanceAndRegistrationCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "PatentMaintenanceAndRegistrationCosts", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/DisclosureOperatingCostsDetails": { "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureOperatingCostsDetails" ], "lang": { "en-us": { "role": { "documentation": "Patent maintenance and registration costs", "label": "Patent maintenance and registration costs", "terseLabel": "Patent maintenance and registration costs" } } }, "auth_ref": [] }, "adxn_PayablesAccrualsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "PayablesAccrualsAbstract", "lang": { "en-us": { "role": { "documentation": "Payables and accruals", "label": "Payables, accruals and other current liabilities" } } }, "auth_ref": [] }, "ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments of lease liabilities, classified as financing activities", "negatedTerseLabel": "Principal element of lease payment" } }, "en": { "role": { "documentation": "The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]" } } }, "auth_ref": [ "r233" ] }, "adxn_PercentageOfCashAndCashEquivalents": { "xbrltype": "percentItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "PercentageOfCashAndCashEquivalents", "presentation": [ "http://addextherapeutics.com/role/DisclosureCashAndCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of cash and cash equivalents", "label": "Percentage of cash and cash equivalents", "terseLabel": "Percentage of cash and cash equivalents" } } }, "auth_ref": [] }, "adxn_PercentageOfEquityInterestReceived": { "xbrltype": "percentItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "PercentageOfEquityInterestReceived", "presentation": [ "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsGeneralDetails", "http://addextherapeutics.com/role/DisclosureInterestsInAssociatesDetails", "http://addextherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of equity interest received", "label": "Percentage of equity interest received", "terseLabel": "Percentage of equity interest received" } } }, "auth_ref": [] }, "ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputAssets": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PercentageOfReasonablyPossibleDecreaseInUnobservableInputAssets", "presentation": [ "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsInputsDetails" ], "lang": { "en-us": { "role": { "label": "Percentage of reasonably possible decrease in unobservable input" } }, "en": { "role": { "documentation": "The percentage of a reasonably possible decrease in an unobservable input used in fair value measurement of assets." } } }, "auth_ref": [ "r273" ] }, "ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputAssets": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PercentageOfReasonablyPossibleIncreaseInUnobservableInputAssets", "presentation": [ "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsInputsDetails" ], "lang": { "en-us": { "role": { "label": "Percentage of reasonably possible increase in unobservable input" } }, "en": { "role": { "documentation": "The percentage of a reasonably possible increase in an unobservable input used in fair value measurement of assets." } } }, "auth_ref": [ "r273" ] }, "adxn_PhantomSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "PhantomSharesMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails", "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsInputsDetails" ], "lang": { "en-us": { "role": { "documentation": "Phantom shares", "label": "Phantom shares" } } }, "auth_ref": [] }, "adxn_PhantomSharesReceivedOnInvestment": { "xbrltype": "sharesItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "PhantomSharesReceivedOnInvestment", "presentation": [ "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "documentation": "Phantom shares received on investment", "label": "Phantom shares received on investment", "terseLabel": "Phantom shares received on investment in Stalicla SA" } } }, "auth_ref": [] }, "ifrs-full_PlanAssetsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PlanAssetsMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureRetirementBenefitsObligationsBalanceSheetDetails" ], "lang": { "en-us": { "role": { "label": "Fair value of plan assets", "terseLabel": "Fair value of plan assets" } }, "en": { "role": { "documentation": "This member stands for defined benefit plan assets. Plan assets comprise: (a) assets held by a long-term employee benefit fund; and (b) qualifying insurance policies." } } }, "auth_ref": [ "r10", "r146" ] }, "ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PostemploymentBenefitExpenseDefinedBenefitPlans", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/DisclosureStaffCostsDetails": { "parentTag": "ifrs-full_EmployeeBenefitsExpense", "weight": 1.0, "order": 2.0 }, "http://addextherapeutics.com/role/DisclosureRetirementBenefitsObligationsComprehensiveLossDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureRetirementBenefitsObligationsComprehensiveLossDetails", "http://addextherapeutics.com/role/DisclosureStaffCostsDetails" ], "lang": { "en-us": { "role": { "label": "Post-employment benefit expense, defined benefit plans", "negatedTotalLabel": "Company pension amount", "terseLabel": "Retirement benefit (note 15)" } } }, "auth_ref": [ "r261", "r262" ] }, "ifrs-full_PotentialOrdinaryShareTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PotentialOrdinaryShareTransactionsMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureEventsAfterBalanceSheetDateDetails" ], "lang": { "en-us": { "role": { "label": "Potential ordinary share transactions [member]", "terseLabel": "Reduction of strike price" } }, "en": { "role": { "documentation": "This member stands for potential ordinary share transactions. [Refer: Ordinary shares [member]]" } } }, "auth_ref": [ "r228", "r246" ] }, "ifrs-full_PreferenceSharesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PreferenceSharesMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails", "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsInputsDetails" ], "lang": { "en-us": { "role": { "label": "Preference shares [member]", "terseLabel": "Preferred shares" } }, "en": { "role": { "documentation": "This member stands for equity instruments that are senior in some aspects to ordinary shares, but subordinate to debt instruments in terms of claim. [Refer: Ordinary shares [member]]" } } }, "auth_ref": [ "r283" ] }, "adxn_PreferredSharesReceivedOnInvestment": { "xbrltype": "sharesItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "PreferredSharesReceivedOnInvestment", "presentation": [ "http://addextherapeutics.com/role/DisclosureFinancialAssetsAtFairValueThroughOtherComprehensiveIncomeDetails" ], "lang": { "en-us": { "role": { "documentation": "Preferred shares received on investment", "label": "Preferred shares received on investment", "terseLabel": "Preferred shares received on investment in Stalicla SA" } } }, "auth_ref": [] }, "ifrs-full_PresentValueOfDefinedBenefitObligationMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PresentValueOfDefinedBenefitObligationMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureRetirementBenefitsObligationsBalanceSheetDetails" ], "lang": { "en-us": { "role": { "label": "Defined benefit obligation", "terseLabel": "Defined benefit obligation" } }, "en": { "role": { "documentation": "This member stands for the present value of a defined benefit obligation. The present value of a defined benefit obligation is the present value, without deducting any plan assets, of expected future payments required to settle the obligation resulting from employee service in the current and prior periods." } } }, "auth_ref": [ "r11", "r147" ] }, "ifrs-full_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from disposal of non-current assets or disposal groups classified as held for sale and discontinued operations", "terseLabel": "Consideration from Neurosterix Transaction" } }, "en": { "role": { "documentation": "The cash inflow from the disposal of non-current assets or disposal groups classified as held for sale and discontinued operations. [Refer: Discontinued operations [member]; Disposal groups classified as held for sale [member]; Non-current assets or disposal groups classified as held for sale]" } } }, "auth_ref": [ "r268" ] }, "ifrs-full_ProceedsFromSaleOrIssueOfTreasuryShares": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProceedsFromSaleOrIssueOfTreasuryShares", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from sale or issue of treasury shares", "terseLabel": "Sale of treasury ADSs and shares" } }, "en": { "role": { "documentation": "The cash inflow from the sale or issuing of treasury shares. [Refer: Sale or issue of treasury shares; Treasury shares]" } } }, "auth_ref": [ "r269" ] }, "adxn_ProceedsFromSalePaymentsForPurchaseOfTreasurySharesUnderLiquidityAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "ProceedsFromSalePaymentsForPurchaseOfTreasurySharesUnderLiquidityAgreement", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Proceeds from sale (payments for purchase) of treasury shares under liquidity agreement", "label": "Proceeds from sale (payments for purchase) of treasury shares under liquidity agreement", "terseLabel": "Movements under liquidity agreement" } } }, "auth_ref": [] }, "ifrs-full_ProfessionalFeesExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProfessionalFeesExpense", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/DisclosureOperatingCostsDetails": { "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureOperatingCostsDetails" ], "lang": { "en-us": { "role": { "label": "Professional fees expense", "terseLabel": "Professional fees" } } }, "auth_ref": [ "r280" ] }, "ifrs-full_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss": { "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0, "order": 2.0 }, "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 15.0 } }, "presentation": [ "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfChangesInEquity", "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Profit (loss)", "totalLabel": "Net loss for the period", "verboseLabel": "Net loss for the period" } }, "en": { "role": { "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r62", "r64", "r119", "r120", "r157", "r172", "r198", "r220", "r234", "r238" ] }, "ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity", "crdr": "credit", "presentation": [ "http://addextherapeutics.com/role/DisclosureLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Profit (loss), attributable to ordinary equity holders of parent entity, used in calculating basic earnings per share", "terseLabel": "Net loss attributable to equity holders of the company - basic" } }, "en": { "role": { "documentation": "The profit (loss) attributable to ordinary equity holders of the parent entity. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r33" ] }, "ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects", "crdr": "credit", "presentation": [ "http://addextherapeutics.com/role/DisclosureLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Profit (loss), attributable to ordinary equity holders of parent entity, used in calculating diluted earnings per share", "terseLabel": "Net loss attributable to equity holders of the company - diluted" } }, "en": { "role": { "documentation": "The profit (loss) attributable to ordinary equity holders of the parent entity, adjusted for the effects of all dilutive potential ordinary shares. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r33" ] }, "ifrs-full_ProfitLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProfitLossBeforeTax", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss": { "parentTag": "ifrs-full_ProfitLossFromContinuingOperations", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Profit (loss) before tax", "totalLabel": "Net loss before tax from continuing operations" } } }, "auth_ref": [ "r105", "r243", "r244", "r250", "r251" ] }, "ifrs-full_ProfitLossFromContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProfitLossFromContinuingOperations", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss": { "parentTag": "ifrs-full_ProfitLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Profit (loss) from continuing operations", "totalLabel": "Net loss from continuing operations" } }, "en": { "role": { "documentation": "The profit (loss) from continuing operations. [Refer: Continuing operations, unless line item indicates otherwise [member]; Profit (loss)]" } } }, "auth_ref": [ "r73", "r119", "r120", "r220" ] }, "ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity", "crdr": "credit", "presentation": [ "http://addextherapeutics.com/role/DisclosureLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Profit (loss) from continuing operations attributable to ordinary equity holders of parent entity, used in calculating basic earnings per share", "terseLabel": "Net loss from continuing operations - basic" } }, "en": { "role": { "documentation": "The profit (loss) from continuing operations attributable to ordinary equity holders of the parent entity. [Refer: Continuing operations, unless line item indicates otherwise [member]; Profit (loss) from continuing operations]" } } }, "auth_ref": [ "r33" ] }, "ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects", "crdr": "credit", "presentation": [ "http://addextherapeutics.com/role/DisclosureLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Profit (loss) from continuing operations attributable to ordinary equity holders of parent entity, used in calculating diluted earnings per share", "terseLabel": "Net loss from continuing operations - diluted" } }, "en": { "role": { "documentation": "The profit (loss) from continuing operations attributable to ordinary equity holders of the parent entity, adjusted for the effects of all dilutive potential ordinary shares. [Refer: Profit (loss) from continuing operations]" } } }, "auth_ref": [ "r33" ] }, "ifrs-full_ProfitLossFromDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProfitLossFromDiscontinuedOperations", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss": { "parentTag": "ifrs-full_ProfitLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Profit (loss) from discontinued operations", "terseLabel": "Net profit from discontinued operations (attributable to equity holders of the Group)" } } }, "auth_ref": [ "r74", "r104", "r224", "r226" ] }, "ifrs-full_ProfitLossFromDiscontinuedOperationsAttributableToOrdinaryEquityHoldersOfParentEntity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProfitLossFromDiscontinuedOperationsAttributableToOrdinaryEquityHoldersOfParentEntity", "crdr": "credit", "presentation": [ "http://addextherapeutics.com/role/DisclosureLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Profit (loss) from discontinued operations attributable to ordinary equity holders of parent entity, used in calculating basic earnings per share", "terseLabel": "Net profit from discontinued operations - basic" } } }, "auth_ref": [ "r33" ] }, "ifrs-full_ProfitLossFromDiscontinuedOperationsAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProfitLossFromDiscontinuedOperationsAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects", "crdr": "credit", "presentation": [ "http://addextherapeutics.com/role/DisclosureLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Profit (loss) from discontinued operations attributable to ordinary equity holders of parent entity, used in calculating diluted earnings per share", "terseLabel": "Net profit from discontinued operations - diluted" } } }, "auth_ref": [ "r33" ] }, "ifrs-full_ProfitLossFromOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProfitLossFromOperatingActivities", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss": { "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Profit (loss) from operating activities", "totalLabel": "Operating loss" } } }, "auth_ref": [ "r231", "r284" ] }, "ifrs-full_PropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PropertyPlantAndEquipment", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureEquipmentDetails", "http://addextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Property, plant and equipment", "periodEndLabel": "Closing amount", "periodStartLabel": "Opening amount", "verboseLabel": "Equipment" } }, "en": { "role": { "documentation": "The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]" } } }, "auth_ref": [ "r4", "r143", "r204" ] }, "ifrs-full_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "label": "Equipment." } } }, "auth_ref": [] }, "ifrs-full_ProportionOfOwnershipInterestInAssociate": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProportionOfOwnershipInterestInAssociate", "presentation": [ "http://addextherapeutics.com/role/DisclosureGeneralInformationDetails", "http://addextherapeutics.com/role/DisclosureMaterialAccountingEstimatesAndJudgmentsDetails" ], "lang": { "en-us": { "role": { "label": "Proportion of ownership interest in associate", "terseLabel": "Equity interest held", "verboseLabel": "Equity interest received" } }, "en": { "role": { "documentation": "The proportion of ownership interest in an associate attributable to the entity. [Refer: Total for all associates [member]]" } } }, "auth_ref": [ "r26", "r28", "r66" ] }, "adxn_PurchaseOfDerivativeFinancialInstruments": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "PurchaseOfDerivativeFinancialInstruments", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Purchase of derivative financial instruments", "label": "Purchase of derivative financial instruments", "negatedLabel": "Investment in Stalicla Ltd - derivative financial instruments" } } }, "auth_ref": [] }, "ifrs-full_PurchaseOfFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeClassifiedAsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PurchaseOfFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeClassifiedAsInvestingActivities", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Purchase of financial assets measured at fair value through other comprehensive income, classified as investing activities", "negatedLabel": "Investment in Stalicla Ltd - preferred shares" } }, "en": { "role": { "documentation": "The cash outflow for the purchase of financial assets measured at fair value through other comprehensive income, classified as investing activities." } } }, "auth_ref": [ "r268" ] }, "adxn_PurchaseOfInvestmentsInOtherEntitiesIncludingRelatedFinancialInstruments": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "PurchaseOfInvestmentsInOtherEntitiesIncludingRelatedFinancialInstruments", "crdr": "credit", "presentation": [ "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsInputsDetails", "http://addextherapeutics.com/role/DisclosureFinancialAssetsAtFairValueThroughOtherComprehensiveIncomeDetails" ], "lang": { "en-us": { "role": { "documentation": "Purchase of investments in other entities, including related financial instruments", "label": "Purchase of investments in other entities, including related financial instruments", "terseLabel": "Investment in Stalicla SA", "verboseLabel": "Subscription price for investment in Stalicla SA" } } }, "auth_ref": [] }, "ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities", "crdr": "credit", "presentation": [ "http://addextherapeutics.com/role/DisclosureSegmentInformationDetails" ], "lang": { "en-us": { "role": { "label": "Purchase of property, plant and equipment, classified as investing activities", "terseLabel": "Capital expenditure" } }, "en": { "role": { "documentation": "The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r232" ] }, "ifrs-full_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RangeAxis", "presentation": [ "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsInputsDetails" ], "lang": { "en-us": { "role": { "label": "Range [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r58", "r85", "r96", "r100", "r138", "r235", "r236", "r277" ] }, "ifrs-full_RangeDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RangeDomain", "presentation": [ "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsInputsDetails" ], "lang": { "en-us": { "role": { "label": "Range [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used." } } }, "auth_ref": [ "r58", "r85", "r96", "r100", "r138", "r235", "r236", "r277" ] }, "ifrs-full_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related party transactions" } } }, "auth_ref": [] }, "ifrs-full_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss": { "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Research and development expense", "negatedLabel": "Research and development" } } }, "auth_ref": [ "r46", "r165" ] }, "ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ReserveOfExchangeDifferencesOnTranslationMember", "presentation": [ "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Foreign Currency Translation Reserve" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing accumulated exchange differences on the translation of financial statements recognised in other comprehensive income. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r17", "r151", "r252" ] }, "ifrs-full_RetainedEarnings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RetainedEarnings", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://addextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Retained earnings", "terseLabel": "Accumulated deficit" } }, "en": { "role": { "documentation": "A component of equity representing the entity's cumulative undistributed earnings or deficit." } } }, "auth_ref": [ "r249", "r255", "r256" ] }, "ifrs-full_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RetainedEarningsMember", "presentation": [ "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Accumulated Deficit" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit." } } }, "auth_ref": [ "r201", "r252" ] }, "ifrs-full_RevenueAndOperatingIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RevenueAndOperatingIncome", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/DisclosureSegmentInformationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureSegmentInformationDetails" ], "lang": { "en-us": { "role": { "label": "Revenue and other operating income", "totalLabel": "Other income" } } }, "auth_ref": [ "r284" ] }, "ifrs-full_RevenueFromContractsWithCustomers": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RevenueFromContractsWithCustomers", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureRevenueFromContractWithCustomerDetails", "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Revenue from contracts with customers", "terseLabel": "Revenue from contract with customer" } } }, "auth_ref": [ "r86", "r87", "r127" ] }, "adxn_RevenueFromContractsWithCustomersAbstract": { "xbrltype": "stringItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "RevenueFromContractsWithCustomersAbstract", "lang": { "en-us": { "role": { "documentation": "Revenue from contracts with customers", "label": "Revenue from contract with customer" } } }, "auth_ref": [] }, "ifrs-full_RightofuseAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RightofuseAssets", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureRightOfUseAssetsDetails", "http://addextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Right-of-use assets.", "periodEndLabel": "Closing amount", "periodStartLabel": "Opening amount", "terseLabel": "Right-of-use assets" } }, "en": { "role": { "documentation": "The amount of assets that represent a lessee's right to use an underlying asset for the lease term that do not meet the definition of investment property. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee." } } }, "auth_ref": [ "r90", "r94", "r130" ] }, "adxn_SaleOfTreasuryShare": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "SaleOfTreasuryShare", "crdr": "credit", "presentation": [ "http://addextherapeutics.com/role/DisclosureEventsAfterBalanceSheetDateDetails", "http://addextherapeutics.com/role/DisclosureShareCapitalDetails", "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "documentation": "Sale of treasury shares", "label": "Sale of treasury share", "terseLabel": "Sale of treasury ADSs and shares", "verboseLabel": "Gross proceeds from sale of treasury shares" } } }, "auth_ref": [] }, "adxn_SaleOfTreasuryShares": { "xbrltype": "sharesItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "SaleOfTreasuryShares", "presentation": [ "http://addextherapeutics.com/role/DisclosureEventsAfterBalanceSheetDateDetails", "http://addextherapeutics.com/role/DisclosureShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "Sale of treasury shares", "label": "Sale of treasury shares", "terseLabel": "Sale of treasury ADS's and shares" } } }, "auth_ref": [] }, "adxn_SalePriceOfSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "SalePriceOfSharesMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsInputsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for sale price of shares", "label": "Sale price of shares" } } }, "auth_ref": [] }, "adxn_ServiceAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "ServiceAgreementMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for a class of intangible assets representing service agreements.", "label": "Service Agreement [Member]", "terseLabel": "Service agreement" } } }, "auth_ref": [] }, "adxn_ShareBasedArrangementIncreaseInFairValueFromModification": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "ShareBasedArrangementIncreaseInFairValueFromModification", "crdr": "credit", "presentation": [ "http://addextherapeutics.com/role/DisclosureEventsAfterBalanceSheetDateDetails" ], "lang": { "en-us": { "role": { "documentation": "Increase in fair value from modification in share based arrangement.", "label": "Share Based Arrangement, Increase in Fair Value from Modification", "terseLabel": "Increase in fair value from modification" } } }, "auth_ref": [] }, "ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss": { "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureInterestsInAssociatesDetails", "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Share of net loss of associates", "terseLabel": "Share of net loss of investments accounted for using the equity method", "verboseLabel": "Share of the net loss for the period of Neurosterix's Group" } } }, "auth_ref": [ "r284" ] }, "ifrs-full_ShareOptionsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ShareOptionsMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionsOrSharesOutstandingDetails" ], "lang": { "en-us": { "role": { "label": "Share option plans", "verboseLabel": "Share options" } }, "en": { "role": { "documentation": "This member stands for share options." } } }, "auth_ref": [ "r264" ] }, "ifrs-full_SharePremium": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SharePremium", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://addextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Share premium.", "terseLabel": "Share premium" } }, "en": { "role": { "documentation": "The amount received or receivable from the issuance of the entity's shares in excess of nominal value." } } }, "auth_ref": [ "r249", "r255" ] }, "ifrs-full_SharePremiumMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SharePremiumMember", "presentation": [ "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Share Premium" } }, "en": { "role": { "documentation": "This member stands for the amount received or receivable from issuance of the entity's shares in excess of nominal value." } } }, "auth_ref": [ "r201" ] }, "adxn_ShareSalePrice": { "xbrltype": "perShareItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "ShareSalePrice", "presentation": [ "http://addextherapeutics.com/role/DisclosureEventsAfterBalanceSheetDateDetails", "http://addextherapeutics.com/role/DisclosureShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "Share sale price", "label": "Share sale price", "terseLabel": "Share sale price" } } }, "auth_ref": [] }, "adxn_SharesHeldInTreasuryMember": { "xbrltype": "domainItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "SharesHeldInTreasuryMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "Shares held in treasury", "label": "Treasury share [member]", "terseLabel": "Treasury shares" } } }, "auth_ref": [] }, "ifrs-full_SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates", "presentation": [ "http://addextherapeutics.com/role/DisclosureEventsAfterBalanceSheetDateDetails", "http://addextherapeutics.com/role/DisclosureShareCapitalDetails" ], "lang": { "en-us": { "role": { "label": "Number of shares in entity held by entity or by its subsidiaries or associates", "negatedPeriodEndLabel": "Number of shares at end of period", "negatedPeriodStartLabel": "Number of shares at beginning of period", "terseLabel": "Number of treasury shares" } }, "en": { "role": { "documentation": "The number of shares in the entity held by the entity or by its subsidiaries or associates. [Refer: Total for all associates [member]; Total for all subsidiaries [member]]" } } }, "auth_ref": [ "r135", "r190", "r217" ] }, "adxn_SignificantAccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "SignificantAccountingPoliciesAbstract", "lang": { "en-us": { "role": { "documentation": "Material accounting policies", "label": "Summary of material accounting policies" } } }, "auth_ref": [] }, "ifrs-full_SignificantInvestmentsInAssociatesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SignificantInvestmentsInAssociatesAxis", "presentation": [ "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsGeneralDetails", "http://addextherapeutics.com/role/DisclosureGeneralInformationDetails", "http://addextherapeutics.com/role/DisclosureInterestsInAssociatesDetails", "http://addextherapeutics.com/role/DisclosureMaterialAccountingEstimatesAndJudgmentsDetails", "http://addextherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Associates [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r27", "r29", "r78", "r184" ] }, "ifrs-full_SignificantInvestmentsInAssociatesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SignificantInvestmentsInAssociatesDomain", "presentation": [ "http://addextherapeutics.com/role/DisclosureDiscontinuedOperationsGeneralDetails", "http://addextherapeutics.com/role/DisclosureGeneralInformationDetails", "http://addextherapeutics.com/role/DisclosureInterestsInAssociatesDetails", "http://addextherapeutics.com/role/DisclosureMaterialAccountingEstimatesAndJudgmentsDetails", "http://addextherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Associates [domain]" } }, "en": { "role": { "documentation": "This member stands for the standard value for the 'Associates' axis if no other member is used." } } }, "auth_ref": [ "r27", "r29", "r78", "r184" ] }, "ifrs-full_SignificantUnobservableInputAssets": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SignificantUnobservableInputAssets", "presentation": [ "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsInputsDetails" ], "lang": { "en-us": { "role": { "label": "Significant unobservable input, assets", "terseLabel": "Significant unobservable input" } }, "en": { "role": { "documentation": "The value of significant unobservable input used in the measurement of the fair value of assets." } } }, "auth_ref": [ "r81" ] }, "ifrs-full_SocialSecurityContributions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SocialSecurityContributions", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/DisclosureStaffCostsDetails": { "parentTag": "ifrs-full_EmployeeBenefitsExpense", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureStaffCostsDetails" ], "lang": { "en-us": { "role": { "label": "Social security contributions", "terseLabel": "Social charges and insurances" } } }, "auth_ref": [ "r263" ] }, "adxn_StaliclaSaMember": { "xbrltype": "domainItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "StaliclaSaMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails", "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsInputsDetails", "http://addextherapeutics.com/role/DisclosureFinancialAssetsAtFairValueThroughOtherComprehensiveIncomeDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Stalicla SA", "label": "Stalicla SA" } } }, "auth_ref": [] }, "ifrs-full_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Condensed Consolidated Statements of Cash Flows" } } }, "auth_ref": [] }, "ifrs-full_StatementOfChangesInEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfChangesInEquityAbstract", "lang": { "en-us": { "role": { "label": "Condensed Consolidated Statements of Changes in Equity" } } }, "auth_ref": [] }, "ifrs-full_StatementOfChangesInEquityLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfChangesInEquityLineItems", "presentation": [ "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Statement of changes in equity [line items]", "verboseLabel": "Consolidated Statements of Changes in Equity" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_StatementOfChangesInEquityTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfChangesInEquityTable", "presentation": [ "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Statement of changes in equity [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to changes in equity." } } }, "auth_ref": [ "r201" ] }, "ifrs-full_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Condensed Consolidated Balance Sheets" } } }, "auth_ref": [] }, "adxn_StrikePriceOfWarrantsReceivedOnInvestment": { "xbrltype": "perShareItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "StrikePriceOfWarrantsReceivedOnInvestment", "presentation": [ "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "documentation": "Strike price of warrants received on investment", "label": "Strike price of warrants received on investment in Stalicla SA" } } }, "auth_ref": [] }, "adxn_TabularDisclosureOfInformationAboutFinancialAssetsAtFairValueThroughOtherComprehensiveIncomeTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "TabularDisclosureOfInformationAboutFinancialAssetsAtFairValueThroughOtherComprehensiveIncomeTableTextBlock", "presentation": [ "http://addextherapeutics.com/role/DisclosureFinancialAssetsAtFairValueThroughOtherComprehensiveIncomeTables" ], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of the fair value of investments in equity instruments that the entity has designated at fair value through other comprehensive income.", "label": "Tabular disclosure Of Information About Financial Assets At Fair Value Through Other Comprehensive Income [Table Text Block]", "terseLabel": "Schedule of investments at fair value through other comprehensive income" } } }, "auth_ref": [] }, "ifrs-full_TopOfRangeMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TopOfRangeMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsInputsDetails" ], "lang": { "en-us": { "role": { "label": "Maximum", "terseLabel": "Maximum" } }, "en": { "role": { "documentation": "This member stands for top of a range." } } }, "auth_ref": [ "r58", "r85", "r96", "r100", "r138", "r235", "r236", "r277" ] }, "ifrs-full_TradeAndOtherCurrentPayables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TradeAndOtherCurrentPayables", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://addextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Trade and other current payables", "terseLabel": "Payables and accruals" } }, "en": { "role": { "documentation": "The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]" } } }, "auth_ref": [ "r209" ] }, "adxn_TradeAndOtherCurrentPayablesAndOtherCurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "TradeAndOtherCurrentPayablesAndOtherCurrentLiabilities", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/DisclosurePayablesAccrualsAndOtherCurrentLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://addextherapeutics.com/role/DisclosurePayablesAccrualsAndOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Trade and other current payables and other current liabilities", "label": "Trade and other current payables and other current liabilities", "totalLabel": "Total payables, accruals and other current liabilities" } } }, "auth_ref": [] }, "ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TradeAndOtherCurrentPayablesToTradeSuppliers", "crdr": "credit", "calculation": { "http://addextherapeutics.com/role/DisclosurePayablesAccrualsAndOtherCurrentLiabilitiesDetails": { "parentTag": "adxn_TradeAndOtherCurrentPayablesAndOtherCurrentLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosurePayablesAccrualsAndOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Current trade payables", "terseLabel": "Trade payables" } }, "en": { "role": { "documentation": "The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]" } } }, "auth_ref": [ "r253", "r282" ] }, "ifrs-full_TradeAndOtherCurrentReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TradeAndOtherCurrentReceivables", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/DisclosureOtherCurrentAssetsDetails": { "parentTag": "ifrs-full_OtherCurrentAssets", "weight": 1.0, "order": 3.0 }, "http://addextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureOtherCurrentAssetsDetails", "http://addextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Trade and other current receivables", "terseLabel": "Trade and other receivables" } }, "en": { "role": { "documentation": "The amount of current trade receivables and current other receivables. [Refer: Current trade receivables; Other current receivables]" } } }, "auth_ref": [ "r193", "r207", "r214" ] }, "ifrs-full_TreasuryShares": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TreasuryShares", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "ifrs-full_Equity", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureShareCapitalDetails", "http://addextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Treasury shares", "negatedLabel": "Treasury shares reserve" } }, "en": { "role": { "documentation": "An entity\u2019s own equity instruments, held by the entity or other members of the consolidated group." } } }, "auth_ref": [ "r30", "r249", "r255" ] }, "ifrs-full_TreasurySharesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TreasurySharesMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareCapitalDetails", "http://addextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Treasury Shares Reserve", "terseLabel": "Treasury shares reserve" } }, "en": { "role": { "documentation": "This member stands for the entity\u2019s own equity instruments, held by the entity or other members of the consolidated group." } } }, "auth_ref": [ "r201" ] }, "adxn_TreasurySharesSoldThroughAtMarketAgreementUnderFormOfAdsMember": { "xbrltype": "domainItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "TreasurySharesSoldThroughAtMarketAgreementUnderFormOfAdsMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureEventsAfterBalanceSheetDateDetails", "http://addextherapeutics.com/role/DisclosureShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "Treasury shares sold through At The Market Agreement under form of ADS", "label": "Treasury shares sold through At The Market Agreement under form of ADS [member]", "terseLabel": "Treasury shares sold through At The Market Agreement under form of ADS" } } }, "auth_ref": [] }, "adxn_TreasurySharesSoldUnderSaleAgencyAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "TreasurySharesSoldUnderSaleAgencyAgreementMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "Treasury shares sold, under sale agency agreement", "label": "Treasury shares sold under sale agency agreement" } } }, "auth_ref": [] }, "adxn_TypeOfTreasuryShareTransactionAxis": { "xbrltype": "stringItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "TypeOfTreasuryShareTransactionAxis", "presentation": [ "http://addextherapeutics.com/role/DisclosureEventsAfterBalanceSheetDateDetails", "http://addextherapeutics.com/role/DisclosureShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "Type of treasury share transaction", "label": "Type of treasury share transaction [Axis]" } } }, "auth_ref": [] }, "adxn_TypeOfTreasuryShareTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "TypeOfTreasuryShareTransactionDomain", "presentation": [ "http://addextherapeutics.com/role/DisclosureEventsAfterBalanceSheetDateDetails", "http://addextherapeutics.com/role/DisclosureShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "Type of treasury share transaction", "label": "Type of treasury share transaction [domain]" } } }, "auth_ref": [] }, "ifrs-full_TypesOfSharebasedPaymentArrangementsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TypesOfSharebasedPaymentArrangementsAxis", "presentation": [ "http://addextherapeutics.com/role/DisclosureEventsAfterBalanceSheetDateDetails", "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionsOrSharesOutstandingDetails" ], "lang": { "en-us": { "role": { "label": "Types of share-based payment arrangements [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r101", "r175" ] }, "ifrs-full_TypesOfSharebasedPaymentArrangementsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TypesOfSharebasedPaymentArrangementsDomain", "presentation": [ "http://addextherapeutics.com/role/DisclosureEventsAfterBalanceSheetDateDetails", "http://addextherapeutics.com/role/DisclosureShareBasedCompensationShareOptionsOrSharesOutstandingDetails" ], "lang": { "en-us": { "role": { "label": "Types of share-based payment arrangements [domain]" } }, "en": { "role": { "documentation": "This member stands for an agreement between the entity or another group entity or any shareholder of the group entity and another party (including an employee) that entitles the other party to receive (a) cash or other assets of the entity for amounts that are based on the price (or value) of equity instruments (including shares or share options) of the entity or another group entity; or (b) equity instruments (including shares or share options) of the entity or another group entity, provided that the specified vesting conditions, if any, are met. It also represents the standard value for the 'Types of share-based payment arrangements' axis if no other member is used." } } }, "auth_ref": [ "r101", "r175" ] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2025", "localname": "US", "presentation": [ "http://addextherapeutics.com/role/DisclosureSegmentInformationDetails" ], "lang": { "en-us": { "role": { "label": "UNITED STATES", "terseLabel": "United States of America" } } }, "auth_ref": [] }, "currency_USD": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2025", "localname": "USD", "presentation": [ "http://addextherapeutics.com/role/DisclosureCashAndCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "label": "USD", "terseLabel": "USD" } } }, "auth_ref": [] }, "adxn_UnderlyingSharePriceMember": { "xbrltype": "domainItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "UnderlyingSharePriceMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsInputsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for underlying share price", "label": "Underlying share price" } } }, "auth_ref": [] }, "ifrs-full_UnobservableInputsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "UnobservableInputsAxis", "presentation": [ "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsInputsDetails" ], "lang": { "en-us": { "role": { "label": "Unobservable inputs [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r81", "r274" ] }, "ifrs-full_UnobservableInputsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "UnobservableInputsDomain", "presentation": [ "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsInputsDetails" ], "lang": { "en-us": { "role": { "label": "Unobservable inputs [domain]" } }, "en": { "role": { "documentation": "This member stands for all the unobservable inputs. It also represents the standard value for the 'Unobservable inputs' axis if no other member is used." } } }, "auth_ref": [ "r81", "r274" ] }, "ifrs-full_WagesAndSalaries": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WagesAndSalaries", "crdr": "debit", "calculation": { "http://addextherapeutics.com/role/DisclosureStaffCostsDetails": { "parentTag": "ifrs-full_EmployeeBenefitsExpense", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://addextherapeutics.com/role/DisclosureStaffCostsDetails" ], "lang": { "en-us": { "role": { "label": "Wages and salaries", "terseLabel": "Wages and salaries" } } }, "auth_ref": [ "r263" ] }, "ifrs-full_WarrantsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WarrantsMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails", "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsInputsDetails" ], "lang": { "en-us": { "role": { "label": "Warrant [member]", "terseLabel": "Warrants" } }, "en": { "role": { "documentation": "This member stands for warrants." } } }, "auth_ref": [ "r264" ] }, "adxn_WarrantsReceivedOnInvestment": { "xbrltype": "decimalItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "WarrantsReceivedOnInvestment", "presentation": [ "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "documentation": "Warrants received on investment", "label": "Warrants received on investment", "terseLabel": "Warrants received on investment in Stalicla SA" } } }, "auth_ref": [] }, "adxn_WarrantsReceivedOnInvestmentsClassOneMember": { "xbrltype": "domainItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "WarrantsReceivedOnInvestmentsClassOneMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails", "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsInputsDetails" ], "lang": { "en-us": { "role": { "documentation": "Warrants received on investments, class one", "label": "Warrants received with ten-year exercise period" } } }, "auth_ref": [] }, "adxn_WarrantsReceivedOnInvestmentsClassTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://addextherapeutics.com/20260630", "localname": "WarrantsReceivedOnInvestmentsClassTwoMember", "presentation": [ "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails", "http://addextherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsInputsDetails" ], "lang": { "en-us": { "role": { "documentation": "Warrants received on investments, class two", "label": "Warrants received with five-year exercise period" } } }, "auth_ref": [] }, "ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019", "presentation": [ "http://addextherapeutics.com/role/DisclosureEventsAfterBalanceSheetDateDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement", "terseLabel": "Exercise price of other equity instruments" } }, "en": { "role": { "documentation": "The weighted average exercise price of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r275" ] }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019", "presentation": [ "http://addextherapeutics.com/role/DisclosureEventsAfterBalanceSheetDateDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price of share options outstanding in share-based payment arrangement", "terseLabel": "Exercise price of share options" } }, "en": { "role": { "documentation": "The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r98", "r99", "r173", "r174" ] }, "ifrs-full_WeightedAverageShares": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageShares", "presentation": [ "http://addextherapeutics.com/role/DisclosureLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average number of ordinary shares outstanding", "verboseLabel": "Weighed average number of shares in issue - basic" } }, "en": { "role": { "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor." } } }, "auth_ref": [ "r34" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "10", "IssueDate": "2025-01-01", "Paragraph": "21", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2025-en-r&anchor=para_21&doctype=Standard", "URIDate": "2025-03-27" }, "r1": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "10", "IssueDate": "2025-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS10_g17-22_TI", "URIDate": "2025-03-27" }, "r2": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "73", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73_d&doctype=Standard", "URIDate": "2025-03-27" }, "r3": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "73", "Subparagraph": "e", "Clause": "vii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73_e_vii&doctype=Standard", "URIDate": "2025-03-27" }, "r4": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "73", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73_e&doctype=Standard", "URIDate": "2025-03-27" }, "r5": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "73", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73&doctype=Standard", "URIDate": "2025-03-27" }, "r6": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "75", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_75_a&doctype=Standard", "URIDate": "2025-03-27" }, "r7": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "75", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_75_b&doctype=Standard", "URIDate": "2025-03-27" }, "r8": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS16_g73-79_TI", "URIDate": "2025-03-27" }, "r9": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "138", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_138&doctype=Standard", "URIDate": "2025-03-27" }, "r10": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "140", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_140_a_i&doctype=Standard", "URIDate": "2025-03-27" }, "r11": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "140", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_140_a_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r12": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "140", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_140_a&doctype=Standard", "URIDate": "2025-03-27" }, "r13": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "141", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_141&doctype=Standard", "URIDate": "2025-03-27" }, "r14": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "142", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_142&doctype=Standard", "URIDate": "2025-03-27" }, "r15": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Section": "Scope", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS19_g2-7_TI", "URIDate": "2025-03-27" }, "r16": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "21", "IssueDate": "2025-01-01", "Paragraph": "52", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2025-en-r&anchor=para_52_a&doctype=Standard", "URIDate": "2025-03-27" }, "r17": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "21", "IssueDate": "2025-01-01", "Paragraph": "52", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2025-en-r&anchor=para_52_b&doctype=Standard", "URIDate": "2025-03-27" }, "r18": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_17_e&doctype=Standard", "URIDate": "2025-03-27" }, "r19": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Paragraph": "17", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_17&doctype=Standard", "URIDate": "2025-03-27" }, "r20": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Paragraph": "18", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_18_b&doctype=Standard", "URIDate": "2025-03-27" }, "r21": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Paragraph": "19", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_19_f&doctype=Standard", "URIDate": "2025-03-27" }, "r22": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Paragraph": "19", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_19&doctype=Standard", "URIDate": "2025-03-27" }, "r23": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Paragraph": "20", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_20&doctype=Standard", "URIDate": "2025-03-27" }, "r24": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Section": "Disclosures", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS24_g13-24_TI", "URIDate": "2025-03-27" }, "r25": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "26", "IssueDate": "2025-01-01", "Paragraph": "35", "Subparagraph": "b", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2025-en-r&anchor=para_35_b_iv&doctype=Standard", "URIDate": "2025-03-27" }, "r26": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "27", "IssueDate": "2025-01-01", "Paragraph": "16", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2025-en-r&anchor=para_16_b_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r27": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "27", "IssueDate": "2025-01-01", "Paragraph": "16", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2025-en-r&anchor=para_16_b&doctype=Standard", "URIDate": "2025-03-27" }, "r28": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "27", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2025-en-r&anchor=para_17_b_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r29": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "27", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2025-en-r&anchor=para_17_b&doctype=Standard", "URIDate": "2025-03-27" }, "r30": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "32", "IssueDate": "2025-01-01", "Paragraph": "34", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2025-en-r&anchor=para_34&doctype=Standard", "URIDate": "2025-03-27" }, "r31": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2025-01-01", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_66&doctype=Standard", "URIDate": "2025-03-27" }, "r32": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2025-01-01", "Paragraph": "67", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_67&doctype=Standard", "URIDate": "2025-03-27" }, "r33": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2025-01-01", "Paragraph": "70", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_70_a&doctype=Standard", "URIDate": "2025-03-27" }, "r34": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2025-01-01", "Paragraph": "70", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_70_b&doctype=Standard", "URIDate": "2025-03-27" }, "r35": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2025-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS33_g70-73A_TI", "URIDate": "2025-03-27" }, "r36": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "34", "IssueDate": "2025-01-01", "Paragraph": "16A", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=34&code=ifrs-tx-2025-en-r&anchor=para_16A_a&doctype=Standard", "URIDate": "2025-03-27" }, "r37": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2025-01-01", "Paragraph": "126", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2025-en-r&anchor=para_126&doctype=Standard", "URIDate": "2025-03-27" }, "r38": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2025-01-01", "Paragraph": "130", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2025-en-r&anchor=para_130_b&doctype=Standard", "URIDate": "2025-03-27" }, "r39": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2025-01-01", "Paragraph": "130", "Subparagraph": "d", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2025-en-r&anchor=para_130_d_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r40": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2025-01-01", "Paragraph": "130", "Subparagraph": "f", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2025-en-r&anchor=para_130_f_i&doctype=Standard", "URIDate": "2025-03-27" }, "r41": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2025-01-01", "Paragraph": "134", "Subparagraph": "e", "Clause": "iiA", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2025-en-r&anchor=para_134_e_iiA&doctype=Standard", "URIDate": "2025-03-27" }, "r42": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "118", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_c&doctype=Standard", "URIDate": "2025-03-27" }, "r43": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "118", "Subparagraph": "e", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_e_i&doctype=Standard", "URIDate": "2025-03-27" }, "r44": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "118", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_e&doctype=Standard", "URIDate": "2025-03-27" }, "r45": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "118", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118&doctype=Standard", "URIDate": "2025-03-27" }, "r46": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "126", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_126&doctype=Standard", "URIDate": "2025-03-27" }, "r47": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS38_g118-128_TI", "URIDate": "2025-03-27" }, "r48": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "40", "IssueDate": "2025-01-01", "Paragraph": "32A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2025-en-r&anchor=para_32A&doctype=Standard", "URIDate": "2025-03-27" }, "r49": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "40", "IssueDate": "2025-01-01", "Paragraph": "76", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2025-en-r&anchor=para_76&doctype=Standard", "URIDate": "2025-03-27" }, "r50": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "40", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2025-en-r&anchor=para_79_c&doctype=Standard", "URIDate": "2025-03-27" }, "r51": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "40", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2025-en-r&anchor=para_79_d&doctype=Standard", "URIDate": "2025-03-27" }, "r52": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "41", "IssueDate": "2025-01-01", "Paragraph": "50", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2025-en-r&anchor=para_50&doctype=Standard", "URIDate": "2025-03-27" }, "r53": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "41", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2025-en-r&anchor=para_54_f&doctype=Standard", "URIDate": "2025-03-27" }, "r54": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "10", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_10&doctype=Standard", "URIDate": "2025-03-27" }, "r55": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "25", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_25&doctype=Standard", "URIDate": "2025-03-27" }, "r56": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "28", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_28&doctype=Standard", "URIDate": "2025-03-27" }, "r57": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "31", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_31&doctype=Standard", "URIDate": "2025-03-27" }, "r58": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "44H", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_44H_b_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r59": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_45&doctype=Standard", "URIDate": "2025-03-27" }, "r60": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "50", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_50_d&doctype=Standard", "URIDate": "2025-03-27" }, "r61": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "24", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_24_a&doctype=Standard", "URIDate": "2025-03-27" }, "r62": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "24", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_24_b&doctype=Standard", "URIDate": "2025-03-27" }, "r63": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "32", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_32_a_i&doctype=Standard", "URIDate": "2025-03-27" }, "r64": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "32", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_32_a_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r65": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "2", "Subparagraph": "b", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_2_b_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r66": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "21", "Subparagraph": "a", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_21_a_iv&doctype=Standard", "URIDate": "2025-03-27" }, "r67": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "21", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_21_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r68": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r69": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r70": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r71": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_iv&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r72": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "ix", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_ix&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r73": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "vi", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_vi&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r74": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "vii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_vii&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r75": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "viii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_viii&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r76": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B13", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r77": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B13", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B13_f&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r78": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B4", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B4_d&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r79": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "93", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_a&doctype=Standard", "URIDate": "2025-03-27" }, "r80": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "93", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_b&doctype=Standard", "URIDate": "2025-03-27" }, "r81": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "93", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_d&doctype=Standard", "URIDate": "2025-03-27" }, "r82": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "93", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_e&doctype=Standard", "URIDate": "2025-03-27" }, "r83": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "93", "Subparagraph": "h", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_h_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r84": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "93", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93&doctype=Standard", "URIDate": "2025-03-27" }, "r85": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "14", "IssueDate": "2025-01-01", "Paragraph": "33", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2025-en-r&anchor=para_33_b&doctype=Standard", "URIDate": "2025-03-27" }, "r86": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2025-01-01", "Paragraph": "113", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_113_a&doctype=Standard", "URIDate": "2025-03-27" }, "r87": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2025-01-01", "Paragraph": "114", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_114&doctype=Standard", "URIDate": "2025-03-27" }, "r88": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2025-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IFRS15_g110-129_TI", "URIDate": "2025-03-27" }, "r89": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2025-01-01", "Section": "Presentation", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IFRS15_g105-109_TI", "URIDate": "2025-03-27" }, "r90": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "47", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_47_a&doctype=Standard", "URIDate": "2025-03-27" }, "r91": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "47", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_47_b&doctype=Standard", "URIDate": "2025-03-27" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "53", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_53_a&doctype=Standard", "URIDate": "2025-03-27" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "53", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_53_b&doctype=Standard", "URIDate": "2025-03-27" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "53", "Subparagraph": "j", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_53_j&doctype=Standard", "URIDate": "2025-03-27" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "53", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_53&doctype=Standard", "URIDate": "2025-03-27" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "120", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_120&doctype=Standard", "URIDate": "2025-03-27" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "44", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_44&doctype=Standard", "URIDate": "2025-03-27" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "vi", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_b_vi&doctype=Standard", "URIDate": "2025-03-27" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_d&doctype=Standard", "URIDate": "2025-03-27" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45&doctype=Standard", "URIDate": "2025-03-27" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "51", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_51_a&doctype=Standard", "URIDate": "2025-03-27" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "3", "IssueDate": "2025-01-01", "Paragraph": "B67", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2025-en-r&anchor=para_B67_d&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "5", "IssueDate": "2025-01-01", "Paragraph": "33", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2025-en-r&anchor=para_33_a&doctype=Standard", "URIDate": "2025-03-27" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "5", "IssueDate": "2025-01-01", "Paragraph": "33", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2025-en-r&anchor=para_33_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "5", "IssueDate": "2025-01-01", "Paragraph": "33", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2025-en-r&anchor=para_33_b&doctype=Standard", "URIDate": "2025-03-27" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "5", "IssueDate": "2025-01-01", "Section": "Presentation and disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IFRS05_g30-42_TI", "URIDate": "2025-03-27" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "25", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_25&doctype=Standard", "URIDate": "2025-03-27" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35H", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35H&doctype=Standard", "URIDate": "2025-03-27" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35I", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35I&doctype=Standard", "URIDate": "2025-03-27" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35K", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35K&doctype=Standard", "URIDate": "2025-03-27" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35M", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35M&doctype=Standard", "URIDate": "2025-03-27" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "36", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_36&doctype=Standard", "URIDate": "2025-03-27" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "8", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_8_a&doctype=Standard", "URIDate": "2025-03-27" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "8", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_8_h&doctype=Standard", "URIDate": "2025-03-27" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "8", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_8&doctype=Standard", "URIDate": "2025-03-27" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "B52", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B52&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "23", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23_d&doctype=Standard", "URIDate": "2025-03-27" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "23", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23&doctype=Standard", "URIDate": "2025-03-27" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_b&doctype=Standard", "URIDate": "2025-03-27" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_c&doctype=Standard", "URIDate": "2025-03-27" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_e&doctype=Standard", "URIDate": "2025-03-27" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "32", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_32&doctype=Standard", "URIDate": "2025-03-27" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_33&doctype=Standard", "URIDate": "2025-03-27" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "34", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_34&doctype=Standard", "URIDate": "2025-03-27" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IFRS08_g20-24_TI", "URIDate": "2025-03-27" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "103", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_103&doctype=Standard", "URIDate": "2025-03-27" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "115", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_115_a&doctype=Standard", "URIDate": "2025-03-27" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "115", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_115_b&doctype=Standard", "URIDate": "2025-03-27" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "115", "Subparagraph": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_115_i&doctype=Standard", "URIDate": "2025-03-27" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "115", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_115&doctype=Standard", "URIDate": "2025-03-27" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "128", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_128&doctype=Standard", "URIDate": "2025-03-27" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "133", "Subparagraph": "a", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_133_a_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "160", "Subparagraph": "a", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160_a_iv&doctype=Standard", "URIDate": "2025-03-27" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "160", "Subparagraph": "a", "Clause": "vi", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160_a_vi&doctype=Standard", "URIDate": "2025-03-27" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "160", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160_a&doctype=Standard", "URIDate": "2025-03-27" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "160", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160&doctype=Standard", "URIDate": "2025-03-27" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "168", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_168_b_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "169", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_169&doctype=Standard", "URIDate": "2025-03-27" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "190", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_190&doctype=Standard", "URIDate": "2025-03-27" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "200", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_200_d&doctype=Standard", "URIDate": "2025-03-27" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "200", "Subparagraph": "e", "Clause": "vii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_200_e_vii&doctype=Standard", "URIDate": "2025-03-27" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "200", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_200_e&doctype=Standard", "URIDate": "2025-03-27" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "200", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_200&doctype=Standard", "URIDate": "2025-03-27" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "204", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_204&doctype=Standard", "URIDate": "2025-03-27" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "206", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_206_a_i&doctype=Standard", "URIDate": "2025-03-27" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "206", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_206_a_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "206", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_206_a&doctype=Standard", "URIDate": "2025-03-27" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "207", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_207&doctype=Standard", "URIDate": "2025-03-27" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "218", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_218_a&doctype=Standard", "URIDate": "2025-03-27" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "218", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_218_b&doctype=Standard", "URIDate": "2025-03-27" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "227", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_227&doctype=Standard", "URIDate": "2025-03-27" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "230", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_230_b&doctype=Standard", "URIDate": "2025-03-27" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "231", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_231_f&doctype=Standard", "URIDate": "2025-03-27" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "231", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_231&doctype=Standard", "URIDate": "2025-03-27" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "24", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_24_a&doctype=Standard", "URIDate": "2025-03-27" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "24", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_24_b&doctype=Standard", "URIDate": "2025-03-27" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "246", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_246_a&doctype=Standard", "URIDate": "2025-03-27" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "250", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_250&doctype=Standard", "URIDate": "2025-03-27" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "254", "Subparagraph": "e", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_254_e_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "263", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263_c&doctype=Standard", "URIDate": "2025-03-27" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "263", "Subparagraph": "e", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263_e_i&doctype=Standard", "URIDate": "2025-03-27" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "263", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263_e&doctype=Standard", "URIDate": "2025-03-27" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "263", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263&doctype=Standard", "URIDate": "2025-03-27" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "266", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_266&doctype=Standard", "URIDate": "2025-03-27" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "269", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_269&doctype=Standard", "URIDate": "2025-03-27" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "271", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_271_c&doctype=Standard", "URIDate": "2025-03-27" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "271", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_271_d&doctype=Standard", "URIDate": "2025-03-27" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "273", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_273&doctype=Standard", "URIDate": "2025-03-27" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "274", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_274_e&doctype=Standard", "URIDate": "2025-03-27" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_28_a_i&doctype=Standard", "URIDate": "2025-03-27" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_28_a_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "31", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "31", "Subparagraph": "b", "Clause": "vi", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_b_vi&doctype=Standard", "URIDate": "2025-03-27" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "31", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31&doctype=Standard", "URIDate": "2025-03-27" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "34", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_34_a&doctype=Standard", "URIDate": "2025-03-27" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "37", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_37&doctype=Standard", "URIDate": "2025-03-27" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "44", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_44_a&doctype=Standard", "URIDate": "2025-03-27" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "44", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_44_e&doctype=Standard", "URIDate": "2025-03-27" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "44", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_44&doctype=Standard", "URIDate": "2025-03-27" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_66&doctype=Standard", "URIDate": "2025-03-27" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "70", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_70&doctype=Standard", "URIDate": "2025-03-27" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "71", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_71&doctype=Standard", "URIDate": "2025-03-27" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "75", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_75_c&doctype=Standard", "URIDate": "2025-03-27" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "88", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_88_a&doctype=Standard", "URIDate": "2025-03-27" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "95", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_95_a&doctype=Standard", "URIDate": "2025-03-27" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "95", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_95_b&doctype=Standard", "URIDate": "2025-03-27" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "95", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_95&doctype=Standard", "URIDate": "2025-03-27" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B10", "Subparagraph": "a", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10_a_iv&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B10", "Subparagraph": "a", "Clause": "vi", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10_a_vi&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B10", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10_a&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B10", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B9", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_b&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B9", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_f&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2026-01-01", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "11A", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-b&anchor=para_11A_c&doctype=Standard", "URIDate": "2025-03-27" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "104", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_104&doctype=Standard", "URIDate": "2025-03-27" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_a&doctype=Standard", "URIDate": "2025-03-27" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "Subparagraph": "d", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d_i&doctype=Standard", "URIDate": "2025-03-27" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "Subparagraph": "d", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "Subparagraph": "d", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106&doctype=Standard", "URIDate": "2025-03-27" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_35&doctype=Standard", "URIDate": "2025-03-27" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "51", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_51&doctype=Standard", "URIDate": "2025-03-27" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_a&doctype=Standard", "URIDate": "2025-03-27" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_c&doctype=Standard", "URIDate": "2025-03-27" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_d&doctype=Standard", "URIDate": "2025-03-27" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_h&doctype=Standard", "URIDate": "2025-03-27" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_i&doctype=Standard", "URIDate": "2025-03-27" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "k", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_k&doctype=Standard", "URIDate": "2025-03-27" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "55", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_55&doctype=Standard", "URIDate": "2025-03-27" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_66&doctype=Standard", "URIDate": "2025-03-27" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "69", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_69&doctype=Standard", "URIDate": "2025-03-27" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_7&doctype=Standard", "URIDate": "2025-03-27" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_b&doctype=Standard", "URIDate": "2025-03-27" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_e&doctype=Standard", "URIDate": "2025-03-27" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "a", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a_iv&doctype=Standard", "URIDate": "2025-03-27" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "a", "Clause": "vi", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a_vi&doctype=Standard", "URIDate": "2025-03-27" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a&doctype=Standard", "URIDate": "2025-03-27" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "79", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79&doctype=Standard", "URIDate": "2025-03-27" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "81A", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81A_a&doctype=Standard", "URIDate": "2025-03-27" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "81A", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81A_b&doctype=Standard", "URIDate": "2025-03-27" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "81A", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81A_c&doctype=Standard", "URIDate": "2025-03-27" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "82", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_82_b&doctype=Standard", "URIDate": "2025-03-27" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "82", "Subparagraph": "ea", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_82_ea&doctype=Standard", "URIDate": "2025-03-27" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "91", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_91_a&doctype=Standard", "URIDate": "2025-03-27" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "98", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_98_e&doctype=Standard", "URIDate": "2025-03-27" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "99", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_99&doctype=Standard", "URIDate": "2025-03-27" }, "r228": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "10", "IssueDate": "2025-01-01", "Paragraph": "22", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2025-en-r&anchor=para_22_f&doctype=Standard", "URIDate": "2025-03-27" }, "r229": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "37", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_37_b&doctype=Standard", "URIDate": "2025-03-27" }, "r230": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "138", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_138_a&doctype=Standard", "URIDate": "2025-03-27" }, "r231": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "32", "IssueDate": "2025-01-01", "Paragraph": "IE33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2025-en-r&anchor=para_IE33&doctype=Illustrative%20Examples", "URIDate": "2025-03-27" }, "r232": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "16", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_16_a&doctype=Standard", "URIDate": "2025-03-27" }, "r233": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_17_e&doctype=Standard", "URIDate": "2025-03-27" }, "r234": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B10", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r235": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "B6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_B6&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r236": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "IE63", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_IE63&doctype=Illustrative%20Examples", "URIDate": "2025-03-27" }, "r237": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "15", "IssueDate": "2025-01-01", "Paragraph": "B89", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_B89_b&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r238": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "113", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_113_b&doctype=Standard", "URIDate": "2025-03-27" }, "r239": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "96", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_96_b&doctype=Standard", "URIDate": "2025-03-27" }, "r240": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35M", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35M&doctype=Standard", "URIDate": "2025-03-27" }, "r241": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35N", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35N&doctype=Standard", "URIDate": "2025-03-27" }, "r242": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "IG20C", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_IG20C&doctype=Implementation%20Guidance", "URIDate": "2025-03-27" }, "r243": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "23", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23&doctype=Standard", "URIDate": "2025-03-27" }, "r244": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_b&doctype=Standard", "URIDate": "2025-03-27" }, "r245": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "103", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_103_b&doctype=Standard", "URIDate": "2025-03-27" }, "r246": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "191", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_191_f&doctype=Standard", "URIDate": "2025-03-27" }, "r247": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "71", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_71&doctype=Standard", "URIDate": "2025-03-27" }, "r248": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B9", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_b&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r249": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B9", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_f&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r250": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "102", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_102&doctype=Standard", "URIDate": "2025-03-27" }, "r251": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "103", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_103&doctype=Standard", "URIDate": "2025-03-27" }, "r252": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "108", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_108&doctype=Standard", "URIDate": "2025-03-27" }, "r253": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "70", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_70&doctype=Standard", "URIDate": "2025-03-27" }, "r254": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_b&doctype=Standard", "URIDate": "2025-03-27" }, "r255": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_e&doctype=Standard", "URIDate": "2025-03-27" }, "r256": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "IG6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_IG6&doctype=Implementation%20Guidance", "URIDate": "2025-03-27" }, "r257": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r258": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d-3" }, "r259": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "73", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73_d&doctype=Standard", "URIDate": "2025-03-27" }, "r260": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "73", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73_e&doctype=Standard", "URIDate": "2025-03-27" }, "r261": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "135", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_135_b&doctype=Standard", "URIDate": "2025-03-27" }, "r262": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "5", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_5&doctype=Standard", "URIDate": "2025-03-27" }, "r263": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "9", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_9&doctype=Standard", "URIDate": "2025-03-27" }, "r264": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "33", "IssueDate": "2025-01-01", "Paragraph": "70", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_70_c&doctype=Standard", "URIDate": "2025-03-27" }, "r265": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "118", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_c&doctype=Standard", "URIDate": "2025-03-27" }, "r266": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "40", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2025-en-r&anchor=para_79_c&doctype=Standard", "URIDate": "2025-03-27" }, "r267": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "41", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2025-en-r&anchor=para_54_f&doctype=Standard", "URIDate": "2025-03-27" }, "r268": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "16", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_16&doctype=Standard", "URIDate": "2025-03-27" }, "r269": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "17", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_17&doctype=Standard", "URIDate": "2025-03-27" }, "r270": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "20", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20_b&doctype=Standard", "URIDate": "2025-03-27" }, "r271": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "20", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20&doctype=Standard", "URIDate": "2025-03-27" }, "r272": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_45&doctype=Standard", "URIDate": "2025-03-27" }, "r273": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "93", "Subparagraph": "h", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_h_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r274": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "93", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_h&doctype=Standard", "URIDate": "2025-03-27" }, "r275": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45&doctype=Standard", "URIDate": "2025-03-27" }, "r276": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "5", "IssueDate": "2025-01-01", "Paragraph": "33", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2025-en-r&anchor=para_33_d&doctype=Standard", "URIDate": "2025-03-27" }, "r277": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_7&doctype=Standard", "URIDate": "2025-03-27" }, "r278": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "10", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_10_e&doctype=Standard", "URIDate": "2025-03-27" }, "r279": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d&doctype=Standard", "URIDate": "2025-03-27" }, "r280": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "112", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_112_c&doctype=Standard", "URIDate": "2025-03-27" }, "r281": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "55", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_55&doctype=Standard", "URIDate": "2025-03-27" }, "r282": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78&doctype=Standard", "URIDate": "2025-03-27" }, "r283": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a&doctype=Standard", "URIDate": "2025-03-27" }, "r284": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "85", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_85&doctype=Standard", "URIDate": "2025-03-27" } } }